

Stroke

American Stroke
AssociationSM

JOURNAL OF THE AMERICAN HEART ASSOCIATION

A Division of American
Heart Association



Primary Prevention of Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline.

Larry B. Goldstein, Robert Adams, Mark J. Alberts, Lawrence J. Appel, Lawrence M. Brass, Cheryl D. Bushnell, Antonio Culebras, Thomas J. DeGraba, Philip B. Gorelick, John R. Guyton, Robert G. Hart, George Howard, Margaret Kelly-Hayes, J.V. (Ian) Nixon and Ralph L. Sacco

Stroke 2006;37;1583-1633; originally published online May 4, 2006;

DOI: 10.1161/01.STR.0000223048.70103.F1

Stroke is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75214
Copyright © 2006 American Heart Association. All rights reserved. Print ISSN: 0039-2499. Online
ISSN: 1524-4628

The online version of this article, along with updated information and services, is
located on the World Wide Web at:

<http://stroke.ahajournals.org/cgi/content/full/37/6/1583>

Subscriptions: Information about subscribing to *Stroke* is online at
<http://stroke.ahajournals.org/subscriptions/>

Permissions: Permissions & Rights Desk, Lippincott Williams & Wilkins, 351 West Camden
Street, Baltimore, MD 21202-2436. Phone 410-5280-4050. Fax: 410-528-8550. Email:
journalpermissions@lww.com

Reprints: Information about reprints can be found online at
<http://www.lww.com/static/html/reprints.html>

Primary Prevention of Ischemic Stroke

A Guideline From the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group

The American Academy of Neurology affirms the value of this guideline.

Larry B. Goldstein, MD, FAAN, FAHA, Chair; Robert Adams, MS, MD, FAHA; Mark J. Alberts, MD, FAHA; Lawrence J. Appel, MD, MPH, FAHA; Lawrence M. Brass, MD, FAHA†; Cheryl D. Bushnell, MD, MHS, FAHA; Antonio Culebras, MD, FAAN, FAHA; Thomas J. DeGraba, MD, FAHA; Philip B. Gorelick, MD, MPH, FAAN, FAHA; John R. Guyton, MD, FAHA; Robert G. Hart, MD, FAHA; George Howard, DrPH, FAHA; Margaret Kelly-Hayes, RN, EdD, MS, FAHA; J.V. (Ian) Nixon, MD, FAHA; Ralph L. Sacco, MD, MS, FAAN, FAHA

Background and Purpose—This guideline provides an overview of the evidence on various established and potential stroke risk factors and provides recommendations for the reduction of stroke risk.

Methods—Writing group members were nominated by the committee chair on the basis of each writer's previous work in relevant topic areas and were approved by the American Heart Association Stroke Council's Scientific Statement Oversight Committee. The writers used systematic literature reviews (covering the time period since the last review published in 2001 up to January 2005), reference to previously published guidelines, personal files, and expert opinion to summarize existing evidence, indicate gaps in current knowledge, and when appropriate, formulate recommendations based on standard American Heart Association criteria. All members of the writing group had numerous opportunities to comment in writing on the recommendations and approved the final version of this document. The guideline underwent extensive peer review before consideration and approval by the AHA Science Advisory and Coordinating Committee.

Results—Schemes for assessing a person's risk of a first stroke were evaluated. Risk factors or risk markers for a first stroke were classified according to their potential for modification (nonmodifiable, modifiable, or potentially modifiable) and strength of evidence (well documented or less well documented). Nonmodifiable risk factors include age, sex, low birth weight, race/ethnicity, and genetic factors. Well-documented and modifiable risk factors include hypertension, exposure to cigarette smoke, diabetes, atrial fibrillation and certain other cardiac conditions, dyslipidemia, carotid artery stenosis, sickle cell disease, postmenopausal hormone therapy, poor diet, physical inactivity, and obesity and body fat distribution. Less well-documented or potentially modifiable risk factors include the metabolic syndrome, alcohol abuse, drug abuse, oral contraceptive use, sleep-disordered breathing, migraine headache, hyperhomocysteinemia, elevated lipoprotein(a), elevated lipoprotein-associated phospholipase, hypercoagulability, inflammation, and infection. Data on the use of aspirin for primary stroke prevention are reviewed.

The authors provided equivalent contributions to this guideline and are listed in alphabetical order.

The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Department of the Navy, the Uniformed Services University of Health Sciences, the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, the Department of Defense, or the US Government.

†Deceased

The American Heart Association makes every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel. Specifically, all members of the writing group are required to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived as real or potential conflicts of interest.

This statement was approved by the American Heart Association Science Advisory and Coordinating Committee on December 23, 2005. A single reprint is available by calling 800-242-8721 (US only) or writing the American Heart Association, Public Information, 7272 Greenville Ave, Dallas, TX 75231-4596. Ask for reprint No. 71-0356. To purchase additional reprints: up to 999 copies, call 800-611-6083 (US only) or fax 413-665-2671; 1000 or more copies, call 410-528-4121, fax 410-528-4264, or E-mail kramsai@lww.com. To make photocopies for personal or educational use, call the Copyright Clearance Center, 978-750-8400.

Expert peer review of AHA Scientific Statements is conducted at the AHA National Center. For more on AHA statements and guidelines development, visit <http://www.americanheart.org/presenter.jhtml?identifier=3023366>.

© 2006 American Heart Association, Inc.

Stroke is available at <http://www.strokeaha.org>

DOI: 10.1161/01.STR.0000223048.70103.F1

Conclusion—Extensive evidence is available identifying a variety of specific factors that increase the risk of a first stroke and providing strategies for reducing that risk. (*Stroke*. 2006;37:1583-1633.)

Key Words: AHA Scientific Statements ■ stroke ■ risk factors ■ primary prevention

Stroke remains a major healthcare problem. Its human and economic toll is staggering. It is estimated that there are >700 000 incident strokes in the United States each year, resulting in >160 000 deaths annually, with 4.8 million stroke survivors alive today.¹ Although there was a 60% decline in stroke mortality over the 29-year period between 1968 and 1996, the rate of decline began to slow in the 1990s and has plateaued in several regions of the country.² Despite an overall 3.4% fall in per capita stroke-related mortality between 1991 and 2001, the actual number of stroke deaths rose by 7.7%.¹ Stroke ranks as the country's third leading cause of death.¹ Stroke incidence may be increasing.³ From 1988 to 1997, the age-adjusted stroke hospitalization rate grew 18.6% (from 560 to 664 per 100 000), while total stroke hospitalizations increased 38.6% (from 592 811 to 821 760 annually).⁴ In 2004, the cost of stroke was estimated at \$53.6 billion (direct and indirect costs), with a mean lifetime cost estimated at \$140 048.¹

Stroke is also a leading cause of functional impairments, with 20% of survivors requiring institutional care after 3 months and 15% to 30% being permanently disabled.¹ Stroke is a life-changing event that affects not only the person who may be disabled, but the entire family and other caregivers as well. Utility analyses show that a major stroke is viewed by more than half of those at risk as being worse than death.⁵ Despite the advent of treatment of selected patients with acute ischemic stroke with intravenous tissue-type plasminogen activator and the promise of other acute therapies, effective prevention remains the best treatment for reducing the burden of stroke.⁶⁻⁸ Primary prevention is particularly important because >70% of strokes are first events.¹ The age-specific incidence of major stroke in Oxfordshire, UK, has fallen by 40% over the past 20 years in association with an increased use of preventive treatments and general reductions in risk factors.⁹ As discussed in the sections that follow, high-risk or stroke-prone individuals can now be identified and targeted for specific interventions.

This guideline provides an overview of the evidence on various established and potential stroke risk factors and represents a complete revision of the last statement on this topic (published in 2001).¹⁰ This guideline largely focuses on an individual patient-oriented approach to stroke prevention. This is in contrast to a population-based approach in which "... the entire distribution of risk factors in the population is shifted to lower levels through population-wide interventions," which is reflected in the AHA Guide for Improving Cardiovascular Health at the Community Level.¹¹

The writing group consisted of experts with special interests in primary prevention representing disciplines including several medical specialties, epidemiology, and the neurosciences. Writing group members were nominated by the committee chair on the basis of each individual's previous work in relevant topic areas and were approved by the American Heart Association Stroke Council's Scientific

TABLE 1. Rating Levels of Evidence and Recommendations

Classification of Recommendations	
Class I	Conditions for which there is evidence for and/or general agreement that the procedure or treatment is useful and effective.
Class II	Conditions for which there is conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of a procedure or treatment.
IIa	The weight of evidence or opinion is in favor of the procedure or treatment.
IIb	Usefulness/efficacy is less well established by evidence or opinion.
Class III	Conditions for which there is evidence and/or general agreement that the procedure or treatment is not useful/effective and in some cases may be harmful.
Level of Evidence	
Level of Evidence A	Data derived from multiple randomized clinical trials.
Level of Evidence B	Data derived from a single randomized trial or nonrandomized studies.
Level of Evidence C	Consensus opinion of experts.
M	

Statement Oversight Committee. The writers used systematic literature reviews (covering the time period since the last review published in 2001 up to January 2005), reference to previously published guidelines, personal files, and expert opinion to summarize existing evidence, indicate gaps in current knowledge, and when appropriate, formulate recommendations based on standard American Heart Association criteria (Table 1, Figure). Because of the diverse nature of the topics, it was not possible to provide a systematic, uniform summary of the magnitude of the effect associated with each of the recommendations. Patient preferences need to be considered, as with all recommendations. All members of the writing group had numerous opportunities to comment in writing on the recommendations and approved the final version of this document. The guideline underwent extensive peer review before consideration and approval by the AHA Science Advisory and Coordinating Committee.

As given in Tables 2, 3, and 4, risk factors or risk markers for a first stroke were classified according to their potential for modification (nonmodifiable, modifiable, or potentially modifiable) and strength of evidence (well documented, less well documented).⁷ Although this classification system is somewhat subjective, well-documented *and* modifiable risk factors (Table 3) were considered as those with clear, supportive epidemiological evidence in addition to evidence of risk reduction with modification as documented by randomized trials. Less well-documented *or* potentially modifiable risk factors (Table 4) were those with either less clear epidemio-

Figure. Applying Classification of Recommendations and Level of Evidence

		"Size of Treatment Effect"			
		Class I <i>Benefit >>> Risk</i>	Class IIa <i>Benefit >> Risk</i> <i>Additional studies with focused objectives needed</i>	Class IIb <i>Benefit ≥ Risk</i> <i>Additional studies with broad objectives needed; Additional registry data would be helpful</i>	Class III <i>Risk ≥ Benefit</i> <i>No additional studies needed</i>
Level A <i>Multiple (3-5) population risk strata evaluated*</i> <i>General consistency of direction and magnitude of effect</i>	Procedure/Treatment SHOULD be performed/administered	<ul style="list-style-type: none"> Recommendation that procedure or treatment is useful/effective Sufficient evidence from multiple randomized trials or meta-analyses 	<p>IT IS REASONABLE to perform procedure/administer treatment</p> <ul style="list-style-type: none"> Recommendation in favor of treatment or procedure being useful/effective Some conflicting evidence from multiple randomized trials or meta-analyses 	<p>Procedure/Treatment should NOT be performed/administered SINCE IT IS NOT HELPFUL AND MAY BE HARMFUL</p> <ul style="list-style-type: none"> Recommendation that procedure or treatment not useful/effective and may be harmful Sufficient evidence from multiple randomized trials or meta-analyses 	
Level B <i>Limited (2-3) population risk strata evaluated*</i>	Recommendation that procedure or treatment is useful/effective	<ul style="list-style-type: none"> Limited evidence from single randomized trial or non-randomized studies 	<ul style="list-style-type: none"> Recommendation in favor of treatment or procedure being useful/effective Some conflicting evidence from single randomized trial or non-randomized studies 	<ul style="list-style-type: none"> Recommendation that procedure or treatment not useful/effective and may be harmful Limited evidence from single randomized trial or non-randomized studies 	
Level C <i>Very limited (1-2) population risk strata evaluated*</i>	Recommendation that procedure or treatment is useful/effective	<ul style="list-style-type: none"> Only expert opinion, case studies, or standard-of-care 	<ul style="list-style-type: none"> Recommendation's usefulness/efficacy less well established Only diverging expert opinion, case studies, or standard-of-care 	<ul style="list-style-type: none"> Recommendation that procedure or treatment not useful/effective and may be harmful Only expert opinion, case studies, or standard-of-care 	

Suggested phrases for writing recommendations †

should be recommended	is reasonable	is not recommended
is indicated	can be useful/effective/ beneficial	is not indicated
is useful/effective/beneficial	is probably recommended or indicated	should not
		is not useful/effective/beneficial
		may be harmful

*Data available from clinical trials or registries about the usefulness/efficacy in different sub-populations, such as gender, age, history of diabetes, history of prior MI, history of heart failure, and prior aspirin use. A recommendation with Level of Evidence B or C does not imply that the recommendation is weak. Many important clinical questions addressed in the guidelines do not lend themselves to clinical trials. Even though randomized trials are not available, there may be a very clear clinical consensus that a particular test or therapy is useful or effective.

†In 2003, the ACC/AHA Task Force on Practice Guidelines developed a list of suggested phrases to use when writing recommendations. All recommendations in this guideline have been written in full sentences that express a complete thought, such that a recommendation, even if separated and presented apart from the rest of the document (including headings above sets of recommendations), would still convey the full intent of the recommendation. It is hoped that this will increase readers' comprehension of the guidelines and will allow queries at the individual recommendation level.

TABLE 2. Nonmodifiable Risk Factors

Factor	Prevalence (per 100 000)				RR
Age, y ^{3,23}	Doubling of stroke rate each 10 y after age 55. Incidence ¹ :				...
	White		Black		
	Men	Women	Men	Women	
45–54	1.4	0.8	2.1	2.5	
55–64	2.6	1.6	4.9	4.6	
65–74	6.7	4.2	10.4	9.8	
75–84	11.8	11.3	23.3	13.5	
≥85	16.8	16.5	24.7	21.8	
Race ²⁴					...
Blacks					233
Hispanics					196
Whites					93
Sex ³					...
Men					174
Women					122
Total					145
Low birth weight ^{29,30}					...
Family history of stroke/TIA ⁴¹					...
					≈2 for birth weights <2500 vs ≥4000 g
					RR paternal history 2.4 (95% CI 0.96–6.03); RR maternal history 1.4 (95% CI 0.60–3.25)

logical evidence or without evidence from randomized trials demonstrating a reduction of stroke risk with modification. The tables give the estimated prevalence, population-attributable risk (ie, the proportion of ischemic stroke in the population that can be attributed to a particular risk factor, given by the formula $100 \times \frac{[\text{Prevalence (Relative Risk-1)}]}{[\text{Prevalence (Relative Risk-1)} + 1]}$),¹² relative risk, and risk reduction with treatment for each factor when known. Gaps in current knowledge are indicated by question marks in the tables. It should also be noted that precise estimates of attributable risk for factors such as hormone replacement therapy are not available because of variation in the estimates of risk and changes in prevalence. Other tables summarize guideline or consensus statement management recommendations as available. Other recommendations are indicated in the text and tables.

Assessing the Risk of a First Stroke

It is helpful for healthcare providers and the public to be able to estimate a person's risk for a first stroke. As detailed in the sections that follow, numerous factors can contribute to a person's stroke risk, and many individuals have >1 risk factor. Some of these risk factors are relatively less well documented, and specific or proven treatments may be lacking. Although most risk factors have an independent effect, there may be important interactions between individual factors that need to be considered in predicting overall risk or choosing an appropriate risk modification program. Risk-assessment tools have been used in community stroke screening programs and utilized in some guideline statements to select certain treatments for primary stroke prevention.^{13,14} Some of the goals of such risk-assessment tools are (1) to identify persons at elevated risk who might be unaware of

their risk; (2) to assess risk in the presence of >1 condition; (3) to measure an individual's risk that can be tracked and lowered by appropriate modifications; (4) to estimate a quantitative risk for selecting treatments or stratification in clinical trials; and (5) to guide appropriate use of further diagnostic testing.

Although stroke risk-assessment tools exist, the complexities of the interactions of risk factors and the effects of certain risk factors stratified by age, gender, race-ethnicity, and geography are incompletely captured by any available global risk-assessment tool. In addition, these tools tend to be focused and generally do not include the full range of possible contributing factors. Some risk-assessment tools are gender specific and give 1-, 5-, or 10-year stroke risk estimates. The Framingham Stroke Profile (FSP) uses a Cox proportional-hazards model with risk factors as covariates and points calculated according to the weight of the model coefficients.¹⁵ Independent stroke predictors include age, systolic blood pressure, hypertension, diabetes mellitus, current smoking, established cardiovascular disease (any one of myocardial infarction [MI], angina or coronary insufficiency, congestive heart failure, or intermittent claudication), atrial fibrillation, and left ventricular (LV) hypertrophy on ECG. Point values can be calculated that correspond to a gender-specific 10-year cumulative stroke risk. The FSP has been updated to account for the use of antihypertensive therapy and the risk of stroke and stroke or death among individuals with new-onset atrial fibrillation (Table 5).^{16,17} Despite its widespread use, the validity of the FSP among individuals of a different age range or belonging to racial-ethnic groups other than those in the Framingham cohort has not been adequately studied. The FSP has been applied to ethnic

TABLE 3. Well-Documented and Modifiable Risk Factors

Factor	Prevalence, %	Population-Attributable Risk, %*	RR	Risk Reduction With Treatment
Cardiovascular disease				
Coronary heart disease ⁵⁵⁰				Overlap with risk factors for first stroke, see other relevant portions of this statement.
Men	8.4	5.8†	1.73 (1.68–1.78) ¹⁶	
Women	5.6	3.9†	1.55 (1.17–2.07) ¹⁶	
Heart failure ⁵⁵⁰				
Men	2.6	1.4†		
Women	2.1	1.1†		
Peripheral arterial disease	4.9	3.0†		
Hypertension⁵⁵¹				
Age 50 y	20	40	4.0	38%; see Table 6 and text.
Age 60 y	30	35	3.0	
Age 70 y	40	30	2.0	
Age 80 y	55	20	1.4	
Age 90 y	60	0	1.0	
Cigarette smoking	25	12–18	1.8	50% within 1 y; baseline after 5 y ⁵⁵²
Diabetes	7.3 ¹	5–27	1.8–6	
Asymptomatic carotid stenosis	2–8 ^{229,230,255,553–556}	2–7‡	2.0 ⁵⁵⁷	Reduction of stroke risk in hypertensive diabetic patients with blood pressure control. No demonstrated benefit in stroke reduction with tight glycemic control; however, reduction in other complications does occur (see text). Reduction of stroke with statins (see text). ≈50% ^{245,246,249} reduction with endarterectomy (see text). Aggressive management of other identifiable vascular risk factors (see text).
Atrial fibrillation (nonvalvular)^{135,140}				
Age 50–59 y	0.5	1.5	4.0	Adjusted-dose warfarin vs control: 62% (CI 48% to 72%); 6 trials, 2900 patients. Aspirin vs placebo: 22% (CI 2% to 38%); 6 trials, 3119 patients. Adjusted-dose warfarin vs aspirin: 45% (CI 29% to 57%); 6 trials, 4025 patients.
Age 60–69 y	1.8	2.8	2.6	
Age 70–79 y	4.8	9.9	3.3	
Age 80–89 y	8.8	23.5	4.5	
Sickle cell disease	0.25 (of African Americans) ⁵⁵⁸	...	200–400 ^{263§}	91% ²⁶³ with transfusion therapy (see text).
Dyslipidemia				
High total cholesterol	25 ²²⁷	15	2.0 for men and for women age <55 y	27% to 32% with statins in high-risk patients with coronary heart disease, hypertension, or diabetes; 25% reduction with high-dose vs low-dose statins (see text).
Low HDL cholesterol	25 ²²⁷	10	1.5–2.5 for men	
Dietary factors				
Na intake >2300 mg	75–90	Unknown	Unknown	Note: Observational studies show an 8% reduction in stroke mortality from a 3-mm Hg reduction in systolic blood pressure. ⁵⁵⁹ The extent of systolic blood pressure reduction from reduced Na and increased K intake can exceed 3 mm Hg according to baseline intake levels and other factors.
K intake <4700 mg	90–99 ²⁹⁹		Unknown	
Obesity	17.9 ⁵⁶⁰	12–20‡	1.75–2.37 ^{40,325}	Unknown
Physical inactivity ³⁰⁸	25	30	2.7‡	Unknown
Postmenopausal hormone therapy	20 ⁵⁶¹ (women age 50–74 y) ⁵⁶²	7	1.4 ²⁷⁷	None (and may increase risk).

Data derived from Hart et al^{143,161} and van Walraven et al.¹³⁹ Stroke includes both ischemic and hemorrhagic stroke. Cardiovascular disease includes coronary heart disease, heart failure, and peripheral arterial disease.

*Population-attributable risk is the proportion of ischemic stroke in the population that can be attributed to a particular risk factor (see text for formula).

†Calculated on the basis of point estimates of referenced data provided in the table. For peripheral arterial disease, calculation was based on average RR for men and women.

‡Calculated based on referenced data provided in the table or text.

§Relative to stroke risk in children without sickle cell disease.

||For high-risk patients treated with transfusion.

TABLE 4. Less Well-Documented or Potentially Modifiable Risk Factors

Factor	Prevalence, %	Population-Attributable		Risk Reduction With Treatment
		Risk, %	RR or OR	
Metabolic syndrome	23.7 ²⁴⁶			
Alcohol abuse ^{366,563}				
≥5 drinks/d	5–7	1–3	1.6†	Unknown
More than moderate (see text)	60	32	1.8†	Unknown
Hyperhomocysteinemia				
Age 40–59 y				
Men	29	26	1.3–2.3 ^{445,446,560}	Unknown
Women	21	37		
Age ≥60 y				
Men	43	35		
Women	47 ⁴⁵⁶	37 ^{445,456}		
Drug abuse	3–14 ¹¹⁹	Unknown	6.5 ³⁶⁹	Unknown
Hypercoagulability				
Anticardiolipin antibody				
Men	19.7 ⁴⁸²	6 ⁴⁸²	1.3 (0.7–2.3)*	0.99 (0.69–1.41) ⁴⁷⁹ ‡
Women overall	17.6 ⁴⁸²	14 ⁴⁸²	1.9 (1.1–3.5)*	Warfarin
Women age 15–44 y	26.9 ⁴⁸⁴	11 ⁴⁸⁴	1.9 (1.24–2.83)†	
Lupus anticoagulant (women age 15–44 y)	12.8 ⁴⁸⁴	9 ⁴⁸⁴	1.80 (1.06–3.06) ⁴⁸⁴	0.78 (0.50–1.21) ⁴⁷⁹ ‡ 1.47 (0.91–2.36)‡ (anticardiolipin antibodies/lupus anticoagulant) ⁴⁷⁹
Factor V Leiden ⁵⁸	7.7	0	0.92 (0.56–1.53)	Unknown
Prothrombin 20210 mutation ⁵⁷	3.7	3	1.9 (0.5–6.2)	Unknown
Protein C deficiency ⁵⁷	2.0	0	0.7 (0.2–3.1)	Unknown
Protein S deficiency ⁵⁷	1.0	0	0.9 (0.1–6.7)	Unknown
Antithrombin III deficiency ⁵⁷	4.1	1	1.3 (0.5–3.3)	Unknown
Oral contraceptive use (women age 25–44 y)	13 ⁵⁶⁴	19	2.8 ³⁹²	None (and may increase risk)
Inflammatory processes				
Periodontal disease				
Age 25–74 y	16.8 ⁵³¹	16	2.11 (1.30–3.42) ⁵³¹	Effects of medical therapy on periodontal disease remain to be studied
Age 60–64 y	15 ⁵⁶⁵			
Age ≥65 y	45 ⁵⁶⁶			
<i>C pneumoniae</i>				
Age ≥65 y	75–100 IgA ^{567,568}	72–78	IgA ≥1:16 4.51 (1.44–14.06) ⁵¹⁹	Trials of antibiotics for general cardiovascular event reduction negative, insufficient power for stroke end points
		85–88	IgG ≥1:512 and/or IgA ≥1:64 8.58 (1.1–68.8) adult men ⁵²¹	
Age <5 yr	0–5			
Age 5–20 y	50			
Cytomegalovirus				
Adults	69 ⁵³⁴	82		
Males	62.5		OR 1.04; 95% CI 0.68–1.58 ⁵³⁴	
Females	72.8		OR 7.6; 95% CI 3.21–17.96 ⁵³³	
<i>H pylori</i> CagA seropositivity	Adults with vascular disease: IgG Ab >40 AU 65.7 ⁵³⁴	39	Atherothrombotic stroke: OR 1.97; CI 1.33–2.91 ⁵³⁶	
		83	Carotid plaque irregularities: OR 8.42; CI 1.58–44.84 ⁵³⁷	
Acute infection				
Systemic respiratory infection				
Days 1–3			Stroke IR 3.19; CI 2.81–3.62	
Days 29–91			Stroke IR 1.27; CI 1.15–1.41	

TABLE 4. Continued

Factor	Prevalence, %	Population-Attributable Risk, %	RR or OR	Risk Reduction With Treatment
Urinary tract infection				
Days 1–3			Stroke IR 1.65 (CI 1.19–2.28)	
Days 19–91 ⁵⁴¹			Stroke IR 1.16 (CI 1.04–1.28)	
CD 40 ligand (CD 54) >3.71 ng/mL in females free of cardiovascular disease	6	12	3.3 (CI 1.2–8.6) stroke, MI, acute coronary syndrome deaths	
IL-18 upper tertile (>235 pg/mL)			Adjusted RR for coronary events 1.82 (1.30–2.55) ⁵¹¹	
Elevated hs-CRP (>3 mg/L) in women age ≥45 y ⁵⁶⁹	28.13		RR 3.0, P<0.001 women ≥45 y for cardiovascular and cerebrovascular events combined (highest vs lowest quartile) ⁴⁹⁰	
			RR 2.0 (CI 1.10–3.79) men age-adjusted for first ischemic stroke and TIA (highest vs lowest quartile)	
			RR 2.7 (CI 1.59–4.79) women age-adjusted for first ischemic stroke and TIA (highest vs lowest quartile) ⁴⁹¹	
Migraine	12	17 (women, 20–44 y) ⁴³³	2.1 ⁴³²	
High Lp(a)	20, age ≥65 men ⁵⁷⁰	27	2.92 (1.53–5.57) ⁵⁷⁰	Unknown
High Lp-PLA ₂			HR=1.97 (1.03–3.79) highest vs lowest quartile ⁴⁷⁴	Unknown
Sleep-disordered breathing				
Men	4	Unknown	1.2%/y ⁵⁷²	Unknown
Women	2 ⁵⁷¹			

IgA indicates immunoglobulin A; IgG, immunoglobulin G; IR, incidence rate; and hs-CRP, high-sensitivity C-reactive protein.

*Adjusted for age, prior cardiovascular disease, systolic blood pressure, diabetes, smoking, plasma CRP, and serum total and HDL cholesterol.

†Adjusted for age, smoking, hypertension, diabetes, angina, ethnicity, BMI, and HDL cholesterol.

‡Warfarin.

minorities in the United Kingdom and found to vary across groups, but the suitability of the scale to predict outcomes has not been well tested.¹⁸

Alternative prediction models have been developed using other cohorts and utilizing different sets of stroke risk factors. Retaining most of the Framingham covariates, one alternative stroke risk scoring system omits cigarette smoking and antihypertensive medication but adds “time to walk 15 feet” and serum creatinine.¹⁹ Another score is derived from a mixed cohort of stroke and stroke-free patients and includes prior history of stroke, marital status, blood pressure as a categorical variable, high-density lipoprotein (HDL) cholesterol, impaired expiratory flow, physical disability, and a depression score.²⁰ Several studies have generated risk-assessment tools for use in subjects with atrial fibrillation (see below).

Summary and Gaps

It is clear that an ideal stroke risk–assessment tool that is generally applicable, simple, and widely accepted does not exist. Each available tool has its own limitations. The impact of newer risk factors for stroke, not collected in older studies, needs to be considered.²¹ Risk-assessment tools should be used with care, as they do not include all the factors that contribute to future disease risk.²² The utility of the FSP

(Table 5) or other stroke risk–assessment scales as a way of improving the effectiveness of primary stroke prevention programs is not well studied. Research is needed to validate risk-assessment tools across age, gender, and racial-ethnic groups; evaluate whether any of the more recently identified risk factors add to the predictive accuracy of existing scales; and determine whether the use of these scales improves primary stroke prevention programs.

Recommendation

Each patient should have an assessment of his or her stroke risk (Class I, Level of Evidence A). The use of a risk-assessment tool such as the FSP should be considered as these tools can help identify individuals who could benefit from therapeutic interventions and who may not be treated on the basis of any 1 risk factor (Class IIa, Level of Evidence B).

Nonmodifiable Risk Factors

Although these factors are not modifiable, they identify those who are at highest risk of stroke and who may benefit from rigorous prevention or treatment of modifiable risk factors (Table 2).

Age

The cumulative effects of aging on the cardiovascular system and the progressive nature of stroke risk factors over a

TABLE 5. Modified Framingham Stroke Risk Profile

	Points										
	0	+1	+2	+3	+4	+5	+6	+7	+8	+9	+10
Men											
Age, y	54–56	57–59	60–62	63–65	66–68	69–72	73–75	76–78	79–81	82–84	85
Untreated systolic blood pressure, mm Hg	97–105	106–115	116–125	126–135	136–145	146–155	156–165	166–175	176–185	186–195	196–205
Treated systolic blood pressure, mm Hg	97–105	106–112	113–117	118–123	124–129	130–135	136–142	143–150	151–161	162–176	177–205
History of diabetes	No		Yes								
Cigarette smoking	No			Yes							
Cardiovascular disease	No				Yes						
Atrial fibrillation	No				Yes						
Left ventricular hypertrophy on electrocardiogram	No					Yes					
Women											
Age, y	54–56	57–59	60–62	63–64	65–67	68–70	71–73	74–76	77–78	79–81	82–84
Untreated systolic blood pressure, mm Hg		95–106	107–118	119–130	131–143	144–155	156–167	168–180	181–192	193–204	205–216
Treated systolic blood pressure, mm Hg		95–106	107–113	114–119	120–125	126–131	132–139	140–148	149–160	161–204	205–216
History of diabetes	No			Yes							
Cigarette smoking	No			Yes							
Cardiovascular disease	No		Yes								
Atrial fibrillation	No						Yes				
Left ventricular hypertrophy on electrocardiogram	No				Yes						

prolonged period of time substantially increase stroke risk. The risk of stroke doubles for each successive decade after age 55 years.^{3,23}

Sex

Stroke is more prevalent in men than in women.³ Men also generally have higher age-specific stroke incidence rates than do women (based on age-specific rates calculated from strata defined by race/ethnicity).²⁴ Exceptions are in 35- to 44-year-olds and in those >85 years of age—groups in which women have slightly greater age-specific stroke incidence than do men.²⁴ Factors such as oral contraceptive (OC) use and pregnancy contribute to the increased risk of stroke in young women,^{25–27} and the earlier cardiac-related deaths of men with cardiovascular disease may contribute to the relatively greater risk of stroke in older women. Women accounted for 61.5% of US stroke deaths in 2002 (100 500 deaths among women were attributed to stroke versus 62 662 among men).¹ Overall, 1 in 6 women die of stroke as compared with 1 in 25 who die of breast cancer.²⁸ In 2002, age-adjusted stroke mortality rates were 53.4/100 000 among white women and 71.8/100 000 among black women, versus rates of 54.2 and 81.7/100 000 among white and black men, respectively.¹

Low Birth Weight

Stroke mortality rates among adults in England and Wales are higher among persons who had lower birth weights.²⁹ A similar study compared a group of South Carolina Medicaid

beneficiaries <50 years of age who had stroke to population controls.³⁰ The odds of stroke were more than double for those with birth weights <2500 g as compared with those weighing \geq 4000 g (with a significant linear trend for intermediate birth weights). Regional differences in birth weight may partially underlie geographic differences in stroke-related mortality. However, the reason for this relationship remains uncertain, and statistical association does not prove causality.

Race-Ethnicity

Racial and ethnic effects on disease risk can be difficult to consider separately. African Americans^{24,31} and some Hispanic Americans^{32,33} have higher stroke incidence and mortality rates as compared with European Americans. In the Atherosclerosis Risk In Communities (ARIC) Study, blacks had an incidence of stroke 38% higher than that of whites.³⁴ Possible reasons for the higher incidence and mortality rate of strokes in blacks include a higher prevalence of hypertension, obesity, and diabetes within the black population.^{35,36} However, a higher incidence of these risk factors does not explain all of the excess risk.³⁵ Epidemiological studies have shown an increase in stroke incidence among self-identified Hispanic racial-ethnic populations.^{24,37,38} Incidence rates are also relatively higher among some Asian groups.³⁹

Genetic Factors

Both paternal and maternal history of stroke have been associated with an increased stroke risk.^{40,41} This increased

TABLE 5. Continued

Points	10-Year Probability, %	
	Men	Women
1	3	1
2	3	1
3	4	2
4	4	2
5	5	2
6	5	3
7	6	4
8	7	4
9	8	5
10	10	6
11	11	8
12	13	9
13	15	11
14	17	13
15	20	16
16	22	19
17	26	23
18	29	27
19	33	32
20	37	37
21	42	43
22	47	50
23	52	57
24	57	64
25	63	71
26	68	78
27	74	84
28	79	
29	84	
30	88	

The table gives the probability of stroke within 10 y for men and women 55–85 y of age and free of previous stroke in the Framingham Heart Study. Modified from D'Agostino et al.¹⁶ History of MI indicates angina pectoris, coronary insufficiency, intermittent claudication, or congestive heart failure.

risk could be mediated through a variety of mechanisms, including (1) genetic heritability of stroke risk factors, (2) the inheritance of susceptibility to the effects of such risk factors, (3) familial sharing of cultural/environmental and lifestyle factors, and (4) the interaction between genetic and environmental factors.⁴² Twin studies provide strong data suggesting familial inheritance of stroke risk. Concordance rates for stroke are markedly higher in monozygotic than in dizygotic twins,⁴³ with a nearly 5-fold increase in stroke prevalence among monozygotic as compared with dizygotic twins.⁴⁴

Genetic influences on stroke risk can be considered on the basis of individual risk factors, the genetics of common stroke types, and uncommon or rare familial stroke types. Many of the established and emerging risk factors that are described in the sections that follow, such as hypertension, diabetes, and hyperlipidemia, have both genetic and environmental/behavioral components.^{43,45,46} In some cases, elevations of blood

homocysteine are due to 1 or more mutations in the methylene-tetrahydrofolate reductase gene.^{47–49} Many coagulopathies are inherited as autosomal dominant traits.⁵⁰ These disorders, including protein C and S deficiencies, factor V Leiden mutations, and various other factor deficiencies, can lead to an increased risk of venous thrombosis.^{51–56} However, as discussed below, there has not been a strong association between several of these disorders and arterial events, such as MI and stroke.^{52,57,58} Some apparently acquired coagulopathies, such as the presence of a lupus anticoagulant or anticardiolipin antibody, can be familial in ≈10% of cases.^{59,60} Inherited disorders of various clotting factors (ie, factors V, VII, X, XI, and XIII) are autosomal recessive traits and can lead to cerebral hemorrhage in childhood or the neonatal period.⁵⁰ Arterial dissections, moyamoya syndrome, and fibromuscular dysplasia have a genetic or familial component in 10% to 20% of cases.^{61,62}

The DeCode genetics group (Iceland) has reported genetic linkage of phosphodiesterase 4D (chromosome 5q12) and 5-lipoxygenase activating protein (chromosome 13q12-13) to common forms of ischemic stroke.^{63,64} In both cases, there appears to be an association between several specific genetic haplotypes and stroke, although no pathogenic mutations have been identified.

Several rare genetic disorders have been associated with stroke. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is characterized by subcortical infarcts, dementia, and migraine headaches.⁶⁵ CADASIL can be caused by any of a series of mutations in the Notch3 gene.^{65,66} Acetazolamide may reduce migraine headaches in patients with CADASIL.⁶⁷ (Class IIb, Level of Evidence C). Marfan syndrome (due to mutations in the fibrillin gene) and neurofibromatosis types I and II are associated with an increased risk of ischemic stroke. Gene-transfer therapy has been attempted to correct the genetic defect.⁶⁸ Fabry disease is a rare inherited disorder that can lead to ischemic stroke. It is caused by lysosomal α -galactosidase A deficiency, which causes the progressive accumulation of globotriaosylceramide and related glycosphingolipids.⁶⁹ Deposition affects mostly small vessels in the brain and other organs, although involvement of the larger vessels has been reported. Two prospective randomized studies using human recombinant lysosomal α -galactosidase A found a significant reduction in microvascular deposits as well as reduced plasma levels of globotriaosylceramide (Class I, Level of Evidence A).^{70–72} These studies had short follow-up periods, and no effects on stroke rates were found. Enzyme replacement therapy also appears to improve cerebral vessel function.⁷³

Summary and Gaps

Genetic factors could arguably be classified as potentially modifiable, but because specific gene therapy is not presently available, these have been placed in the “nonmodifiable” section. It should be recognized that treatments are available for some of the factors that have a genetic predisposition or cause (such as Fabry disease), and as described in the sections that follow.

Recommendations

Referral for genetic counseling may be considered for patients with rare genetic causes of stroke (Class IIb, Level of

Evidence C). There remain insufficient data to recommend genetic screening for the prevention of a first stroke.

Well-Documented and Modifiable Risk Factors

There are several well-documented risk factors for first ischemic stroke with clear data showing a reduction in stroke risk with treatment. An important risk factor for a first stroke that is not adequately reflected in the organizational scheme used in this guideline is the presence of atherosclerotic vascular disease in another vascular bed. Those with a history of cardiovascular disease (coronary heart disease, cardiac failure, or symptomatic peripheral arterial disease) have a significant increased risk of a first stroke as compared with those without such a history, after adjustment for other risk factors (relative risk [RR]=1.73, 95% confidence interval [CI] 1.68 to 1.78 for men; RR=1.55, 95% CI 1.17 to 2.07 for women; adjusted for age, blood pressure, LV hypertrophy, cigarette smoking, atrial fibrillation, and diabetes).¹⁶ Treatments used in the management of these other conditions (eg, platelet antiaggregants) may also reduce the risk of stroke. The risk factors for first stroke and the risk factors for cardiovascular disease overlap. The impact of management of these common risk factors is reviewed in the context of their specific impact on stroke throughout this statement but should also be considered in the context of global reduction of vascular disease.

Recommendations

Persons with evidence of noncerebrovascular atherosclerotic vascular disease (coronary heart disease, cardiac failure, or symptomatic peripheral arterial disease) are at increased risk for a first stroke. Treatments used in the management of these other conditions (eg, platelet antiaggregants) and as recommended in other sections of this guideline can reduce the risk of stroke (Class and Level of Evidence as indicated in the relevant sections).

Hypertension

Hypertension (Table 3) affects at least 65 million persons in the United States and is a major risk factor for both cerebral infarction and intracerebral hemorrhage.^{74,75} The relationship between blood pressure and cardiovascular risk is “continuous, consistent, and independent of other risk factors.”⁷⁶ The higher the blood pressure, the greater the stroke risk.⁷⁷ Blood pressure, particularly systolic blood pressure, increases with increasing age.⁷⁸ The Framingham Study found that individuals who are normotensive at 55 years of age have a 90% lifetime risk for developing hypertension.⁷⁹ More than two thirds of persons >65 years of age are hypertensive.⁷⁶

There has been compelling evidence for more than 30 years that the control of high blood pressure contributes to the prevention of stroke as well as to the prevention or reduction of other target-organ damage, including congestive heart failure and renal failure.⁷⁶ A meta-analysis of 18 long-term randomized trials found that both β -blocker therapy (RR=0.71; 95% CI 0.59 to 0.86) and treatment with diuretics (RR=0.49; 95% CI 0.39 to 0.62) were effective in preventing stroke.⁸⁰ Overall, antihypertensive therapy is associated with a 35% to 44% reduction in the incidence of stroke.⁸¹ In at

least 1 study, there was no significant difference in the rates of stroke among groups of hypertensive persons (mean diastolic blood pressures between 100 and 115 mm Hg) who achieved mean diastolic blood pressures of 85.2, 83.2, or 81.1 mm Hg.⁸² Recent national guidelines recommend lowering blood pressure to <140/90 mm Hg (with lower targets in some subgroups, such as individuals with diabetes; see section on diabetes), and ongoing trials are exploring optimal lower general targets.⁷⁶

Several categories of antihypertensive agents, including thiazide diuretics, angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β -adrenergic receptor blockers, and calcium channel blockers, reduce cardiovascular risk, including the risk of stroke, in patients with hypertension.^{81,83–86} Blood pressure control can be achieved in most patients, but the majority require combination therapy with ≥ 2 antihypertensive agents.^{87,88} Direct comparisons among the various types of antihypertensives are limited. At least 1 study compared the effects of an angiotensin II type 1 receptor blocker with a β -adrenergic receptor blocker in 9193 persons with essential hypertension (160 to 200/95 to 115 mm Hg) and electrocardiographically determined LV hypertrophy over 4 years.⁸⁵ Blood pressure reductions were similar for each group. There was a 13% (RR=0.87; 95% CI 0.77 to 0.98) reduction in MI, stroke, or death among the ARB-treated patients as compared with those given a β -adrenergic receptor blocker, which included a 25% (RR=0.75; 95% CI 0.63 to 0.89) reduction in fatal or nonfatal stroke. It remains unsettled whether specific classes of antihypertensive agents offer special protection against stroke in addition to their blood pressure-lowering effects in other settings.

Controlling isolated systolic hypertension (systolic blood pressure >160 mm Hg and diastolic blood pressure <90 mm Hg) in the elderly is also important. The Systolic Hypertension in Europe (Syst-Eur) Trial randomized 4695 patients with isolated systolic hypertension to active treatment with a calcium channel blocker or placebo and showed a 42% risk reduction in the actively treated group.⁸⁹ The Systolic Hypertension in the Elderly Program (SHEP) Trial found a 36% reduction in the incidence of stroke with treatment with a thiazide diuretic with or without a β -blocker.⁹⁰

Despite the efficacy of antihypertensive therapy and the ease of diagnosis and monitoring, a significant proportion of the population has undiagnosed or inadequately treated hypertension.⁹¹ Only 70% of Americans with hypertension are aware that they have the condition; 60% are being treated and 34% are controlled (<140/90 mm Hg).⁷⁶ Lack of diagnosis and inadequate treatment are particularly evident in minority populations and in the elderly.^{76,92} Because the risk of stroke increases progressively with increasing blood pressure and because a substantial number of individuals have a blood pressure level below current drug treatment thresholds, non-drug or lifestyle approaches have been recommended as a means to reduce the risk of stroke in nonhypertensive individuals.⁹³

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High

TABLE 6. Classification and Treatment of Blood Pressure (JNC 7)⁷⁶

Classification	Systolic Blood Pressure, mm Hg		Diastolic Blood Pressure, mm Hg	No Compelling Indication*	With Compelling Indication*
Normal	<120	and	<80	No antihypertensive drug	No antihypertensive drug
Prehypertension	120–139	or	80–90	No antihypertensive drug	Drugs for the compelling indication
Stage 1 hypertension	140–159	or	90–99	Thiazide-type diuretics for most. May consider ACEIs, ARBs, β -blockers, calcium channel blockers, or combination.	Drugs for the compelling indication. Other drugs (diuretics, ACEIs, ARBs, β -blockers, calcium channel blockers) as needed.
Stage 2 hypertension	\geq 160	or	\geq 100	Two-drug combination for most† (usually thiazide-type diuretic and ACEI or ARB or β -blocker or calcium channel blocker).	Drugs for the compelling indication. Other drugs (diuretics, ACEIs, ARBs, β -blockers, calcium channel blockers) as needed.

*Lifestyle modifications are encouraged for all and include (1) weight reduction if overweight, (2) limitation of ethyl alcohol intake, (3) increased aerobic physical activity (30–45 minutes daily), (4) reduction of sodium intake (<2.34 g), (5) maintenance of adequate dietary potassium (>120 mmol/d), (6) smoking cessation, and (7) DASH diet (rich in fruit, vegetables, and low-fat dairy products and reduced in saturated and total fat). Compelling indications include (1) congestive heart failure, (2) MI, (3) diabetes, (4) chronic renal failure, and (5) prior stroke.

†Initial combined therapy should be used cautiously in those at risk for orthostatic hypotension.

Blood Pressure (JNC 7) provides a comprehensive, evidence-based approach to the classification and treatment of hypertension.⁷⁶ Although somewhat controversial, this recent revision classifies blood pressure into 4 groupings (Table 6). Treatment recommendations are based on this revised classification scheme (Table 6).

Summary and Gaps

The benefit of hypertension treatment for primary prevention of stroke is clear. Choice of a specific regimen must be individualized, but reduction in blood pressure is generally more important than the specific agent used to achieve this goal. Hypertension remains undertreated in the community, and programs to improve treatment compliance need to be developed and supported.

Recommendations

Regular screening for hypertension (at least every 2 years in most adults and more frequently in minority populations and the elderly) and appropriate management (Class I, Level of Evidence A), including dietary changes, lifestyle modification, and pharmacological therapy as summarized in JNC 7,⁷⁶ are recommended (Table 6).

Cigarette Smoke

Virtually every multivariable assessment of stroke risk factors (eg, Framingham,¹⁵ Cardiovascular Health Study,⁹⁴ and the Honolulu Heart Study⁹⁵) has identified cigarette smoking as a potent risk factor for ischemic stroke (Table 3), associated with an approximate doubling of ischemic stroke risk (after adjustment for other risk factors). In addition, smoking has been clearly associated with a 2- to 4-fold increased risk for hemorrhagic stroke.^{96,97} A meta-analysis of 32 studies estimated the RR for ischemic stroke to be 1.9 (95% CI 1.7 to 2.2) for smokers versus nonsmokers and the RR for subarachnoid hemorrhage to be 2.9 (95% CI 2.5 to 3.5).⁹⁸ The annual number of stroke deaths attributed to smoking in the United States has been estimated to be between 21 400 (without adjustment for potential confounding factors) and 17 800 (with adjustments), which suggests that smoking contributes to 12% to 14% of all stroke deaths.⁹⁹ In 1989, these and other

studies led the US Surgeon General to conclude that a definite relationship exists between smoking and both ischemic and hemorrhagic stroke, particularly at young ages.^{100,101}

Cigarette smoking may also potentiate the effects of other stroke risk factors. For example, a synergistic effect exists between the use of OCs and smoking on the risk of cerebral infarction. With nonsmoking, non-OC-using women used as the reference group, the odds of cerebral infarction were 1.3 times greater (95% CI 0.7 to 2.1) for women who smoked but did not use OC, 2.1 times greater (95% CI 1.0 to 4.5) for nonsmoking OC users, but 7.2 times greater (95% CI 3.2 to 16.1) for OC users who smoked (note that the “expected” odds ratio [OR] in the absence of interaction for the smoking OC users would be \approx 2.7).¹⁰² There was also a synergistic impact of smoking and OC use on hemorrhagic stroke risk. With nonsmoking, non-OC-using women used as the reference group, the odds of hemorrhagic stroke were 1.6 times greater (95% CI 1.2 to 2.0) for women who smoked but did not use OC, 1.5 times greater (95% CI 1.1 to 2.1) for nonsmoking OC users, but 3.7 times greater (95% CI 2.4 to 5.7) for OC users who smoked (note that the “expected” OR in the absence of interaction for the smoking OC users would be \approx 2.4).¹⁰³

There is growing acceptance that exposure to environmental tobacco smoke (passive cigarette smoke) is a risk factor for heart disease.¹⁰⁴ Several studies suggest that environmental tobacco smoke is also a substantial risk factor for stroke, with a risk approaching the doubling found for active smoking.^{105,106} Because the dose of exposure to environmental tobacco smoke is substantially lower than for active smoking, the magnitude of the risk associated with environmental tobacco smoke seems surprising. This lack of an apparent dose–response relationship between the level of exposure and risk may in part be explained by physiological studies suggesting that there is a tobacco smoke exposure “threshold” rather than a linear dose–effect relationship.¹⁰⁷

Smoking likely contributes to increased stroke risk through both acute effects on the risk of thrombus generation in narrowed arteries and chronic effects related to an increased burden of atherosclerosis.¹⁰⁸ Smoking as little as a single

cigarette increases heart rate, mean blood pressure, and cardiac index and decreases arterial distensibility.^{109,110} In addition to the immediate effects of smoking, both active and passive cigarette smoke are associated with the development of atherosclerosis.¹¹¹ In addition to placing individuals at increased risk for both thrombotic and embolic stroke, cigarette smoking approximately triples the risk of cryptogenic stroke among individuals with low atherosclerotic burdens and no evidence of cardiac sources of emboli.¹¹²

Although the most effective preventive measures are to never smoke and to minimize exposure to environmental tobacco smoke, risk is reduced with smoking cessation. Smoking cessation is associated with a rapid reduction in the risk of stroke and other cardiovascular events to a level that approaches but does not reach that of those who never smoked.^{108,113,114}

Sustained smoking cessation is difficult to achieve. However, effective behavioral and pharmacological treatments for nicotine dependence now exist.^{115,116} A combination of nicotine replacement therapy, social support, and skills training provides an effective approach for quitting.¹¹⁷ A comprehensive review of the public health impact of smoking is provided in the 2004 Surgeon General's report.¹¹⁸

Summary and Gaps

Cigarette smoking is clearly associated with the risk of stroke. Epidemiological studies show a reduction in risk with smoking cessation over time. Although effective programs to facilitate smoking cessation exist, data showing that participation in these programs leads to a reduction in stroke are lacking.

Recommendations

Abstinence from cigarette smoking and (for current smokers) smoking cessation are recommended (Table 7) (Class I, Level of Evidence B). Data from cohort and epidemiological studies are consistent and overwhelming. Avoidance of environmental tobacco smoke for stroke prevention should also be considered (Class IIa, Level of Evidence C). The use of counseling, nicotine replacement, and oral smoking-cessation medications has been found to be effective for smokers and should be considered (Class IIa, Level of Evidence B).

Diabetes

Persons with type 2 diabetes have both an increased susceptibility to atherosclerosis and an increased prevalence of atherogenic risk factors, notably hypertension, obesity, and abnormal blood lipids. Since 1990, the prevalence of those diagnosed with diabetes rose 61%, with an increase of 8.2% from 2000 to 2001.¹ In 2001, 11.1 million Americans had physician-diagnosed diabetes, and an estimated additional 5.1 million had undiagnosed disease.¹

Case-control studies of stroke patients and prospective epidemiological studies have confirmed an independent effect of diabetes on ischemic stroke, with an increased RR in persons with diabetes ranging from 1.8-fold to nearly 6-fold (Table 3).¹¹⁹ Among Hawaiian Japanese men in the Honolulu Heart Program, those with diabetes had twice the risk of thromboembolic stroke as compared with those who did not have diabetes—an increase in risk that was independent of

other factors.¹²⁰ In the Framingham Heart Study, although the impact of diabetes was greatest on peripheral arterial disease with intermittent claudication, where the RR was increased 4-fold, coronary and cerebral artery territories were also affected.¹²¹ The impact of diabetes was greater in women than in men, reaching significance as an independent contributor in older women.¹²¹ In 2000, 1.1 million persons ≥ 35 years of age with diabetes reported being diagnosed with a stroke.¹

Stroke risk can be reduced in patients with diabetes. A small randomized trial of multifactorial intensive interventions in patients with type 2 diabetes and microalbuminuria targeted hyperglycemia, hypertension, dyslipidemia, and microalbuminuria with interventions including behavioral risk factor modification and the use of a statin, ACEI, ARB, or an antiplatelet drug as appropriate.¹²² After a mean of 7.8 years, the risk of cardiovascular events was reduced by nearly 50% (adjusted hazard ratio [HR]=0.47; 95% CI 0.22 to 0.74; $P=0.01$) with intensive treatment versus conventional therapy. First events included 3 nonfatal strokes, 4 nonfatal MIs, and 3 cardiovascular deaths in the 80 patients in the intensive arm versus 11 nonfatal strokes, 8 nonfatal MIs, and 1 cardiovascular death in the 80 patients in the control arm.

The combination of hyperglycemia and hypertension has long been believed to increase the frequency of diabetic complications, including stroke. Several trials have compared the effect on stroke and other cardiovascular outcomes of tight control of blood glucose and blood pressure in type 2 diabetic patients versus less stringent management. For example, the UK Prospective Diabetes Study Group found that for combined fatal and nonfatal stroke, tight blood pressure control (mean blood pressure achieved 144/82 mm Hg) resulted in a 44% RR reduction as compared with more liberal control (mean blood pressure achieved 154/87 mm Hg).¹²³ There was also a $\geq 20\%$ risk reduction with antihypertensive treatment in diabetic subjects in the Systolic Hypertension in the Elderly Program.¹²⁴ Although tight control of hypertension in diabetic individuals significantly reduces stroke incidence,¹²⁵ improved glycemic control did not produce a significant reduction in stroke over 9 years of follow-up (although the use of oral hypoglycemic drugs, potentially working through other mechanisms, may reduce stroke risk).¹²³ Nevertheless, intensive therapy to achieve tight control of hyperglycemia in patients with recent-onset insulin-dependent (type 1) diabetes mellitus was shown to reduce microvascular complications of the disease, such as nephropathy, retinopathy, and peripheral neuropathy.¹²⁶

The Heart Outcomes Prevention Evaluation (HOPE) Study compared the addition of an ACEI to the current medical regimen of high-risk patients. The substudy of 3577 diabetic patients (of a total population of 9541 participants in the HOPE Study) showed a reduction of the primary combined outcome of MI, stroke, and cardiovascular death by 25% (95% CI 12 to 36; $P=0.0004$) and stroke by 33% (95% CI 10 to 50; $P=0.0074$) among diabetic patients with a previous cardiovascular event or an additional cardiovascular risk factor.¹²⁷ Whether these benefits were a specific effect of the ACEI or were an effect of blood pressure lowering has been the subject of debate. Diabetic complications (overt nephropathy, dialysis, or need for laser therapy) were also reduced.

TABLE 7. Other Guideline Recommendations

Factor	Goal	Recommendations
Cigarette smoking ¹¹⁹	Cessation	Strongly encourage patient and family to stop smoking. Provide counseling, nicotine replacement, and formal programs as available.
Diabetes	Avoid environmental tobacco smoke	Improve glucose control through diet, oral hypoglycemics, and insulin. See guidelines and policy statements.*
	Improved glucose control	
	Treatment of hypertension	
Asymptomatic carotid stenosis	Consider statin	Endarterectomy may be considered in selected patients with $\geq 60\%$ and $< 100\%$ carotid stenosis, performed by surgeon with surgical morbidity/mortality rate $< 3\%$. Careful patient selection should be guided by comorbid conditions, life expectancy, patient preference, and other individual factors. Patients with asymptomatic stenosis should be fully evaluated for other treatable causes of stroke.
	...	
Sickle cell disease	Monitor children with SCD with transcranial Doppler for development of vasculopathy (see text)	Institute transfusion therapy for children who develop evidence of sickle cell vasculopathy (see text).
Physical activity ³¹⁸	≥ 30 Minutes of moderate-intensity activity daily	Encourage moderate exercise (eg, brisk walking, jogging, cycling, or other aerobic activity). Incorporate medically supervised programs for high-risk patients (eg, cardiac disease) and adaptive programs according to physical/neurological deficits.
Poor diet/nutrition	Well-balanced diet	A diet containing ≥ 5 servings of fruits and vegetables per day may reduce the risk of stroke.
Alcohol ¹¹⁹	Moderation	Men should consume no more than 2 drinks/day, and nonpregnant women should consume no more than 1 drink/day.
Drug abuse ¹¹⁹	Cessation	An in-depth history of substance abuse should be included as part of a complete health evaluation for all patients.
Oral contraceptive use	Avoid in those at high risk	Inform patients about stroke risk and encourage alternative forms of birth control among women who smoke cigarettes, have migraines (especially with older age or smoking), are ≥ 35 y of age, or have had prior thromboembolic events.
Sleep-disordered breathing	Successful treatment of sleep-disordered breathing	Consider sleep laboratory evaluation in patients with snoring, excessive sleepiness, and vascular risk factors, particularly if body mass index is > 30 and drug-resistant hypertension is present.

Refer to text for Class and Level of Evidence.

The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study compared the effects of an angiotensin II type 1 receptor blocker with a β -adrenergic receptor blocker in 9193 persons with essential hypertension (160 to 200/95 to 115 mm Hg) and electrocardiographically determined LV hypertrophy over 4 years.⁸⁵ Blood pressure reductions were similar for each group. The 2 regimens were compared among the subgroup of 1195 persons who also had diabetes in a prespecified analysis.¹²⁸ There was a 24% reduction (RR=0.76; 95% CI 0.58 to 0.98) in major vascular events and a nonsignificant 21% reduction (RR=0.79; 95% CI 0.55 to 1.14) in stroke among those treated with the ARB.

Although secondary subgroup analyses of some studies did not find a benefit of statins in diabetic subjects,^{129,130} the Medical Research Council/British Heart Foundation Heart Protection Study (HPS) found that the addition of a statin to existing treatments in high-risk patients resulted in a 24% reduction (95% CI 19% to 28%) in the rate of major vascular events.¹³¹ A 22% reduction (95% CI 13% to 30%) in major vascular events (regardless of the presence of known coronary heart disease or cholesterol levels) and

a 24% reduction (95% CI 6% to 39%; $P=0.01$) in strokes occurred among 5963 diabetic individuals treated with the statin in addition to best medical care.¹³² The Collaborative Atorvastatin Diabetes Study (CARDS) reported that in type 2 diabetic subjects with at least 1 additional risk factor (retinopathy, albuminuria, current smoking, or hypertension) and a low-density lipoprotein (LDL) cholesterol level < 160 mg/dL but without a prior history of cardiovascular disease, treatment with a statin resulted in a 48% reduction (95% CI 11% to 69%) in stroke.¹³³

Summary and Gaps

A comprehensive program that includes tight control of hypertension with ACEI or ARB treatment reduces the risk of stroke in persons with diabetes. Glycemic control reduces microvascular complications, but evidence showing a reduction in stroke risk with tight glycemic control is lacking. Adequately powered studies show that treatment of diabetic patients with a statin decreases their risk of a first stroke.

Recommendations

It is recommended that hypertension be tightly controlled in patients with either type 1 or type 2 diabetes (the JNC 7

recommendation of <130/80 mm Hg in diabetic patients is endorsed) as part of a comprehensive risk-reduction program (Table 6) (Class I, Level of Evidence A). Treatment of adults with diabetes, especially those with additional risk factors, with a statin to lower the risk of a first stroke is recommended (Class I, Level of Evidence A) (Table 7).¹³⁴ Recommendations to consider treatment of diabetic patients with an ACEI or ARB^{76,134} are endorsed (Table 7).

Atrial Fibrillation

With or without atrial fibrillation, all patients with mechanical heart valves require anticoagulation, with the target level of anticoagulation varying according to the type and position of the valve and the presence of other risk factors (Class I).¹³⁵ The rate of thromboembolism in patients with mechanical heart valves is 4.4 per 100 patient-years without antithrombotic therapy, 2.2 per 100 patient-years with antiplatelet drugs, and 1 per 100 patient-years with warfarin.¹³⁶ Patients with paroxysmal or persistent atrial fibrillation and valvular heart disease such as mitral stenosis are at the highest risk for future embolic events and should also be anticoagulated (Class I).¹³⁵

Atrial fibrillation alone is associated with a 3- to 4-fold increased risk of stroke after adjustment for other vascular risk factors (Table 3).¹³⁷ For those without prior transient ischemic attack (TIA) or stroke, 2% to 4% per year have an ischemic stroke.^{138,139} About 60 000 strokes occur annually among the estimated 2.3 million Americans with this cardiac dysrhythmia, with the number of atrial fibrillation-related strokes anticipated to more than double in coming decades.¹⁴⁰

The prevalence of atrial fibrillation increases with age. Atrial fibrillation affects $\approx 5\%$ of those ≥ 70 years of age, and the mean age of atrial fibrillation patients is 75 years.^{137,140} Estimates of attributable risk reveal that about one quarter of strokes in the very elderly (≥ 80 years old) are due to atrial fibrillation.¹³⁷ Atrial fibrillation is also associated with increased mortality after adjustment for other vascular risk factors.¹⁴¹ Strokes associated with atrial fibrillation are espe-

cially large and disabling. Importantly, rhythm control does not appear to reduce stroke rates,¹⁴² and as discussed below, antithrombotic therapies remain the mainstay for stroke prevention.

Randomized clinical trials have firmly established the value of antithrombotic therapies for reducing the risk of stroke in patients with atrial fibrillation (Table 3). Risk is reduced by $\approx 60\%$ with adjusted-dose warfarin and by $\approx 20\%$ with aspirin.¹⁴³ Adjusted-dose warfarin reduces stroke by $\approx 45\%$ as compared with aspirin.¹³⁹ Randomized trials have also been conducted comparing a direct thrombin inhibitor to high-quality adjusted-dose warfarin in persons with atrial fibrillation, but the US Food and Drug Administration has not approved its use.^{144,145}

The absolute risk of stroke varies 20-fold among atrial fibrillation patients, according to age and associated vascular diseases. Several stroke risk-stratification schemes have been developed and validated.¹⁴⁶⁻¹⁴⁸ The 2001 American College of Cardiology (ACC)/AHA/European Society of Cardiology (ESC) guideline recommends anticoagulation for patients with atrial fibrillation who are >60 years of age and have a history of hypertension, diabetes, coronary artery disease (CAD), impaired LV systolic function, heart failure, or prior thromboembolism, and for all those with atrial fibrillation who are >75 years of age.¹⁴⁹ However, this stratification scheme had not been prospectively validated (although the individual factors had been validated). Since publication of the 2001 ACC/AHA/ESC guideline, the so-called CHADS₂ stratification scheme has been proposed and validated.¹⁴⁶ (CHADS₂ is an acronym for congestive heart failure, hypertension, age >75 years, diabetes mellitus, and prior stroke or TIA.) The CHADS₂ score was derived from independent predictors of stroke risk in patients with nonvalvular atrial fibrillation (Table 8).¹⁴⁶ The score gives 1 point each for congestive heart failure, hypertension, age ≥ 75 years, and diabetes mellitus and 2 points for prior stroke or TIA.¹⁴⁶ The score was validated in a large cohort study and in clinical trials.^{138,147} Atrial fibrillation patients with low ($\approx 1\%$ /year,

TABLE 8. Nonvalvular Atrial Fibrillation Risk Stratification and Treatment Recommendations: Risk Stratification by CHADS₂ Scheme

CHADS ₂ Score	Risk Level	Stroke Rate	Treatment Recommendations Based on Risk Stratification
0	Low	1.0%/y	Aspirin (75–325 mg/d)
1	Low-moderate	1.5%/y	Warfarin INR 2–3 or aspirin (75–325 mg/d)†
2*	Moderate	2.5%/y	Warfarin INR 2–3†
3	High	5.0%/y	Warfarin INR 2–3‡
≥ 4	Very high	$>7\%/y$	

Congestive heart failure, hypertension, age >75 y, or diabetes = 1 point. Stroke or TIA* = 2 points.

For validation of the CHADS₂ scheme, see Gage et al^{146,147} and Go et al.¹³⁸

*All nonvalvular atrial fibrillation patients with prior stroke or transient ischemic attack should be considered high risk and treated with anticoagulants (see text); the CHADS₂ scheme should be applied for primary prevention.

†Consider patient preferences, bleeding risk, and access to good INR monitoring. For those with a CHADS₂ score=1, the number needed to treat to prevent 1 stroke over 1 y with warfarin is ≈ 100 ; excellent anticoagulation control is essential to achieve this benefit.

‡If patient is >75 y of age, an INR target of 1.6–2.5 is recommended by some, but not all, experts (see text).

CHADS₂ score=0 to 1, about half of patients), moderate (2.5%/year, CHADS₂ score=2, ≈25% of patients), and high (>5%/year, CHADS₂ score ≥3, ≈25% of patients) stroke risk were reliably predicted.¹³⁸ An apparent limitation of the CHADS₂ scheme that applies to secondary prevention involves patients with prior stroke or TIA and no other risk factors. These rare patients score 2 on the CHADS₂ scale (moderate risk), but in the validation study of the CHADS₂ score, patients with prior stroke or TIA averaged 10.8 strokes per 100 patient-years.¹⁴⁷ In the Stroke Prevention in Atrial Fibrillation (SPAF) 2012 aspirin analysis, the few patients with prior stroke or TIA without other risk factors (which included the CHADS₂ risk factors except heart failure) had a stroke rate of 5.9%/year (95% CI 2 to 18).¹⁵⁰ Therefore, patients with prior stroke or TIA in the setting of atrial fibrillation without additional risk factors should be considered at high risk for recurrence and should be treated with warfarin unless contraindicated. For patients with echocardiographic data, the SPAF III scheme has also been validated.^{147,148}

The threshold of absolute stroke risk warranting anticoagulation is importantly influenced by the estimated bleeding risk if anticoagulated, patient preferences, and access to high-quality anticoagulation monitoring. Risk stratification is the first step in the decision process (Table 8). Most patients with atrial fibrillation who are <75 years of age without prior stroke or TIA have a relatively low risk of stroke (1% to 2% per year) if given aspirin, and they do not benefit sufficiently from anticoagulation to warrant its use for primary stroke prevention.^{138,151,152} It is generally agreed that atrial fibrillation patients whose estimated stroke risk exceeds 4% per year should be anticoagulated in the absence of contraindications.¹⁵³

Several studies have found that only about half of patients with atrial fibrillation who are candidates for anticoagulation receive warfarin.^{154–156} Anticoagulation is particularly underused in elderly patients with atrial fibrillation.¹⁵⁷ Although the attributable risk of stroke associated with atrial fibrillation increases with age,¹³⁵ elderly (ie, ≥75 years of age) atrial fibrillation patients have about twice the risk of serious bleeding complications during anticoagulation as compared with younger patients.¹⁵⁸ Nevertheless, anticoagulation is still warranted if their risk of ischemic stroke without warfarin is greater than their risk of bleeding.¹³⁹ In addition to age, poorly controlled hypertension and concomitant aspirin or nonsteroidal antiinflammatory drug use confer higher bleeding risk during anticoagulation. Therefore, age per se is not a contraindication to the anticoagulation of high-risk atrial fibrillation patients.

The optimal target international normalized ratio (INR) for primary prevention of stroke in patients with nonvalvular atrial fibrillation appears to be 2.0 to 2.5.¹⁵⁹ This range is too narrow for practical management, and a range of 2 to 3 is generally recommended for most atrial fibrillation patients.^{153,160} For primary prevention in the very elderly (for whom the lowest efficacious intensity of anticoagulation is particularly important to minimize bleeding), a target INR of 2 (target range 1.6 to 2.5) is recommended by some experts,^{153,159,161} although others favor a target range of 2 to 3 for atrial fibrillation patients of all ages.¹⁶²

The importance of treatment of hypertension is discussed in a previous section. Hypertension is also an independent risk factor for stroke in atrial fibrillation patients (particularly those with systolic blood pressure >160 mm Hg). It is unclear whether sustained control of hypertension in atrial fibrillation patients reduces cardiogenic embolism. However, intracerebral bleeding, the most devastating complication of anticoagulation in the elderly, is exquisitely sensitive to blood pressure control.¹⁶³ Control of hypertension in atrial fibrillation patients is therefore critically important, reducing both the risk of ischemic stroke and the risk of intracerebral hemorrhage complicating antithrombotic therapy.¹⁶⁴

Summary and Gaps

Atrial fibrillation is an important, treatable stroke risk factor. Validated stroke risk-stratification schemes identify those at particularly low risk (<2% per year) who can be treated with aspirin. It should be noted that guideline statements from different groups may vary in their recommendations about risk stratification. Long-term anticoagulation importantly reduces stroke risk in those at higher risk and without contraindications to this treatment. The development of safer, easier-to-use oral anticoagulants might improve the risk-benefit ratio. Controversy remains about the optimal target level of anticoagulation in those at risk of increased bleeding. Many patients with atrial fibrillation, particularly those >75 years of age, who would benefit from anticoagulation do not receive this treatment.¹⁶⁵

Recommendations

Anticoagulation of patients with atrial fibrillation who have valvular heart disease (particularly those with mechanical heart valves) is recommended (Class I, Level of Evidence A). Antithrombotic therapy (warfarin or aspirin) is recommended to prevent stroke in patients with nonvalvular atrial fibrillation according to assessment of their absolute stroke risk, estimated bleeding risk, patient preferences, and access to high-quality anticoagulation monitoring (Table 8) (Class I, Level of Evidence A). Warfarin (INR 2.0 to 3.0) is recommended for high-risk (>4% annual risk of stroke) patients (and most moderate-risk patients according to an assessment of bleeding risk) with atrial fibrillation who have no clinically significant contraindications to oral anticoagulants (Class I, Level of Evidence A).

Other Cardiac Conditions

Other types of cardiac disease that can contribute to the risk of thromboembolic stroke include dilated cardiomyopathy, valvular heart disease (eg, mitral valve prolapse, endocarditis, prosthetic cardiac valves), and intracardiac congenital defects (eg, patent foramen ovale [PFO], atrial septal defect, atrial septal aneurysm). Potential cardiac sources of emboli are associated with up to 40% of cryptogenic strokes in some series involving the younger population.¹⁶⁶ The presence of cerebrovascular disease is strongly associated with the presence of symptomatic^{167–169} and asymptomatic^{170–174} cardiac disease. In addition, MI is associated with the development of atrial fibrillation and is a source of cardiogenic emboli.¹⁴¹ Because of shared risk factors, patients with MI represent a group that is also at increased risk of stroke. Acute coronary

syndromes are infrequently associated with stroke in the acute setting, occurring in 0.8% of patients.^{175–177} The majority of these strokes (0.6%) are ischemic.¹⁷⁶

Although a detailed review of the management of cardiac conditions is beyond the scope of this guideline, several points will be highlighted. The incidence of stroke is inversely proportional to cardiac ejection fraction. Patients with MI who have an ejection fraction <29% have a RR of stroke of 1.86, as compared with patients who have an ejection fraction of >35% ($P=0.01$; an 18% increase in stroke risk for every 5% decline in ejection fraction).¹⁷⁸ The use of warfarin for cardioembolic prophylaxis in patients with reduced LV ejection fraction in the setting of idiopathic cardiomyopathy remains controversial, and trials are in progress comparing warfarin with antiplatelet treatment.

Perioperative stroke occurs in 1% to 7% of patients undergoing cardiac surgical procedures (predominantly coronary artery bypass procedures and open heart surgery). A history of prior neurological events, increasing age, diabetes, and atrial fibrillation have been identified as risk factors for early and delayed stroke after cardiac surgery.^{179–190} Other factors associated with perioperative stroke include duration of cardiopulmonary bypass and the presence of aortic atherosclerosis.^{191,192} Studies proving the benefits of specific prophylactic procedures are lacking.

Summary and Gaps

In addition to atrial fibrillation, a variety of cardiac conditions have been associated with an increased risk of stroke. Data on the relative benefits and risks of specific prophylactic interventions are beyond the scope of this document.

Recommendations

Various AHA/ACC practice guidelines recommend strategies to reduce the risk of stroke in patients with a variety of cardiac conditions. These include the management of patients with valvular heart disease,¹³⁶ unstable angina,¹⁹³ chronic stable angina,¹⁹⁴ and acute MI.¹⁹⁵ Strategies to prevent postoperative neurological injury and stroke in patients undergoing surgical revascularization for atherosclerotic heart disease are discussed in detail in the recently published coronary artery bypass graft surgery guidelines.¹⁹⁶ It is reasonable to prescribe warfarin to post-ST-segment-elevation MI patients with LV dysfunction with extensive regional wall-motion abnormalities (Class IIa, Level of Evidence A), and warfarin may be considered in patients with severe LV dysfunction, with or without congestive heart failure (Class IIb, Level of Evidence C).¹⁹⁷

Dyslipidemia

Epidemiological studies initially found no consistent association between cholesterol levels and overall stroke rates but were likely confounded by the inclusion of hemorrhagic as well as ischemic stroke.^{198–201} Three prospective studies in men subsequently showed increases in ischemic stroke rates at higher levels of total cholesterol, particularly for levels above 240 to 270 mg/dL.^{199,200,202} The Asia Pacific Cohort Studies Collaboration, which included 352 033 individuals, found a 25% increase in ischemic stroke rates for every 1-mmol/L (38.7-mg/dL) increase in total cholesterol.²⁰³ The

Eurostroke project (22 183 subjects, 34% female) found only a trend toward increased risk with 6% more cases of cerebral infarction for every 1-mmol/L increase in total cholesterol.²⁰⁴ The US Women's Pooling Project (24 343 women at risk) found a 25% increased risk of fatal ischemic stroke for each 1-mmol/L increase in total cholesterol in women 30 to 54 years of age.²⁰⁵ Therefore, there does appear to be a clear relationship between dyslipidemia and the risk of ischemic stroke in both men and women (Table 3).

Only a few studies have analyzed the relationship between LDL cholesterol (the major component of total cholesterol) and ischemic stroke. No consistent association has been found, although the total number of subjects at risk in these studies is limited.^{206–208}

The relationship between HDL cholesterol and ischemic stroke is best determined from prospective studies because tissue inflammation and caloric deficit can reduce HDL levels after stroke. The Copenhagen City Heart Study, including both sexes, found a 47% reduction of ischemic stroke events for every 1-mmol/L increase in HDL cholesterol.²⁰⁹ In 3 prospective population-based studies, men had significantly increased rates of ischemic stroke at low HDL cholesterol levels, especially levels <30 to 35 mg/dL.^{202,210,211} The Eurostroke project found fewer ischemic strokes in men with low HDL (nonsignificant trend) but more ischemic strokes in women with low HDL (marginally significant).²⁰⁴ Studies in Japan and the United States found trends toward higher ischemic stroke rates in women with low HDL.^{208,211} Thus, it appears that low HDL is a risk factor for ischemic stroke in men, but more data are needed to verify its effect in women.

Triglyceride levels vary considerably, making elevated levels difficult to evaluate as a risk factor for stroke. Elevated triglycerides are a component of the metabolic syndrome. Trends toward higher triglyceride levels in patients who subsequently experience ischemic stroke have been reported.^{206,209} In a study of 11 117 subjects with CAD, ischemic cerebrovascular events were significantly associated with high triglyceride and low HDL cholesterol levels.²⁰⁷

Carotid intima-media thickness, measured by B-mode ultrasound, is an atherosclerotic disease marker. Lipoprotein levels have been correlated with carotid intima-media thickness.²¹² In clinical trials, colestipol-niacin combination therapy, statin monotherapy, and statin-niacin combination therapy each retarded the progression of asymptomatic carotid atherosclerosis assessed by carotid intima-media thickness.^{213–217}

HMG-CoA reductase inhibitors (statins) have received regulatory approval for the prevention of ischemic stroke in patients with CAD; the approval was based on consistent benefits in large randomized trials using these agents.^{27,83,214,218} Additional studies include the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT), which enrolled high-risk hypertensive subjects, and the Heart Protection Study, which enrolled high-risk subjects mostly with previous coronary events.^{129,219} In these studies, stroke rates were reduced 27% to 32% among subjects assigned to the statin as compared with placebo. Another statin trial including elderly people (≥ 70 years of age) found no effect on total stroke rate but did find a 25% reduction in TIAs. However, confidence intervals in this study were wide, so a beneficial effect on stroke cannot be excluded.²²⁰ Among a comparable

number of elderly people in the Heart Protection Study, statin therapy reduced the rate of first strokes by 29%.²¹⁹ In a combined analysis of 9 trials, statin treatment was estimated to prevent 9 strokes per 1000 coronary heart disease or high-risk patients treated for 5 years.²²¹ The Treating to New Targets (TNT) Trial randomized 10 001 persons with stable coronary heart disease and an LDL cholesterol level <130 mg/dL to high- and low-dose statins, achieving mean LDL cholesterol levels of 101 and 77 mg/dL, respectively.²²² Those in the high-dose group had fewer major vascular events (10.9% versus 8.7%; HR=0.78; 95% CI 0.69 to 0.89; $P<0.0001$), including fewer fatal and nonfatal strokes (3.1% versus 2.3%; HR=0.75; 95% CI 0.59 to 0.96; $P=0.02$).

Nonstatin lipid-modifying therapies may also offer stroke protection, although the supporting data are less certain. Niacin treatment was associated with a 24% reduction in known or suspected cerebrovascular events (including TIAs) in the Coronary Drug Project.²²³ The effect of niacin on stroke rate was similar but not significant.²²³ The Veterans Administration HDL Intervention Trial (VA-HIT) evaluated the effect of gemfibrozil in men with coronary heart disease and low levels of HDL cholesterol (≤ 40 mg/dL).²²⁴ There was a trend toward a reduction in strokes in the treated group (6.0% versus 4.6%; HR=0.75; 95% CI 0.53 to 1.06; $P=0.10$). HDL cholesterol can be increased by 25% to 40% when multiple modalities are used, especially when niacin is included.^{225,226}

Summary and Gaps

Plasma lipids and lipoproteins (total cholesterol, triglycerides, LDL cholesterol, HDL cholesterol, and lipoprotein[a]) affect the risk of ischemic stroke, but the exact relationships are still being clarified. In general, increasing levels of total cholesterol are associated with higher rates of ischemic stroke. Low HDL is a risk factor for ischemic stroke in men, but more data are needed to determine its effect in women. Lipid-modifying medications can substantially reduce the risk of stroke in patients with coronary heart disease. Additional studies are needed to clarify the risk associated with lipoproteins in women and the effect of treatment in older persons (>70 to 75 years of age).

Recommendations

National Cholesterol Education Program III guidelines for the management of patients who have not had a cerebrovascular event and who have elevated total cholesterol or elevated non-HDL cholesterol in the presence of hypertriglyceridemia are endorsed (Table 9).^{227,228} It is recommended that patients with known CAD and high-risk hypertensive patients even with normal LDL cholesterol levels be treated with lifestyle measures and a statin (Class I, Level of Evidence A). The use of lipid-lowering therapy in diabetic patients is specifically addressed in that section of this guideline. Suggested treatments for patients with known CAD and low HDL cholesterol include weight loss, increased physical activity, smoking cessation, and possibly niacin or gemfibrozil (Class IIa, Level of Evidence B).

Asymptomatic Carotid Stenosis

In the Cardiovascular Health Study, a carotid stenosis >50% was detected in 7% of the men and 5% of the women >65

years of age, with 1.2% and 1.1% having a 75% to 99% stenosis, respectively.²²⁹ Similarly, stenoses of $\geq 50\%$ were detected in 9% of men and 7% of women in the Framingham cohort 66 to 93 years of age; 2% of men and 0.7% of women had stenoses in the 81% to 100% range.²³⁰ The Berlin Aging Study, a population-based study of functionally healthy volunteers 70 to 100 years of age, found a 4% prevalence of $\geq 75\%$ carotid stenoses among both men and women.²³¹ Therefore, it seems likely that between 5% and 10% of men and women >65 years of age have carotid stenoses >50%, with $\approx 1\%$ having stenoses >80%.

Natural history studies reflect an annual stroke risk between $\approx 1\%$ and 3.4% among persons with an asymptomatic carotid artery stenosis between 50% and 99%.^{232–237} Most of these studies focused on short-term follow-up (ie, 2 to 3 years). However, at least 1 cohort study found similar rates of ipsilateral stroke over 10 years (9.3%; 95% CI 1% to 18%; 0.9%/year) and 15 years (16.6%; 95% CI 1% to 32%; 1.1%/year).²³⁸

Several studies have attempted to identify subgroups of patients with asymptomatic carotid artery stenosis who may be at particularly elevated stroke risk. The Toronto Asymptomatic Cervical Bruit Study followed a cohort of 500 patients for a mean of 23 months.²³⁴ Overall, cerebral ischemic events (TIA or stroke) were more frequent in patients with severe (narrowed >75%) carotid artery stenosis, progressing carotid artery stenosis, or heart disease, and in men. A total of 8 patients (1.6%) had an unheralded stroke; however, only 2 (0.4%) were ipsilateral to a high-grade extracranial carotid artery stenosis as demonstrated by Doppler ultrasonography. In another study, 38 asymptomatic patients with >90% stenosis of the internal carotid artery were followed up for a mean period of 48 months.²³⁵ Each year, 1.7% of the patients had an unheralded ipsilateral stroke. The North American Symptomatic Carotid Endarterectomy Trial investigators retrospectively reviewed their data on the risk of stroke in the territory of an asymptomatic carotid artery stenosis contralateral to the side of a symptomatic vessel.^{239,240} The annual risk of stroke was 3.2% (over 5 years) in patients with a 60% to 99% asymptomatic stenosis. The average annual risk of ipsilateral stroke increased from 3.0% for those with 60% to 74% stenosis to 3.7% for those with 75% to 94% stenosis and decreased to 2.9% for those with 95% to 99% stenosis, with a rate of 1.9% for those with complete occlusion. Overall, 45% of ipsilateral strokes in patients with asymptomatic stenosis contralateral to a symptomatic stenosis could be attributable to lacunes or cardioemboli, underscoring the need to fully evaluate patients with asymptomatic carotid stenosis for other treatable causes of stroke.

Taken together, these and other observational studies suggest that the rate of unheralded stroke ipsilateral to a hemodynamically significant extracranial carotid artery stenosis is $\approx 1\%$ to 2% annually, with some data suggesting that the rate of stroke may be higher in those persons with progressing stenosis and in those with more severe stenosis (Table 3). However, it should be noted that most of these studies were carried out before the widespread use of HMG-CoA reductase inhibitors (ie, statins), which may be associated with a stabilization or reduction in carotid atherosclerotic

TABLE 9. Dyslipidemia: Guideline Management Recommendations*

Factor	Goal	Recommendations
LDL-C ^{227,228}		
0–1 CHD risk factor*	LDL-C <160 mg/dL	Diet, weight management, physical activity. Drug therapy recommended if LDL-C remains \geq 190 mg/dL. Drug therapy optional for LDL-C 160–189 mg/dL.
\geq 2 CHD risk factors and 10-y CHD risk <20%	LDL-C <130 mg/dL	Diet, weight management, physical activity. Drug therapy recommended if LDL-C remains \geq 160 mg/dL.
\geq 2 CHD risk factors and 10-y CHD risk 10% to 20%	LDL-C <130 mg/dL, or optionally LDL-C <100 mg/dL	Diet, weight management, physical activity. Drug therapy recommended if LDL-C remains \geq 130 mg/dL (optionally \geq 100 mg/dL).
CHD or CHD risk equivalent† (10-y risk >20%)	LDL-C <100 mg/dL, or optionally LDL-C <70 mg/dL	Diet, weight management, physical activity. Drug therapy recommended if LDL-C is \geq 130 mg/dL. Drug therapy optional for LDL-C 70–129 mg/dL.
Non-HDL-C in persons with triglycerides \geq 200 mg/dL ²²⁷	Goals are 30 mg/dL higher than LDL-C goal.	Same as LDL-C with goals 30 mg/dL higher.
Low HDL-C ²²⁷	No consensus goal	Weight management, physical activity. Consider niacin (nicotinic acid) or a fibrate in high-risk individuals with HDL-C <40 mg/dL.
Lp(a)	No consensus goal	Treat other atherosclerotic risk factors in subjects with high Lp(a). Consider niacin (immediate- or extended-release formulation) up to 2000 mg/d ⁴⁶⁹ for reduction of Lp(a) levels, optimally in conjunction with glycemic control ⁴⁶⁸ and LDL control. ⁴⁵⁸

CHD indicates coronary heart disease; HDL-C, HDL cholesterol; LDL-C, LDL cholesterol; and Lp(a), lipoprotein a.

*To screen for dyslipidemia, a fasting lipoprotein profile (cholesterol, triglycerides, HDL-C, and LDL-C) should be obtained every 5 y in adults. It should be obtained more often if \geq 2 CHD risk factors are present (risk factors include cigarette smoking, hypertension, HDL-C <40 mg/dL, CHD in a male first-degree relative <55 y of age or in a female first-degree relative <65 y of age, or age \geq 45 y for men or \geq 65 y for women) or if LDL-C levels are borderline or high. Screening for Lp(a) is not recommended for primary prevention unless (1) unexplained early cardiovascular events have occurred in first-degree relatives or (2) high Lp(a) is known to be present in first-degree relatives.²²⁷

†CHD risk equivalents include diabetes or other forms of atherosclerotic disease (peripheral arterial disease, abdominal aortic aneurysm, symptomatic carotid artery disease).

disease,^{214–216,241–243} and the rigor of adherence to other preventive strategies as reviewed in this guideline is not known. As with asymptomatic carotid bruit, an asymptomatic stenosis of the carotid artery is an important indicator of concomitant ischemic cardiac disease.^{234,235,237,238}

There have been 2 underpowered and 3 larger published randomized controlled trials designed to assess the benefit of carotid endarterectomy in patients with asymptomatic carotid artery stenosis. The Mayo Clinic Asymptomatic Carotid Endarterectomy (MACE) Study included 71 randomized and 87 nonrandomized patients.²⁴⁴ Surgically treated patients were not given aspirin. There were no major strokes or deaths in either group. However, the study was stopped because MI occurred in 26% of those in the surgical arm (no aspirin) as compared with 9% of those in the aspirin-treated medical arm ($P=0.002$), reflecting the high incidence of concomitant CAD in patients with an asymptomatic carotid artery stenosis.

Of the larger trials, the VA Cooperative Study of carotid endarterectomy for patients with asymptomatic carotid artery stenosis included 444 men followed up for a mean of 48 months.²⁴⁵ Two hundred eleven patients received best medical therapy plus carotid endarterectomy, and 233 received medical therapy alone (including 650 mg of aspirin twice

daily). Patients had >50% stenosis of the extracranial carotid artery demonstrated by angiography. Combined perioperative and angiographic risk was 4.7%. There was a 38% risk reduction for the combined end points of ipsilateral TIA, transient monocular blindness, and stroke over 2 years ($P<0.001$). Although the rate of fatal and nonfatal stroke was reduced in the surgical group (4.7% versus 9.4%, or 1.2%/year versus 2.4%/year), the difference was not significant ($P=0.08$). However, the study was not powered to detect differences in outcome subgroups.

The Asymptomatic Carotid Atherosclerosis Study (ACAS) was a randomized trial investigating the efficacy of carotid endarterectomy in patients with asymptomatic high-grade (>60% diameter reduction) carotid artery stenosis.²⁴⁶ Patients ($n=1662$) were randomized to surgery plus medical therapy ($n=828$) or to medical therapy without carotid endarterectomy ($n=834$). There was a 1.2% risk of angiography-related complications among the 414 patients undergoing postrandomization angiograms and a 1.5% 30-day risk of stroke or death among those having endarterectomy (overall 2.7% rate of perioperative stroke or death). The study was halted after a median follow-up of 2.7 years (4465 patient-years) because a significant benefit of surgery was

found. The aggregate rate of ipsilateral stroke, any perioperative stroke, or death in surgically treated patients was estimated at 5% over 5 years; in medically treated patients, the corresponding rate was 11% (53% risk reduction, approximate 2%/year event rate reduced to 1%/year; $P=0.004$). The benefit began to accrue after 1 to 2 years. As with the VA Trial, the study was not powered to detect differences among patient subgroups. However, there was no relationship between benefit and the degree of carotid artery stenosis, and women appeared to benefit less than men (17% nonsignificant risk reduction in women, 95% CI -4% to 65%, versus a 66% risk reduction in men, 95% CI 36% to 82%), a difference at least partially ascribed to a higher rate of perioperative complications in women (3.6% versus 1.7%). Despite the differences in point estimates, a definite difference between men and women cannot be concluded because of the wide confidence intervals and the post hoc nature of analysis. Although a large population-based study did not find a significant overall difference in endarterectomy complication rates in women as compared with men, asymptomatic patients were not analyzed separately.²⁴⁷ Consistent with the ACAS observation, a retrospective study also noted an increased risk of perioperative complications after endarterectomy in asymptomatic women as compared with men.²⁴⁸

Begun before the completion of ACAS, the Medical Research Council Asymptomatic Surgery Trial (ACST) is the largest randomized trial comparing a strategy of immediate versus deferred carotid endarterectomy in persons with asymptomatic stenosis.²⁴⁹ Between 1993 and 2003, ACST enrolled 3120 patients without relevant symptoms in the prior 6 months who had at least a 60% diameter reduction carotid stenosis according to ultrasound (few had cerebral angiograms). There was a 3.1% (95% CI 2.3% to 4.1%) risk of stroke or death within 30 days of the operation. It should be noted that although the overall periprocedural complication rate was similar to that in ACAS, the point estimate of the ACST surgical complication rate was approximately twice that of ACAS (ACAS: 1.2% arteriography + 1.5% surgical = 2.7%; ACST: 3.1% surgical). The overall 5-year risk of any stroke or perioperative death was 11.8% with deferred surgery versus 6.4% with immediate endarterectomy ($P<0.0001$; 2.4%/year reduced to 1.3%/year). For fatal or disabling strokes, the respective rates were 6.1% versus 3.5% ($P=0.004$; 1.2%/year reduced to 0.7%/year). The benefit began to accrue after ≈ 2 years. Although subgroup analyses again need to be interpreted with caution, as in ACAS, there did not appear to be any difference in benefit based on the degree of carotid stenosis (70% versus 80% or 90% stenosis). Although not significantly different, women benefited somewhat less than men after successful endarterectomy (4.1% [95% CI 0.7% to 7.4%] absolute 5-year benefit in women versus 8.2% [95% CI 5.6 to 10.8%] in men) but had a somewhat higher rate (albeit nonsignificant) of perioperative complications (3.8% versus 2.7%). Calculated from data provided in ACAS and ACST, surgical benefit (any stroke or perioperative death) is greater in men than in women (men: pooled interaction $P=0.01$, OR 0.49, 95% CI 0.36 to 0.60; women: OR 0.96, 95% CI 0.63 to 1.45). Therefore, it remains uncertain whether there is a benefit in women.²⁵⁰

Data presented in the ACST publication also permit calculation of the comparative rates of any stroke or death and of any major stroke or death. Similar to ACAS, the overall rate of any stroke or death was 31.2% for deferred endarterectomy versus 28.9% for immediate endarterectomy (RR reduction [RRR]=7%, 95% CI -3% to 17%; $P=0.172$). For any major stroke or death, the respective ACST rates were 25.5% versus 25.3% (RRR=7%; 95% CI -5% to 18%; $P=0.242$). These sobering data must be taken into account when the procedure is considered.

It should be noted that the benefit of endarterectomy in the setting of asymptomatic carotid artery stenosis is highly dependent on surgical risk, with the benefit being obviated by periprocedural complication rates in excess of the 2.7% to 3.1% rates observed in ACAS and ACST. Even after community-wide performance measurement and feedback, the overall risk for stroke or death after endarterectomy performed for asymptomatic stenosis in 10 US states was 3.8% (including 1% mortality).²⁵¹ Nevertheless, most physicians are not aware of the complication rates of the surgeon to whom they refer patients for the operation.^{252,253}

It is also important to recognize that surgery is only one of several potential treatments that can be used to reduce the risk of stroke in patients with asymptomatic carotid artery stenosis. Medical therapy was different at the time ACAS was performed as compared with current practice. Carried out later than ACAS, the ACST report indicates that at randomization there was "widespread use of antiplatelet and antihypertensive drugs" ($\approx 80\%$ and 60% to 75% , respectively) and increasing use of lipid-lowering drugs (17% among those randomized in the period 1993 to 1996, 58% in the period 2002 to 2003), with $>90\%$ on antiplatelet therapy, 81% on antihypertensives, and 70% on lipid-lowering therapy at the last follow-up visit.

Although highly selected patients may benefit, screening of general populations for asymptomatic carotid stenosis is unlikely to be cost-effective.²⁵⁴⁻²⁵⁶ The cost-effectiveness of even a one-time screening approach would be highly dependent on the ability to identify a group of persons with a high pretest likelihood of having high-grade asymptomatic disease, the availability of a screening test with a very high sensitivity and specificity when used on a wide-scale basis, and very low perioperative complication rates.

Carotid angioplasty with stenting has been available for several years, but clinical studies showing that it is equivalent or superior to carotid endarterectomy have been limited. The Stenting & Angioplasty with Protection in Patients at High Risk for Endarterectomy (SAPPHIRE) Trial found that this procedure was not inferior (within 3%, $P=0.004$) to carotid endarterectomy (based on a composite of stroke, death, or MI within 30 days, or death from neurological causes or ipsilateral stroke between 31 days and 1 year) in a cohort of patients considered at high risk for the operation.²⁵⁷ Approximately 70% of the enrolled patients had asymptomatic stenoses, with rates of stroke, MI, or death of 5.4% for stenting versus 10.2% for endarterectomy at 30 days ($P=0.20$) and 9.9% versus 21.5% at 1 year, respectively ($P=0.02$). Because these rates include MI (including those defined by cardiac enzyme elevations in the absence of electrocardiographic changes),

the results are not directly comparable to ACAS or ACST. However, even in the stenting arm, the cumulative 1-year end point rate of 9.9% is high as compared with the stroke risk associated with asymptomatic carotid artery stenosis (1% to 2%/year). There was no evidence in any subgroup that carotid stenting was superior to endarterectomy for the prevention of stroke as an end point. Because the study did not include medically treated controls, we cannot be certain how these asymptomatic, high-surgical-risk patients would have fared without either procedure.

Summary and Gaps

The results of ACST substantially support those of ACAS. Combining data from ACAS and ACST, the total 5-year risk of stroke or procedural morbidity was calculated at 11.5% for deferred endarterectomy versus 6.0% for immediate endarterectomy (5.5% absolute difference, number needed to treat=18 to prevent 1 event over 5 years).²⁴⁹ Perioperative risk is not balanced by benefit for ≈ 2 years. These types of results can only be achieved with periprocedural complication rates as low as those reported in these trials (ie, <3%). Although limited by post hoc and nonprespecified analyses, it is clear that careful patient selection is critical, with substantially less benefit or no benefit if all-cause mortality is considered as a part of the end points. The advent of carotid angioplasty-stenting offers another potential intervention. Given the low likelihood of ipsilateral stroke among patients with asymptomatic stenosis, complication rates will need to be in a similar range, and careful patient selection is imperative.

Recommendations

It is recommended that patients with asymptomatic carotid artery stenosis be screened for other treatable causes of stroke and that intensive therapy of all identified stroke risk factors be pursued (Class I, Level of Evidence C). The use of aspirin is recommended unless contraindicated because aspirin was used in all of the cited trials as an antiplatelet drug except in the surgical arm of 1 study, in which there was a higher rate of MI in those who were not given aspirin (Class I, Level of Evidence B). Prophylactic carotid endarterectomy is recommended in highly selected patients with high-grade asymptomatic carotid stenosis performed by surgeons with <3% morbidity/mortality rates (Table 7) (Class I, Level of Evidence A). Patient selection should be guided by an assessment of comorbid conditions and life expectancy, as well as other individual factors, should be balanced by an understanding of the overall impact of the procedure if all-cause mortality is considered as one of the end points, and should include a thorough discussion of the risks and benefits of the procedure with an understanding of patient preferences. Carotid angioplasty-stenting might be a reasonable alternative to endarterectomy in asymptomatic patients at high risk for the surgical procedure (Class IIb, Level of Evidence B); however, given the reported periprocedural and overall 1-year event rates, it remains uncertain whether this group of patients should have either procedure.

Sickle Cell Disease

Sickle cell disease (SCD) is inherited as an autosomal dominant disorder in which the abnormal gene product is an

altered hemoglobin β -chain. Although the clinical manifestations are highly variable, SCD typically manifests early in life as a severe hemolytic anemia with painful episodes involving the extremities and bones ("vaso-occlusive crises"), bacterial infections, and organ infarctions, including stroke. Other systemic effects include impaired growth and possible cognitive developmental retardation.²⁵⁸

Stroke prevention is most important for patients with homozygous SCD disease because most of the strokes associated with SCD occur in these patients. The prevalence of stroke by 20 years of age is at least 11%,²⁵⁹ with a substantial number having "silent" strokes on brain magnetic resonance imaging (MRI) (Table 3).²⁶⁰ The highest stroke rates occur in early childhood. Transcranial Doppler ultrasound (TCD) has made identification of those at highest risk of stroke possible, allowing rational decisions about treatment for primary stroke prevention.^{261,262} The risk of stroke during childhood in those with SCD is 1% per year, but patients with TCD evidence of high cerebral blood flow velocities (time-averaged mean velocity >200 cm/s) have a stroke rate in excess of 10% per year.²⁶² A randomized trial (Stroke Prevention Trial in Sickle Cell Anemia [STOP]) compared periodic blood transfusion with standard care in 130 children with SCD ranging in age from 2 to 16 years (mean 8 years).²⁶³ Blood transfusions were given an average of 14 times per year for >2 years in the treatment group, with a target reduction of hemoglobin S from a baseline of >90% to <30%. The risk of stroke was reduced from 10% per year to <1%.

The frequency of screening needed to detect most cases at risk has not been determined. Although the STOP study used time-averaged means of the maximum velocity, peak systolic velocity may also be used, with a threshold for prophylactic transfusion placed at 250 cm/s.²⁶⁴ In general, younger children and those with relatively high cerebral blood flow velocities should be monitored more frequently because of a higher risk of conversion to abnormal in younger patients and in those with TCD velocities closer to the 200-cm/s cutoff.²⁶⁵ In practice, studies may need to be repeated within days or weeks in cases at or near the threshold for treatment or may be performed annually for cases in which the risk of conversion to abnormal is low.

Unless exchange methods in which blood is removed from the patient with each transfusion are used, long-term transfusion is associated with iron toxicity that must be treated with chelation.²⁶⁶ In the STOP study, there was no evidence of transfusion-related infection, but iron overload and alloimmunization remain important transfusion risks.²⁶³ To address these risks, a randomized controlled trial of withdrawal of transfusion was conducted. This trial (STOP II) tested whether chronic transfusions for primary stroke prevention could be safely discontinued after at least 30 months (range 30 to 91 months) in children who had not had an overt stroke and who had reversion to low-risk TCD velocity with chronic transfusion therapy. Low-risk TCD velocity was defined as <170 cm/s time-averaged mean of the maximum. The study end points were the first occurrence of reversion of TCD to abnormal, confirmed by ≥ 2 TCDs with mean velocities of 200 cm/s or higher, or stroke. The study was stopped after 79 of a planned sample of 100 children were randomized when

an interim analysis showed poorer outcomes in those who had transfusion therapy discontinued. Eight children ($\approx 20\%$) tolerated removal from chronic transfusion therapy without apparent adverse consequences, but discontinuation of transfusion after 30 months is not recommended on the basis of STOP II because of a high TCD reversion rate and the small risk of overt stroke despite frequent TCD surveillance.²⁶⁷

MRI has also been used to identify children with SCD who are at risk before clinical events. Observational data from the Cooperative Study of Sickle Cell Disease, which preceded the use of TCD-based monitoring, found that 8.1% of children with an asymptomatic MRI lesion versus 0.5% of those with a normal MRI had a stroke during the ensuing 5 years.²⁶⁸ A randomized controlled trial of MRI-guided prophylactic transfusion is in progress (the Silent Infarct Treatment Trial [SITT]).²⁶⁹ The role of therapies other than transfusion, such as bone marrow transplantation or hydroxyurea, which reduce the number of painful crises but have an uncertain effect on organ damage (including stroke), requires further study.^{270,271}

No systematic data are available on prevention of stroke in adults with SCD. Improvements in care have increased life expectancy in SCD, and it may be anticipated that stroke prophylaxis in older SCD patients will pose an increasing challenge in the future.

Summary and Gaps

TCD can be used to identify children with SCD who are at high risk of stroke and who may benefit from transfusion therapy. The optimal screening interval has not been established. As reviewed above, treatment criteria using peak systolic velocities have now been published. On the basis of STOP II, even those whose risk of stroke decreases with transfusion therapy according to TCD criteria have an $\approx 50\%$ probability of reverting to high risk or having a stroke if transfusion therapy is discontinued. Alternative methods of maintenance therapy that are safer than transfusion need to be developed in view of the data indicating the need for ongoing active treatment despite TCD normalization. Predictive methods other than TCD (eg, magnetic resonance–based techniques) should be systematically compared with, and combined with, TCD to further refine the estimation of stroke risk in individuals. Preventive therapies other than transfusion need to be tested. Data on risk and prevention options in adults with SCD are sorely inadequate, and a stroke prevention strategy for adults needs to be developed.

Recommendations

It is recommended that children with SCD be screened with TCD starting at 2 years of age (Table 7) (Class I, Level of Evidence B). It is recommended that transfusion therapy be considered for those at elevated stroke risk (Class I, Level of Evidence B). Although the optimal screening interval has not been established, it is reasonable that younger children and those with TCD velocities in the conditional range should be rescreened more frequently to detect development of high-risk TCD indications for intervention (Class IIa, Level of Evidence B). Pending further studies, it is reasonable to continue transfusion even in those whose TCD velocities revert to normal (Class IIa, Level of Evidence B). MRI and magnetic resonance angiography (MRA) criteria for selection

of children for primary stroke prevention using transfusion have not been established, and these tests should not be substituted for TCD (Class III, Level of Evidence B). Adults with SCD should be evaluated for known stroke risk factors and managed according to the general guidelines in this statement (Class I, Level of Evidence A).

Postmenopausal Hormone Therapy

Although laboratory and observational studies of postmenopausal hormone therapy have suggested a beneficial effect for the prevention of cardiovascular disease²⁷² and a reduction of stroke severity,²⁷³ randomized trials suggest harm. Previously, these guidelines surmised that the impact of postmenopausal hormone replacement therapy on stroke risk appeared to be neutral, but because of a lack of controlled studies, definitive conclusions could not be reached.¹⁰ Since that time, 3 consistent prospective trials have been completed (Table 4).

The Women's Estrogen for Stroke Trial (WEST) was designed to determine the effects of hormone therapy on the incidence of vascular events after stroke.²⁷⁴ Although more relevant for secondary prevention, hormone therapy with estradiol did not reduce the risk of recurrent stroke or death. Within the first 6 months, the risk of stroke was higher among those randomized to estradiol (RR 2.3; 95% CI 1.1 to 5.0). In addition, those who had a recurrent stroke and were randomized to hormonal therapy were less likely to recover.

The Heart and Estrogen/Progesterone Replacement Study (HERS) Trial examined the role of hormone therapy (equine estrogens and the progestin medroxyprogesterone) for secondary prevention among postmenopausal women who had an MI.²⁷⁵ The overall trial was negative, with no net effect on the risk of stroke.²⁷⁶

A goal of the Women's Health Initiative (WHI) was to examine the role of hormone therapy for primary prevention of cardiovascular disease among postmenopausal women.²⁷⁷ Stroke was a prespecified end point. The first results from the WHI were for women with an intact uterus in whom a combination therapy (conjugated equine estrogen and medroxyprogesterone) was used as the active treatment. The trial was stopped because of an increase in vascular events that included an absolute increase of 8 strokes per 10 000 person-years. A parallel trial included women with a previous hysterectomy who were treated with conjugated equine estrogen.²⁷⁸ The risk of stroke was increased with active treatment (RR 1.39; 95% CI 1.10 to 1.77).

Selective estrogen receptor molecules lack the steroidal structure of estrogen but have a tertiary structure that permits binding to estrogen receptors.²⁷⁹ Exploratory analyses from a trial using a selective estrogen receptor molecule for osteoporosis suggest that these drugs may decrease cardiovascular and cerebrovascular events in women at high risk for vascular disease.²⁸⁰

Summary and Gaps

An increased risk of stroke is associated with the tested forms of hormone therapy. Two trials focused on women without a prior history of stroke and are directly relevant to primary stroke prevention. Prospective randomized data for other forms of hormone therapy are lacking.

Recommendations

It is recommended that postmenopausal hormone therapy (estrogen with or without a progestin) not be used for primary prevention of stroke (Class III, Level of Evidence A).^{277,278} The use of hormone replacement therapy for other indications should be informed by the risk estimate for vascular outcomes provided by the reviewed clinical trials. There are not sufficient data to provide recommendations about the use of other forms of therapy such as selective estrogen receptor modulators.

Diet and Nutrition

In observational studies, several aspects of diet are associated with stroke risk. As reviewed by Bazzano et al²⁸¹ and as corroborated by more recent publications,^{282–284} a generally consistent body of evidence from prospective studies has documented that increased fruit and vegetable consumption is associated with a reduced risk of stroke in a dose-response fashion. For example, in analyses of the Nurses' Health Study and the Health Professionals' Follow-Up Study,²⁸⁵ the RR of incident stroke was 0.69 (95% CI 0.52 to 0.92) for persons in the highest versus lowest quintile of fruit and vegetable intake. Median intake in the highest quintile was 10.2 servings of fruit and vegetables in men and 9.2 in women. For each 1-serving/day increment in fruit and vegetable intake, the risk of stroke was reduced by 6%. According to national survey data, daily servings of fruits and vegetables for individuals ≥ 2 years of age have remained low, just 4.9 servings in 1994 to 1996 and 4.7 servings in 1999 to 2000 (National Cancer Institute Web site: <http://cancer.gov/cancerinfo/pdq/prevention/>).

In ecological²⁸⁶ and some prospective studies,^{287,288} a higher level of sodium intake is associated with an increased risk of stroke. A higher level of potassium intake is also associated with a reduced risk of stroke in prospective studies.^{289,290} It should be emphasized that a plethora of methodological limitations, particularly difficulties in estimating dietary electrolyte intake, hinder risk assessment and may lead to false-negative results in observational studies.

The potential effects of sodium and potassium on stroke risk appear to be at least partially mediated through blood pressure. In clinical trials, particularly dose-response studies, the relationship between sodium intake and blood pressure is direct and progressive without an apparent threshold.^{291–293} In other trials, an increased intake of potassium has been shown to lower blood pressure²⁹⁴ and blunt the pressor effects of sodium.²⁹⁵ Diets rich in fruits and vegetables, including the Dietary Approaches to Stop Hypertension (DASH) diet (rich in fruit, vegetables, and low-fat dairy products and reduced in saturated and total fat), lower blood pressure.^{296,297} However, there is a reasonable biological basis, and some empirical evidence from animal studies, that the effects of sodium and potassium on stroke are also mediated through mechanisms that are independent of blood pressure.²⁹⁸ As documented in a recent review by the Institute of Medicine,²⁹⁹ sodium intake remains high and potassium intake quite low in the United States.

Other dietary factors may affect the risk of stroke, but the evidence is insufficient to make specific recommendations. In

Asian countries, a low intake of animal protein, saturated fat, and cholesterol has been associated with an increased risk of stroke,³⁰⁰ but such relationships have been less apparent in Western countries.³⁰¹

Summary and Gaps

Randomized controlled trials that are focused on diet and specifically target stroke do not exist. According to epidemiological studies, it is likely that diets rich in fruits and vegetables and with reduced sodium and increased potassium intake would reduce stroke risk.

Recommendations

A reduced intake of sodium and increased intake of potassium are recommended to lower blood pressure (Class I, Level of Evidence A), which may thereby reduce the risk of stroke. The recommended sodium intake is ≤ 2.3 g/d (100 mmol/d), and the recommended potassium intake is ≥ 4.7 g/d (120 mmol/d). The DASH diet, which emphasizes fruit, vegetables, and low-fat dairy products and is reduced in saturated and total fat, also lowers blood pressure and is recommended (Class I, Level of Evidence A). A diet that is rich in fruits and vegetables may lower the risk of stroke and may be considered (Table 7) (Class IIb, Level of Evidence C).

Physical Inactivity

Regular physical activity has well-established benefits for reducing the risk of premature death and cardiovascular disease. The beneficial effects of physical activity have also been documented for stroke.^{302–310} The Framingham Heart Study, Honolulu Heart Program, and Oslo Study have shown the protective effect of physical activity for men.^{303–305} For women, the Nurses' Health Study and Copenhagen City Heart Study demonstrated an inverse association between level of physical activity and stroke incidence.^{309,310} The protective effects of leisure-time physical activity have also been found for blacks and Hispanics in the National Health and Nutrition Examination Survey (NHANES) I Follow-Up Study and the Northern Manhattan Stroke Study.^{306,308}

Dose-response studies comparing the effects of vigorous and lower levels of physical activity are limited.^{304,307,311} In the Northern Manhattan Stroke Study, intensive forms of physical activity provided additional benefits as compared with light to moderate activities. Additional protection was observed with increasing duration of exercise; however, the prevalence of such activities in the elderly was quite low.³⁰⁸ The protective effect of physical activity may be partly mediated through its role in reducing blood pressure³¹⁰ and controlling other risk factors for cardiovascular disease,^{312,313} diabetes,³¹⁰ and increased body weight. Other biological mechanisms have also been associated with physical activity, including reductions in plasma fibrinogen and platelet activity and elevations in plasma tissue plasminogen activator activity and HDL concentrations.^{314–316}

Currently available data support the benefits of physical activity (Table 7). Guidelines endorsed by the Centers for Disease Control and Prevention (CDC) and the National Institutes of Health recommend that Americans should exercise moderately for ≥ 30 minutes on most, and preferably all, days of the week.^{317,318} For stroke, the benefits are apparent

even for light to moderate activities, such as walking, and the data support additional benefit from increasing the level and duration of recreational activity. Physical activity is a modifiable behavior that requires greater emphasis in stroke prevention campaigns (Table 4).

Summary and Gaps

A sedentary lifestyle is associated with an increased risk of stroke. Clinical trials documenting a reduction in the risk of a first stroke with regular exercise have not been done; however, exercise has beneficial effects on several other important stroke risk factors and is associated with a reduction in stroke risk in epidemiological studies.

Recommendations

Increased physical activity is recommended because it is associated with a reduction in the risk of stroke (Class I, Level of Evidence B). Exercise guidelines as recommended by the CDC and the National Institutes of Health of regular exercise (≥ 30 minutes of moderate-intensity activity daily) as part of a healthy lifestyle are reasonable (Table 7) (Class IIa, Level of Evidence B).

Obesity and Body Fat Distribution

The traditional classification of weight status is defined by body mass index (BMI: weight [in kilograms] divided by the square of height [in meters]). Persons with a BMI of 25 to 29.9 kg/m² are classified as being overweight, and those with a BMI of ≥ 30 kg/m² are classified as being obese.^{317,319} Abdominal obesity is commonly measured by either the waist-to-hip ratio or waist circumference. Clinically, abdominal obesity is defined by a waist circumference >102 cm (40 in) in men and 88 cm (35 in) in women.³¹⁹ The prevalence rates of obesity and overweight have been increasing in the United States and elsewhere,^{320–324} with the epidemic affecting children as well as adults (Table 4). Being overweight is particularly common among black and Hispanic children.³²⁵ According to national survey data collected in the period 2000 to 2001, the prevalence of overweight and obesity remains extraordinarily high: 65.7% of US adults are either overweight or obese, and 30.4% are obese.³²⁶

A growing body of evidence from large-scale prospective studies has documented that increased weight is associated with an increased risk of stroke in a dose-response fashion.^{327–329} Among 234 863 middle-aged men enrolled in the Korean Medical Insurance Corporation Study, the adjusted RR of stroke per 1 U BMI was 1.04 (95% CI 1.03 to 1.05) for total stroke, 1.06 (95% CI 1.04 to 1.07) for ischemic stroke, and 1.02 (95% CI 1.00 to 1.05) for hemorrhagic stroke.³²⁹ Among 21 414 male health professionals, the adjusted RRs in overweight and obese men as compared with nonoverweight men were 1.32 (95% CI 1.14 to 1.54) and 1.91 (95% CI 1.45 to 2.52) for total stroke, 1.35 (95% CI 1.15 to 1.59) and 1.87 (95% CI 1.38 to 2.54) for ischemic stroke, and 1.25 (95% CI 0.84 to 1.88) and 1.92 (95% CI 0.94 to 3.93) for hemorrhagic stroke.³²⁸ In those studies that examined the effects of obesity (typically defined by BMI) and abdominal body fat, abdominal body fat tended to be a stronger predictor of stroke risk.^{40,330–333} The age-adjusted RR of stroke was 2.33 (95%

CI 1.25 to 4.37) in a comparison of the extreme quintiles of waist-to-hip ratios in male health professionals.³³²

In multivariate analyses that control for other cardiovascular risk factors (blood pressure, blood lipids, and diabetes/insulin resistance), the direct relationship of BMI with stroke often persists; however, the strength of the relationship is typically attenuated. This apparent reduction in the strength of the association between BMI and stroke risk may be misleading because overweight is hypothesized to cause stroke via these other factors.

To date, no clinical trial has tested the effects of weight reduction on reducing stroke risk. However, numerous trials have examined the effects of weight reduction on blood pressure in both nonhypertensive and hypertensive individuals. In a meta-analysis that aggregated results across 25 trials, mean systolic and diastolic blood pressure reductions from an average weight loss of 5.1 kg were 4.4 and 3.6 mm Hg, respectively.³³⁴

Summary and Gaps

A growing body of evidence shows that increased weight is associated with an increased risk of stroke in a dose-response fashion. Although no clinical trial has tested the effects of weight reduction on stroke outcomes, weight reduction is associated with a lowering in blood pressure (see section on hypertension) and may thereby contribute to a reduced stroke risk. Randomized trials of weight reduction for reducing stroke risk should be conducted.

Recommendations

Epidemiological studies indicate that increased body weight and abdominal fat are directly associated with stroke risk. Weight reduction is recommended because it lowers blood pressure (Class I, Level of Evidence A) and may thereby reduce the risk of stroke.

Less Well-Documented or Potentially Modifiable Risk Factors

Metabolic Syndrome

The National Cholesterol Education Program (Adult Treatment Panel III [ATP III]) defined metabolic syndrome as the presence of ≥ 3 of the following: (1) abdominal obesity as determined by waist circumference >102 cm or >40 inches for men and >88 cm or >35 inches for women; (2) triglycerides ≥ 150 mg/dL; (3) HDL cholesterol <40 mg/dL for men and <50 mg/dL for women; (4) blood pressure $\geq 130/\geq 85$ mm Hg; and (5) fasting glucose ≥ 110 mg/dL.¹³⁴ The World Health Organization modified the definition for epidemiological studies with the addition of hyperinsulinemia (fasting insulin levels in the upper quartile of the nondiabetic population).³³⁵ Obesity and sedentary lifestyle coupled with diet and other factors seem to interact to produce the metabolic syndrome.

Obesity, discussed separately in the previous section, is an important component of the metabolic syndrome and is associated with major health risk factors (such as diabetes, hypertension, and hypercholesterolemia), poor health status, and lower life expectancy.^{324,336} The visceral adiposity characteristic of the metabolic syndrome is associated with insulin

resistance, inflammation, diabetes, and other metabolic and cardiovascular derangements.³³⁷ Visceral adipocytes provoke insulin resistance by promoting extensive lipolysis and release of fatty acids. They also stimulate inflammation by releasing cytokines and may play a role in the pathophysiology of dyslipidemia, hypertension, impaired thrombolysis, and renal damage.³³⁷ Leptin, nonesterified fatty acids, plasminogen activator inhibitor-1, tumor necrosis factor, and other factors have been implicated in the adipocyte-mediated pathophysiological processes.³³⁷

Hyperinsulinemia/insulin resistance is an important marker of the metabolic syndrome. A variety of studies support or refute a relationship between glucose intolerance and stroke risk.^{338–341} However, fasting insulin levels are associated with stroke risk in nondiabetic individuals,³⁴² hyperinsulinemia is associated with risk indicators of carotid atherosclerosis,³⁴³ and high proinsulin levels may predict first-ever stroke in nondiabetic individuals.³⁴⁴ A review of 5 prospective and 4 case-control studies concluded that insulin resistance may be a prevalent risk factor for stroke and speculated that new drugs can safely reduce insulin resistance and may be effective for stroke prevention.³⁴⁵ The relationship between other individual components of the metabolic syndrome and stroke risk is reviewed in other sections.

The metabolic syndrome is highly prevalent in the United States (Table 4).^{335,346} It is estimated that 47 million Americans have the metabolic syndrome, with an age-adjusted prevalence of 23.7% (1988–1994).³⁴⁶ Mexican Americans have the highest age-adjusted prevalence (31.9%), and among African Americans, women have a 57% higher prevalence as compared with men.

The metabolic syndrome is a substantial predictor of coronary heart disease, cardiovascular disease (which includes coronary heart disease and stroke), and all-cause mortality.³⁴⁶ However, there is a paucity of information about the specific risk of stroke. Most stroke risk estimates are combined with other outcomes (eg, “cardiovascular disease”), making it difficult to determine the specific stroke risk component.

Summary and Gaps

Individual components of the metabolic syndrome have been associated with an increased risk of ischemic stroke and should be treated as appropriate. The specific risk of stroke in persons with the metabolic syndrome is uncertain, as is the impact of treatment of the combined syndrome.

Recommendations

Management of individual components of the metabolic syndrome, including lifestyle measures and pharmacotherapy as recommended in the National Cholesterol Education Program ATP III³⁴ and the JNC 7,⁷⁶ as reviewed in other sections of this guideline, are endorsed. Lifestyle management should include exercise, appropriate weight loss, and proper diet. Pharmacotherapy may include medications for blood pressure lowering, lipid lowering, glycemic control, treatment of microalbuminuria or proteinuria, and antiplatelet therapy (eg, aspirin) according to the individual circumstance and risk. It is not known whether agents that ameliorate

aspects of the insulin resistance syndrome are useful for reducing stroke risk.

Alcohol Abuse

Alcohol abuse can lead to multiple medical complications, including stroke. Strong evidence indicates that alcoholism and heavy drinking are risk factors for all stroke subtypes (Table 4).^{347–351} The majority of studies have suggested a J-shaped relationship between alcohol consumption and ischemic stroke risk, with a protective effect in light or moderate drinkers and an elevated risk with heavy alcohol consumption.^{347,348,352–358} Light-to-moderate alcohol consumption (for women ≤ 1 drink/day and for men ≤ 2 drinks/day³⁵⁹) can increase HDL cholesterol,^{211,360} reduce platelet aggregation,^{361,362} and lower plasma fibrinogen concentration.^{363,364} Heavy alcohol consumption can lead to hypertension, hypercoagulability, reduced cerebral blood flow, and a greater likelihood of atrial fibrillation.^{347,352,365} A meta-analysis of 35 observational studies categorized alcohol consumption as abstinence, <1 , 1 to 2, >2 to ≤ 5 , or >5 drinks per day (1 drink defined as 12 g of alcohol).³⁶⁶ As compared with abstainers, those who consumed >5 drinks per day had a 69% increased stroke risk (RR=1.69; 95% CI 1.34 to 2.15). Consumption of <1 drink per day, but not abstaining, was associated with a reduced risk (RR=0.80, 95% CI 0.67 to 0.96), as was consumption of 1 to 2 drinks per day (RR=0.72; 95% CI 0.57 to 0.91).

The amount and possibly type of alcohol consumed influence risk. In the Copenhagen City Heart Study, consumption of 3 to 5 glasses of wine per day, but not beer or spirits, was associated with a reduced risk of stroke-related mortality.³⁶⁷ Several other studies have found light-to-moderate consumption of wine to reduce the risk of a first stroke.^{358,365,368} A meta-analysis of 13 studies of beer and wine consumption found light-to-moderate consumption of wine and to a lesser extent beer was associated with reduced vascular risk.³⁶⁹

Summary and Gaps

In retrospective cohort studies, light-to-moderate consumption of alcohol in the form of wine has been associated with a reduced risk of stroke, whereas risk is increased with heavier consumption. Prospective trials are lacking. It is well established that alcohol can induce dependence and that alcoholism is a major public health problem.

Recommendations

For a variety of health benefits, reduction of alcohol consumption in heavy drinkers through established screening and counseling methods as outlined in the US Preventive Services Task Force Update 2004 is endorsed (Table 7).³⁷⁰ For those who consume alcohol, a recommendation of ≤ 2 drinks per day for men and ≤ 1 drink per day for nonpregnant women best reflects the state of the science for alcohol and stroke risk³⁵⁹ (Class IIb, Level of Evidence B).

Drug Abuse

Drug addiction is often a chronic relapsing disorder associated with a number of societal and health-related problems.³⁷¹ Drugs of abuse, including cocaine, amphetamines, and heroin, have been associated with an increased risk of stroke.³⁷²

These drugs can cause abrupt changes in blood pressure, induce vasculitic-type changes, lead to embolization caused by infective endocarditis, and induce hemostatic and hematologic abnormalities that can result in increased blood viscosity and platelet aggregation.^{373–376} Information about stroke-related drug abuse is mainly limited to epidemiological studies focused on urban populations. An increase in the risk of both ischemic and hemorrhagic stroke has been reported.^{377–381} In 1 study, drug abuse increased the risk of stroke 6.5-fold (95% CI 3.1 to 13.6) across all age groups and with an RR of 11.2 (95% CI 3.2 to 42.5) in persons <35 years of age.³⁷⁷ Long-term treatment strategies based on medication, psychological support, and outreach programs play an important part in treatment of drug dependency.^{371,382,383}

Summary and Gaps

Several drugs of abuse have been associated with stroke (Table 4). However, there is a paucity of data on the independent risk of stroke associated with drugs of abuse and no controlled trials demonstrating a reduction in risk with abstinence.

Recommendation

Successful identification and management of drug abuse can be challenging. When a patient is identified as having a drug addiction problem, referral for appropriate counseling may be considered (Table 7) (Class IIb, Level of Evidence C).

Oral Contraceptive Use

Much of the perceived increased stroke risk associated with the use of OCs is based on early studies with high-dose preparations (ie, first-generation OCs containing ≥ 50 μg of estradiol).^{384–387} The majority of studies of later-generation OCs containing lower doses of estrogens did not find an increased risk of stroke.^{102,386–390} However, at least 1 study reported an increased risk of stroke in women using first-, second-, or third-generation OCs.³⁹¹ Meta-analyses have also been conflicting,^{390,392} and the reasons for the discrepancy are not certain.³⁹² Fewer data are available on the association between OC use and hemorrhagic stroke. The reported risks appear lower than for ischemic stroke,^{390,393} except among older women in whom the risk of hemorrhagic stroke is greatest.^{103,394} Few studies have examined the association between the use of OCs and less common stroke mechanisms. One exception is cerebral venous thrombosis, for which there are data to suggest an association, especially among women with congenital thrombophilias such as factor V Leiden or a prothrombin gene mutation.^{395,396}

Some groups of women appear to be at higher risk for stroke associated with OC use. Women who are >35 years of age, smoke cigarettes, are hypertensive, are diabetic, have migraines, or have had prior thromboembolic events (especially if while on OCs) may be at increased stroke risk if they use OCs. Some data suggest that the total stroke risk may be more than additive for combinations of smoking, migraine with aura, and age >35 years, but the issue remains unsettled for low-dose OCs.^{102,389,390,397–399}

The absolute increase in stroke risk with low-dose OCs, if one exists, is small.^{390,392} Estimates of the incidence of ischemic stroke in young women range from 0.9 to ≈ 10 per

100 000.^{389,400–402} Using the highest part of this range, even if the risk of stroke is increased by as much as 30% (ie, 3 per 100 000),³⁹⁰ the excess number of strokes associated with OC medication remains several-fold lower than the mortality rate for pregnancy in the United States (9 per 100 000 live births).⁴⁰³

Summary and Gaps

The risk of stroke associated with OC use is low (Table 4). Certain women, particularly those who have had a prior thrombotic event, may be at higher risk. Estimates are primarily based on epidemiological studies.

Recommendations

The incremental risk of stroke associated with use of low-dose OCs in women without additional risk factors, if one exists, appears low (Class III, Level of Evidence B).^{390,398} It is suggested that OCs be discouraged in women with additional risk factors (eg, cigarette smoking or prior thromboembolic events) (Class III, Level of Evidence C).^{390,404} For those who elect to assume the increased risk, aggressive therapy of stroke risk factors may be useful (Class IIb, Level of Evidence C).^{390,398,404}

Sleep-Disordered Breathing

Epidemiological studies suggest that habitual snoring is a risk factor for ischemic stroke and is independent of confounding factors such as hypertension, ischemic heart disease, obesity, and age (Table 4).^{405,406} Consistent with these observations, a case-control study of 181 patients found that excessive daytime sleepiness likely due to obstructive sleep apnea was associated with stroke (OR=3.07, 95% CI 1.65 to 6.08).⁴⁰⁷ A 10-year observational study of 1651 men found that severe obstructive sleep apnea-hypopnea (apnea-hypopnea index >30/h of sleep) increased the risk of fatal (OR=2.87, 95% CI 1.17 to 7.51) and nonfatal (OR=3.17, 95% CI 1.12 to 7.52) cardiovascular events (MI, acute coronary insufficiency requiring coronary artery bypass surgery and/or percutaneous transluminal angioplasty, and stroke) as compared with healthy participants.⁴⁰⁸ The outcomes of those who were compliant with continuous positive airway pressure (CPAP) treatment did not differ from outcomes of controls. Those with obstructive sleep apnea who were treated with CPAP did not differ with regard to fatal (OR=1.05, 95% CI 0.39 to 2.21) or nonfatal (OR=1.42, 95% CI 0.52 to 3.40) cardiovascular events as compared with healthy participants. However, the outcomes of those who were or were not treated with CPAP did not significantly differ (the 95% CIs overlap). Data on stroke was not reported separately.

Snoring may be a marker for sleep-disordered breathing (SDB), which can secondarily increase stroke risk by leading to or worsening hypertension and heart disease and possibly by causing reductions in cerebral blood flow, altered cerebral autoregulation, impaired endothelial function, accelerated atherogenesis, hypercoagulability, inflammation, and paradoxical embolism in patients with PFO.^{409–411} For example, the community-based Sleep Heart Health Study found a dose-response relationship between SDB and hypertension.⁴¹² Another study found a similar association.⁴¹³ Each additional apneic event per hour of sleep increases the odds of

hypertension by 1%, and each 10% decrease in nocturnal oxygen saturation increases the odds by 13%.⁴¹⁴ The association of SDB with drug-resistant hypertension is particularly high.⁴¹⁵ In patients with advanced SDB, cardiac arrhythmias, atrioventricular block, and atrial fibrillation appear when the oxyhemoglobin saturation falls to <65%.^{416–419} Rapid eye movement sleep-related apneic events with oxygen desaturation can be profound in the setting of abdominal obesity,⁴²⁰ which may contribute to the observed epidemiological link between abdominal obesity, hypertension,⁴²¹ and vascular risk.

Treatment of SDB must be individualized and can include CPAP ventilation, bi-level positive airway pressure, and automatic control of airway pressure delivery with CPAP devices. A variety of surgical interventions and prosthetic oral devices are available. Successful treatment of SDB can lead to a reduction in blood pressure.^{422–424}

Summary and Gaps

SDB (sleep apnea) is associated with a variety of other stroke risk factors and adverse cardiovascular events and may independently contribute to stroke risk (Table 4). Successful treatment of sleep apnea can reduce blood pressure. There are no prospective randomized studies showing that treatment of sleep apnea reduces stroke risk.

Recommendations

Questioning bed partners and patients, particularly those with abdominal obesity and hypertension, about symptoms of SDB and referral to a sleep specialist for further evaluation as appropriate may be reasonable, especially in the setting of drug-resistant hypertension (Table 7) (Class IIb, Level of Evidence C).

Migraine

Migraine headache has been most consistently associated with stroke in young women (Table 4).^{385,425–430} Most studies have not found any association between migraine and stroke in those >60 years of age.^{429,431} The OR for migraine in stroke patients ranges from 1.48 (95% CI 1.0 to 2.2)⁴²⁸ in a study of working adults to 6.2 (95% CI 2.1 to 18.0) in young women who have migraine with aura.⁴²⁶ A meta-analysis of 6 case-control studies focusing on migraine and stroke reported a summary OR of 2.08 (95% CI 1.68 to 2.58).⁴³² On the basis of an OR of \approx 2.0, the population-attributable risk for migraine is estimated to be 17% for women between 20 and 44 years of age.⁴³³ This estimate does not take into consideration additional vascular risk factors that have consistently been associated with an increased stroke risk in young adults with migraine (Table 4).^{426,430,432}

Migraine headache characteristics, such as frequency or severity, have not been accounted for in most case-control studies. A Dutch population-based study of migraine patients and matched controls investigated the relationship between silent infarction on MRI and headache characteristics.⁴³⁴ Although there was no overall difference between the 2 groups, migraine patients had a 7-fold increased odds of silent brain infarction localized to the posterior circulation.⁴³⁴ This also correlated positively with attack frequency. Risk factors such as hypertension, smoking, and OC use did not modify

the effect of migraine on deep white matter lesions in women.⁴³⁴ Whether this represents a true risk for clinical stroke is uncertain, and there is no evidence that prevention of migraine attacks decreases the risk of silent ischemic damage.

Several of the mechanisms underlying the pathophysiology of migraine with aura have been linked to stroke risk. These include reduced blood flow, blood volume,⁴³⁵ and oligemia, especially the posterior circulation.⁴³⁶ Another mechanism that links migraine and stroke in young adults is paradoxical embolism via a PFO. PFOs are more common in both young patients with cryptogenic stroke^{437–439} and those with migraine, particularly migraine with aura.⁴⁴⁰ Speculation has suggested a relationship between PFO and migraine whereby microemboli flowing through the PFO cause brain ischemia and thereby trigger migraine, especially migraine with aura.⁴⁴¹ Migraine patients also have increased platelet activation and platelet-leukocyte aggregation,⁴⁴² a mechanism that may increase the risk for emboli formation as well as provide a link between migraine and stroke risk at a cellular level. The majority of patients who are diagnosed with a PFO have already had a first ischemic stroke or TIA; therefore, this diagnostic information is most appropriate for secondary rather than primary prevention. However, primary prevention may become an issue if more patients undergo evaluation for PFO because of migraine headaches.

Summary and Gaps

Migraine headache has been most consistently associated with stroke in young women. Specific data showing that migraine prophylaxis decreases stroke risk are lacking. No proven primary prevention strategies exist for patients with migraine and/or PFO.

Recommendations

There are insufficient data to recommend a specific treatment approach that would reduce the risk of first stroke in women with migraine, including migraine with aura.

Hyperhomocysteinemia

Homocysteine is a sulfhydryl-containing amino acid derived from dietary methionine.^{443,444} Numerous studies support an association between elevated homocysteine levels and atherosclerotic disease.^{445–448} The NHANES Epidemiologic Follow-up Study III found that subjects in the highest quartile for serum homocysteine concentration had an adjusted OR for stroke of 2.3 (95% CI 1.2 to 2.6).⁴⁴⁵ The Homocysteine Studies Collaboration meta-analysis, correcting for other cardiovascular risk factors, demonstrated that a 3- μ mol/L reduction in homocysteine was associated with a 19% lower risk of stroke (OR=0.81; 95% CI 0.69 to 0.95).⁴⁴⁵ The Framingham Study also found that baseline total homocysteine levels were an independent risk factor for incident stroke in the elderly.⁴⁴⁴ In the Framingham Heart Study, the RR for stroke, in a comparison of the lowest quartile with the highest, was 1.82 (95% CI 1.14 to 2.91).⁴⁴⁶ A nested case-control study from the Bezafibrate Infarction Prevention cohort found that patients with preexisting coronary heart disease and a homocysteine level at the highest quartile (>17.4 μ mol/L) had an adjusted OR of 4.6 (95% CI 1.3 to 18.9) for ischemic stroke as compared with those in the

lowest quartile. There was a linear trend across all quartiles of homocysteine concentrations that was independent of traditional risk factors or inflammatory markers.⁴⁴⁸ The risk estimate from NHANES III coupled with prevalence estimates gives a population-attributable risk of 26% for men 40 to 59 years of age, 35% for men ≥ 60 years of age, 21% for women 40 to 59 years of age, and 37% for women ≥ 60 years of age. These population-attributable risk estimates must be interpreted with caution because no data are available that would permit the estimation of population-attributable risk after adjustment for other cerebrovascular risk factors that are positively correlated with homocysteine levels.

A single-nucleotide polymorphism in the gene methylenetetrahydrofolate reductase (*MTHFR*), in which cytosine (C) is replaced by thymidine (T) at base position 677, reduces activity of the enzyme that metabolizes homocysteine, resulting in an increase in serum homocysteine concentration.⁴⁴⁹ The homozygous TT genotype is found in $\approx 10\%$ to 12% of the population and is associated with a 25% higher homocysteine level than in those patients with a wild-type CC genotype. A recent meta-analysis was performed on 72 studies of *MTHFR* gene prevalence in vascular disease and 20 prospective studies of serum homocysteine in disease risk. A 5- $\mu\text{mol/L}$ increase in serum homocysteine was associated with an increased OR in ischemic heart disease (OR=1.42; 95% CI 1.11 to 1.89) and an OR for stroke of 1.59 (95% CI 1.2 to 1.96). Furthermore, a 3- $\mu\text{mol/L}$ decrement of homocysteine concentration was associated with decrements in the risk of ischemic coronary disease by 16% and stroke by 24%.^{450,451}

Although the definition of hyperhomocysteinemia has not been standardized across epidemiological studies, fasting plasma levels of homocysteine $\geq 16 \mu\text{mol/L}$ are frequently classified as indicating hyperhomocysteinemia⁴⁵² (although the risk is likely continuous).^{452,453} In the Framingham Heart Study original cohort (67 to 96 years of age), 19% had homocysteine concentrations $>16.4 \mu\text{mol/L}$.⁴⁵⁴ Homocysteine concentrations increase with age, with men having higher levels than women, especially at younger ages.⁴⁵⁵ From NHANES III, the prevalence of high homocyst(e)ine (defined as $>11.4 \mu\text{mol/L}$) for men 40 to 59 years of age and ≥ 60 years of age are 28.6% and 43.2%, respectively.⁴⁵⁶ For women 40 to 59 years of age and ≥ 60 years of age, the prevalences of high homocysteine (defined as $>10.4 \mu\text{mol/L}$) are 21.1% and 46.5%, respectively. Age-related reductions in renal function may be partially responsible for this relationship because homocysteine levels increase in persons with kidney disease.

The B vitamins (folic acid, B₁₂, and B₆) reduce homocysteine serum levels across the range of baseline homocysteine.⁴⁵⁷ This information holds great promise given that B vitamin supplementation has been associated with a reduction in atherosclerotic plaque progression.⁴⁵⁸ However, no randomized trials have been conducted showing that lowering elevated homocysteine levels reduces the risk of a first stroke. The Vitamin Intervention for Stroke Prevention (VISP) trial tested whether high doses of B vitamins (25 mg of pyridoxine, 0.4 mg of cobalamin, and 2.5 mg of folic acid) given to reduce total homocysteine levels would reduce the risk of

recurrent stroke over 2 years as compared with lower doses (200 μg of pyridoxine, 6 μg of cobalamin, and 20 μg of folic acid).⁴⁵⁹ The mean reduction of total homocysteine was only 2 $\mu\text{mol/L}$ greater in the high- versus low-dose groups, with no treatment effect on the risk of recurrent stroke (RR=1.0, 95% CI 0.8 to 1.3) or on the combined risk of any stroke, coronary heart event, or death (RR=1.0, 95% CI 0.8 to 1.1). However, as with observational studies, there was a consistent overall relationship between homocysteine levels and vascular risk. The VISP trial was methodologically complex, and a benefit of treatment of elevated homocysteine levels cannot be excluded.

Summary and Gaps

Epidemiological and prospective studies show a positive relationship between blood homocysteine levels and stroke risk (Table 4). Prospective trials designed to determine whether pharmacological lowering of total homocysteine reduces the risk of a first stroke are needed.

Recommendations

Recommendations to meet current guidelines for daily intake of folate (400 $\mu\text{g/d}$), B₆ (1.7 mg/d), and B₁₂ (2.4 $\mu\text{g/d}$) by consumption of vegetables, fruits, legumes, meats, fish, and fortified grains and cereals (for nonpregnant, nonlactating individuals) may be useful in reducing the risk of stroke (Class IIb, Level of Evidence C). There are insufficient data to recommend a specific treatment approach that would reduce the risk of first stroke in patients with elevated homocysteine levels. In the interim, use of folic acid and B vitamins in patients with known elevated homocysteine levels may be useful given their safety and low cost (Class IIb, Level of Evidence C).

Elevated Lipoprotein(a)

Lipoprotein(a) [Lp(a)], a lipid-protein complex with proatherogenic and prothrombotic properties, has emerged as a risk factor for coronary heart disease.⁴⁶⁰ Lp(a) resembles an LDL particle in which apolipoprotein B-100 is linked by a single interchain disulfide bridge to apolipoprotein(a) [apo(a)]. It enhances arterial cholesterol deposition, thereby promoting atherogenesis.⁴⁶¹ Furthermore, apo(a) has a high sequence homology with plasminogen and is believed to increase the risk of thrombosis through inhibition of plasminogen activation resulting from the interaction with the ternary complex of tissue plasminogen activator, plasminogen, and fibrin.⁴⁶² Lp(a) plasma concentration and fibrinolytic activity are reported to be dependent on the apo(a) isoform size.^{462,463} A meta-analysis of 27 prospective studies with a mean follow-up period of 10 years found that patients with baseline Lp(a) levels in the top third of the concentration distribution have an $\approx 60\%$ increased risk of coronary heart disease as compared with those with Lp(a) levels in the bottom third (RR=1.6; 95% CI 1.4 to 1.8; $P<0.00001$).⁴⁶⁴

Considerable evidence suggests that high Lp(a) levels promote ischemic stroke, but findings have not been completely consistent (Table 4).⁴⁶⁵ Along with other prothrombotic factors, elevated Lp(a) has been associated with the rare occurrence of ischemic stroke in childhood.^{466,467} A population study identifying 166 consecutive first-ever TIA or

stroke patients with intracranial stenosis demonstrated by TCD showed that patients in the highest Lp(a) quartile had an increased likelihood of having ≥ 3 high-grade intracranial stenotic lesions (OR=3.43; 95% CI 1.04 to 11.33; $P=0.04$) as compared with those in the lowest quartile. Multiple logistic regression models identified diabetes and high Lp(a) as independent markers for intracranial large-artery occlusive disease.⁴⁶⁸ A prospective study of 5888 adults >65 years of age enrolled in the Cardiovascular Health Study found that men in the highest quintile had an adjusted RR of stroke of 2.92 (95% CI 1.53 to 5.57; $P=0.003$). The increase in RR was identified in elderly men, but no increase in risk was seen in elderly women. Elevated levels of Lp(a) can be reduced by $\approx 25\%$ with niacin.⁴⁶⁹ Other lipid-lowering medications do not affect Lp(a) levels but may reduce overall lipoprotein-associated risk.

Summary and Gaps

Additional studies are necessary to determine whether reduction of Lp(a) is associated with a reduction in stroke risk.

Recommendations

Although no definitive recommendations about Lp(a) modification can be made because of an absence of outcome studies showing clinical benefit, treatment with niacin (extended-release or immediate-release formulation at a total daily dose of 2000 mg/d as tolerated) can be considered because it reduces Lp(a) levels by $\approx 25\%$ (Class IIb, Level of Evidence C). Further recommendations must await the results of prospective trials utilizing niacin and statins in subjects stratified for Lp(a) concentration and apo(a) isoform subtypes.⁴⁶⁹

Elevated Lipoprotein-Associated Phospholipase A₂

Lipoprotein-associated phospholipase A₂ (Lp-PLA₂) is a calcium-independent serine lipase that is associated with LDL in human plasma.⁴⁷⁰ Elevated plasma levels of Lp-PLA₂ are associated with an increased risk of cardiovascular events, independent of other risk factors.^{471–473} In a population-based study, those in the highest versus the lowest quartile of Lp-PLA₂ levels had a 2-fold increased risk of ischemic stroke (HR=1.97, 95% CI 1.03 to 3.79), even after adjustment for age, sex, BMI, systolic blood pressure, non-HDL cholesterol level, HDL cholesterol level, diabetes, smoking, cholesterol-lowering medication, C-reactive protein (CRP), white blood cell count, and alcohol consumption.⁴⁷⁴ Lp-PLA₂ levels can be reduced with statins,⁴⁷⁵ fenofibrate,⁴⁷⁶ and β -blockers.⁴⁷⁷ There are no outcome studies showing whether reducing Lp-PLA₂ levels, independent of other risk factors, reduces the risk of ischemic stroke.

Summary and Gaps

Elevated Lp-PLA₂ is associated with an increased risk of cardiovascular events, and in 1 population-based study, an increased risk of stroke. Additional studies are required to better define its independent impact on stroke risk and the effects of treatment.

Recommendations

No recommendations about Lp-PLA₂ modification can be made because of an absence of outcome studies showing clinical benefit with reduction in blood levels of Lp-PLA₂.

Hypercoagulability

Most of the acquired and hereditary hypercoagulable states (thrombophilias) are associated with venous thrombosis but not cerebral infarction (Table 4). Of these, the presence of antiphospholipid antibodies (aPLs) is most likely to be associated with arterial thrombosis. Anticardiolipin antibody (more prevalent but less specific) and lupus anticoagulant (less prevalent but more specific) tests are most frequently used to detect aPL. Although previous retrospective studies suggested an association between anticardiolipin antibodies (ACLs) and ischemic stroke,⁴⁷⁸ the Antiphospholipid Antibody and Stroke Study (APASS) (using a cutoff of ACL immunoglobulin G titer of >21 $\mu\text{g/dL}$) did not find an association between aPL and subsequent ischemic stroke (or any vascular occlusive event).⁴⁷⁹ Similarly, 2 other well-designed longitudinal studies in the elderly found no association between stroke recurrence and elevated ACL titers.^{480,481} The Framingham Offspring Cohort Study did find an association between ACL titers and ischemic stroke or TIA, but only in women.⁴⁸² Even if an elevated ACL titer is found in a stroke patient, APASS found no differential response to aspirin versus warfarin in the prevention of recurrent events.⁴⁷⁹ Overall, although elevated ACL titers may be commonly found in ischemic stroke patients, the strength of the association between elevated ACL titers and stroke etiology or risk is questionable.

The shortcoming of many studies of ACL in stroke patients has been the use of the ACL ELISA, a test with low sensitivity. The assay for anti- β_2 glycoprotein 1 antibodies, a cofactor for antiphospholipid binding, is specific for thrombosis, including stroke and MI.⁴⁸³ However, only a few studies have utilized this test.^{480,483}

There are data suggesting that young women with ischemic stroke have a higher prevalence of aPL.⁴⁸⁴ Therefore, those stroke patients (primarily young women) who have a history of thrombotic events and meet the laboratory criteria for antiphospholipid syndrome⁴⁸⁵ might benefit from primary prevention strategies, such as moderate-intensity warfarin (INR 2.0 to 3.0)²¹⁴ or other antithrombotic therapies. This is currently being tested in a primary prevention trial of warfarin therapy (INR 2.0 to 2.5) to decrease thromboembolic events in patients with lupus and aPL.⁴⁸⁶

The majority of the case-control studies have not found an association between other hereditary hypercoagulable states, such as factor V Leiden or prothrombin 20210 mutations, or deficiencies of protein C, protein S, or antithrombin III, and stroke (Table 4).^{57,58} However, 1 study has suggested that hypercoagulable states may be more frequent in stroke patients with a PFO as compared with those without a PFO. That study found no difference in the prevalence of either the factor V Leiden or prothrombin 20210 mutation in patients with cryptogenic strokes versus controls. However, the prevalence of prothrombin 20210 mutation alone (OR 10.09; 95% CI 1.09 to 109) was higher in those with cryptogenic stroke and PFO versus those without PFO,⁴⁸⁷ suggesting a greater thrombotic risk in the setting of a PFO versus either condition alone.

Summary and Gaps

Young women with ischemic stroke have a higher prevalence of aPL. The majority of case-control studies have not found an association between other hereditary hypercoagulable states and stroke. The relationship between the presence of a PFO and thrombophilia deserves further study, as it may impact primary and secondary stroke prevention strategies.

Recommendations

There are insufficient data to support specific recommendations for primary stroke prevention in patients with a hereditary or acquired thrombophilia.

Inflammation

Risk factors and medical conditions that disrupt the integrity of the endothelial lining of the cerebral blood vessels increase the potential for intraluminal thrombosis and stroke. Atherosclerosis, one of the most common causes of stroke, is a chronic inflammatory condition initiated by a host of agents that injure the endothelial surface.⁴⁸⁸ CRP is an acute phase-reactant and a component of the human innate immunity, which increases in response to inflammatory stimuli and is a known mediator of complement activity, adhesion molecule production, and chemokine and thrombogenic factor release. Numerous cohort studies have shown a strong correlation between elevated CRP levels and cardiovascular/cerebrovascular events and indicate a 2- and 3-fold increase in stroke risk in healthy men and women, respectively.^{489,490} When comparing the highest versus the lowest quartile for CRP, the age-adjusted risk of first ischemic stroke and TIA is 2.0 ($P=0.027$) for men and 2.7 ($P=0.0003$) for women (Table 4). The multivariate-adjusted trend in RR of ischemic stroke across CRP quartiles is 1.25 (95% CI 1.01 to 1.54) for men and 1.30 (95% CI 1.07 to 1.55) for women.⁴⁹¹ CRP levels correlate with the 10-year Framingham Coronary Heart Disease Risk Score (FCRS) but not with its individual components.⁴⁹² CRP adds to the predictive value of the Framingham Risk Score⁴⁹² and to the vascular risk associated with the metabolic syndrome.⁴⁹⁰ Population-based studies provide data supporting cutpoints in CRP levels associated with increased risk and the determination of survival curves associated with CRP and LDL cholesterol levels.⁴⁹⁰ CRP cutoff levels for cardiovascular events, which include coronary heart disease, ischemic stroke, and cardiovascular death, are RR 1.6 (95% CI 1.1 to 2.4) for CRP levels 1.08 to 2.09 mg/L; RR 2.0 (95% CI 1.3 to 3.0) for CRP levels 2.09 to 4.19; and RR 2.3 (95% CI 1.6 to 3.4) for CRP levels >4.19 mg/L; $P<0.001$.⁴⁹⁰ RR for ischemic stroke is significantly increased in patients with CRP levels >1.08 (RR >2.0), and CRP levels of >4.19 mg/L are associated with RR for ischemic stroke of 3.0 compared with the lowest quintile of CRP level <0.5.⁴⁹⁰ CRP levels are dependent on the patient's ethnic/racial group, which must be taken into consideration when the influence of CRP-associated risk is determined.^{493–495}

Prospective randomized treatment trials with statins show reductions in coronary atherosclerotic plaque progression and cardiovascular events and a strong association between the utilization of statins and a reduction of CRP levels.^{496–498} Patients who have had an acute coronary syndrome and have

low CRP levels (<2 mg/L) after statin therapy have better clinical outcomes (ie, reduction of recurrent MI or coronary death) as compared with those with higher CRP levels, regardless of whether the LDL cholesterol level was reduced to <70 mg/dL.⁴⁹⁹ Statin dose was not altered to achieve these levels. Another study found a reduction in coronary events in those with relatively low lipid levels but with elevated CRP levels who were treated with a statin, but patients were not randomized according to CRP levels and there was no mention of an effect on stroke.⁵⁰⁰ It remains uncertain whether asymptomatic persons at otherwise low cardiovascular risk and without dyslipidemia who have elevated CRP levels have a reduced risk of stroke associated with statins.

The vascular response to injury is characterized by an upregulation of adhesion molecules (such as P-selectin, intracellular adhesion molecule-1, E-selectin, and vascular cell adhesion molecule-1) and prompts the migration of inflammatory cells, monocytes, T lymphocytes, and lipids into the wall of the vessel. Macrophage and T-cell interaction, in part mediated by CD40–CD40L interactions, results in the release of proinflammatory cytokines such as tumor necrosis factor- α and interleukin (IL)-1 β , and chemokines such as IL-8 and monocyte chemoattractant protein-1, that serve to convert the endothelial surface over the plaque from an anticoagulant to a procoagulant and prothrombotic state.^{501–503}

Intraplaque inflammatory cells mediate the release of matrix metalloproteinases, such as gelatinase-B (MMP-9), stromelysin (MMP-3), and gelatinase-A (MMP-2), that cause instability of the fibrous cap leading to rupture. Symptomatic carotid atherosclerotic plaques have an increase of inflammatory and prothrombotic mediators as compared with plaques from asymptomatic patients.^{504,505} Antigen-driven T-cell activation provides a pathway by which quiescent plaques can be rapidly activated to a symptomatic state.⁵⁰⁶

Numerous inflammatory markers are emerging as identifiable factors associated with atherosclerotic plaque instability. The CD40/CD40 ligand system (CD40/CD40L) plays a role in the activation of inflammatory mediators in atherogenesis as well as representing a biologically active soluble mediator released by platelets that is associated with cardiovascular risk.^{507,508} Elevated CD40L (>5.0 $\mu\text{g/L}$) had an adjusted HR of 2.71 (95% CI 1.51 to 5.35) for death and nonfatal MI as compared with patients with low levels of the ligand. The risk was significantly reduced by treatment with the glycoprotein IIb/IIIa receptor inhibitor abciximab (HR=0.39; CI 0.20 to 0.68) as compared with those given placebo. This suggests that CD40L expression may identify a subgroup of patients most likely to benefit from antiplatelet therapy. A nested case-control analysis among participants in the Women's Health Study revealed that women with CD40L concentrations above the 95th percentile of the control distribution (>3.7 ng/mL) had a significantly increased RR of developing MI, stroke, and cardiac death (RR=3.3; 95% CI 1.2 to 8.6).⁵⁰⁷ In a study evaluating markers after first acute ischemic cerebrovascular events, soluble CD40L was significantly elevated in patients with noncardioembolic stroke as compared with control subjects with comparable atherosclerotic risk profiles (17.1 \pm 7.5 ng/mL versus 3.4 \pm 1.6 mg/mL).⁵⁰⁹ Levels remain significantly elevated in both stroke and TIA

patients at 3 months, indicating continuous marker elevation associated with the disease state.

IL-18 is a potent proinflammatory cytokine with proatherogenic properties. With the use of real-time quantitative polymerase chain reaction, significant expression of IL-18 messenger RNA was found in human carotid atherosclerotic plaque as compared with little or no expression in normal arteries. Furthermore, IL-18 messenger RNA was >3-fold higher in symptomatic (unstable) carotid plaque versus asymptomatic (stable) plaque ($P<0.01$).⁵¹⁰ In a nested case-control comparison of 10 600 healthy European men in a prospective epidemiological study of MI, plasma levels of soluble IL-18 were significantly higher in men who developed coronary events ($n=335$ cases) than in age-matched controls ($n=678$), 225.1 versus 203.9 pg/mL, $P=0.005$,⁵¹¹ with a RR for coronary events of 1.82 (95% CI 1.30 to 2.55).

Polymorphisms of genes that regulate inflammation are being identified as risk factors individually and in combination. A study examining the IL-6 GG, IL-6 GC, monocyte chemoattractant protein-1 GG, intracellular adhesion molecule-1 EE, E-sel AA, and MMP-3 5A5A genotypes reveals that carrying 1 proinflammatory gene variant confers a risk of ischemic stroke of 3.3 (95% CI 1.6 to 6.9), whereas concomitantly carrying 2 or 3 gene variants had an adjusted OR of 21 (95% CI 7.6 to 57.5) and 50.3 (95% CI 10.2 to 248), respectively.⁵¹²

Data from 2 prospective studies suggest that plaque stabilization can be achieved within several months by reducing the proinflammatory profile.^{513,514} Administration of a statin to patients with symptomatic carotid stenosis for 3 months before endarterectomy resulted in a significant reduction in the concentration of T lymphocytes, macrophages, oxidized LDL, and matrix metalloproteinases while increasing collagen and inhibitors to MMPs as compared with symptomatic patients randomized to placebo.⁵¹⁴ Furthermore, a study evaluating the inflammatory characteristics of carotid atherosclerotic plaques in 70 symptomatic patients undergoing carotid endarterectomy was performed, with patients randomized to either an ARB or a diuretic. There was a significant reduction in inflammatory mediators, including macrophages, T lymphocytes, human leukocyte antigen-DR, cyclooxygenase-2, MMP-2, and MMP-9, with the use of the ARB.⁵¹³

To take full advantage of the evolving understanding of the inflammatory profile in atherosclerosis from the standpoint of both predictive value and primary risk reduction, treatment based on reliable biomarkers must be subjected to prospective randomized trials.⁴⁸⁴

Summary and Gaps

Data supporting the importance of inflammation in the pathophysiology of atherosclerotic vascular disease are mounting; however, prospective studies demonstrating a reduction in risk of stroke due to the treatment of persons with elevated inflammatory markers or due to treatment to achieve a target level of any inflammatory marker (eg, CRP) are currently lacking.

Recommendations

Currently, no evidence supports the use of high-sensitivity CRP (hs-CRP) screening of the entire adult population as a marker of general vascular risk. Aggressive risk factor modification is recommended for patients at high risk for stroke

given exposure to traditional risk factors regardless of hs-CRP level. In agreement with AHA/CDC guidelines, hs-CRP can be useful in considering the intensity of risk factor modification in those at moderate general cardiovascular risk on the basis of traditional risk factors (Class IIa, Level of Evidence B).²⁶³

Infection

Case-control studies have found that recent infections (within 1 week) are associated with acute stroke.^{515–517} This may be in part related to generalized activation of circulating leukocytes that enhance the tendency for thrombosis at the site of atherosclerotic plaque. In addition, numerous pathogens have been associated with the initiation, progression, and development of atherosclerotic disease and increased risk for future ischemic vascular events. Among these, *Chlamydia pneumoniae*, an obligate intracellular organism, has been identified in atherosclerotic plaques.⁵¹⁸ In the population-based Northern Manhattan Stroke Study, elevated *C pneumoniae* immunoglobulin A titers were associated with the risk of ischemic stroke (adjusted OR 4.51; 95% CI 1.44 to 14.06). An association with stroke risk was identified in both younger and older persons, men and women, and in Hispanics, blacks, and whites.⁵¹⁹ Despite numerous studies finding an association between elevated serum antibody titers for *C pneumoniae* and cerebrovascular and cardiovascular events,^{520–522} there remains no clear evidence of risk reduction associated with antibiotic therapy.^{523,524} One study reported a 5-fold decrease in recurrent cardiovascular events in patients with high positive immunoglobulin G titers for *C pneumoniae* ($\geq 1:64$) who were treated with azithromycin (OR=0.2; 95% CI 0.05 to 0.8).⁵²⁵ Subsequent studies failed to demonstrate benefit of antibiotics in patients who were seropositive for *C pneumoniae*.^{526–528} In a randomized placebo-controlled trial, patients with previous MI and a *C pneumoniae* immunoglobulin G titer of $\geq 1:16$ treated with 12 weeks of azithromycin ($n=3879$) or placebo ($n=3868$) had no reduction in the number of vascular end points with antibiotic therapy. A study randomizing 4162 patients with acute coronary syndrome to gatifloxacin or placebo for treatment of *C pneumoniae* found no reduction in a combined end point of death, MI, revascularization procedures, hospitalization for unstable angina, or stroke over 2 years (HR=0.95; 95% CI 0.84 to 1.08; $P=0.41$), including no independent reduction in stroke (1.1% with treatment versus 1.07% without treatment over 2 years).⁵²⁹ A second study randomized 4012 patients with stable CAD to azithromycin or placebo and found no reduction in death due to coronary heart disease, nonfatal MI, coronary revascularization, or hospitalization for unstable angina with treatment (risk reduction=1%; 95% CI –13% to 13%) and no reduction in stroke (a secondary end point, 2.2% versus 2.0%; risk reduction=–13%; 95% CI –73% to 26%) over 4 years.⁵³⁰ Because of the low rates of stroke ($\approx 0.5\%$ per year), these studies, although negative, were not sufficiently powered to detect an effect of antibiotic treatment for *C pneumoniae* on stroke risk.

Periodontal disease found to be related to continuous and intermittent seeding of the bloodstream with Gram-negative organisms has been associated with carotid atherosclerosis

and the risk of stroke. NHANES I found an adjusted OR of 2.11 (95% CI 1.3 to 3.42) for ischemic stroke among those with periodontal disease.⁵³¹

Cytomegalovirus (CMV) is purported to increase the risk of development of vascular disease by increasing inflammatory mediators, facilitating the coagulation cascade, and enhancing adhesion molecule expression on vascular endothelial cells. Seropositivity for CMV was associated with increased risk for combined end points of carotid artery intimal-medial thickness and stenosis for immunoglobulin G titers (adjusted OR 1.7; 95% CI 1.1 to 2.8) and for immunoglobulin A (adjusted OR 2.3; 95% CI 1.1 to 4.9).⁵³² Additionally, case-control studies found that CMV-specific immune complexes represent a strong independent stroke risk factor (OR 7.60; 95% CI 3.21 to 17.96).⁵³³ Subgroup analysis from the Heart Outcomes Prevention Evaluation (HOPE) study revealed that CMV seropositivity was associated with all vascular events (OR 1.24; 95% CI 1.01 to 1.53) but not for stroke alone (OR 1.04; 95% CI 0.68 to 1.58).⁵³⁴

Helicobacter pylori has also been identified in human atherosclerotic plaque.⁵³⁵ Case-control studies found that the association between *H pylori* and stroke appears to be dependent on strain. *H pylori* with cytotoxin-associated gene-A seropositivity was associated with ischemic stroke (OR 1.97; 95% CI 1.33 to 2.91) in contrast to general *H pylori* seropositivity (OR 1.20; 95% CI 0.82 to 1.76).⁵³⁶ CagA-positive *H pylori* have further been shown to be independently associated with carotid plaque irregularities (adjusted OR 8.42; 95% CI 1.58 to 44.64).⁵³⁷ Future studies on *H pylori* influence on both the development of atherosclerosis and symptomatic disease will require knowledge of strain specificity.⁵³⁸

Aggregate data suggest that no single organism is likely to account for atherosclerosis. The evolving concept of “infectious burden” proposes that lifelong exposure to multiple organisms enhances the development and activation of atherosclerotic plaque. In a prospective study evaluating the aggregate burden of 8 pathogens on the progression of carotid atherosclerosis, an increased number of seropositive organisms, including *C pneumoniae*, *H pylori*, *H influenzae*, *M pneumoniae*, CMV, Epstein-Barr virus, and Herpes simplex virus types I and II, was associated with atherosclerotic plaque progression. Infectious burden of 4 to 5 seropositivities had an OR of 1.8 (95% CI 1.1 to 2.9), and 6 to 8 seropositivities had an OR of 3.8 (95% CI 1.6 to 8.8) for atherosclerotic plaque progression, as compared with 0 to 3 seropositivities.⁵³⁹ Under the same paradigm, an increased risk for coronary and peripheral vascular disease, as well as cardiovascular death, was associated with a person’s increasing number of seropositive organisms.⁵⁴⁰ In a study using within-person comparison and case-series methodology in which 50 766 patients with first stroke (median age at stroke 78.3 years) were studied, the presence of a systemic respiratory tract infection imparted an age-adjusted incidence ratio of 3.19 (95% CI 2.8 to 3.62) in the first 3 days, with a persistently increased, although less robust, incidence ratio of 1.33 (95% CI 1.26 to 1.40) at 91 days for stroke. Urinary tract infections were also associated with an increased incidence ratio for stroke over the first 3 days (incidence ratio 2.72;

95% CI 2.32 to 3.20) that persisted at 91 days (incidence ratio 1.22; 95% CI 1.15 to 1.30). These data support the concept that exposure to multiple organisms can influence stroke incidence in the population.⁵⁴¹

Summary and Gaps

Despite numerous studies demonstrating bacterial pathogens in coronary and carotid atherosclerotic plaque, treatment with antibiotics has not been proven to lower the risk of ischemic stroke, and no specific recommendation can be made about the usefulness of this approach for primary stroke prevention. The concept of infectious burden implies that no single anti-infectious regimen is likely to be effective. Further studies are required to test this hypothesis.

Recommendations

Data are insufficient to recommend antibiotic therapy for stroke prevention on the basis of seropositivity for 1 or a combination of putative pathogenic organisms. Future studies on stroke risk reduction based on treatment of infectious diseases will require careful stratification and identification of patients at risk for organism exposure.

Aspirin for Primary Stroke Prevention

The US Preventive Services Task Force recommends aspirin at a dosage of 75 mg/d for cardiac prophylaxis for persons whose 5-year coronary heart disease risk is $\geq 3\%$.⁵⁴² The 2002 update of the AHA Guidelines for the primary prevention of cardiovascular disease and stroke agrees with the US Preventive Services Task Force Report on the use of aspirin in persons at high coronary risk but use a $\geq 10\%$ risk per 10 years, rather than $>3\%$ risk over 5 years, to improve the likelihood of a positive balance of coronary risk reduction over bleeding and hemorrhagic stroke caused by aspirin.⁵⁴³ The benefit of platelet antiaggregants for secondary stroke prevention in patients with a prior history of stroke or TIA is also well established.^{544–546} There is no evidence that this class of drugs reduces the risk of stroke in the general population of persons at low risk.^{542,547,548}

There were relatively few women enrolled in the primary prevention trials that showed a benefit of aspirin in the prevention of coronary heart events but no reduction in stroke. The Women’s Health Study randomized 39 876 initially asymptomatic women ≥ 45 years of age to receive 100 mg of aspirin or placebo on alternate days and followed them for 10 years for a first major vascular event (nonfatal MI, nonfatal stroke, or cardiovascular death).⁵⁴⁹ Unlike data from prior studies that included mainly men, this study found a nonsignificant 9% reduction (RR=0.91; 95% CI 0.80 to 1.03; $P=0.13$) for the combined primary end point among women but a 17% reduction in the risk of stroke (RR=0.83; 95% CI 0.69 to 0.99; $P=0.04$). This was based on a 24% reduction in the risk of ischemic stroke (RR=0.76; 95% CI 0.63 to 0.93; $P=0.009$) and a nonsignificant increase in the risk of hemorrhagic stroke (RR=1.24; 95% CI 0.82 to 1.87; $P=0.31$). The overall average stroke rates were 0.11% per year in aspirin-treated patients and 0.13% per year in placebo-treated patients (absolute risk reduction=0.02% per year, number needed to treat [NNT]=5000). Gastrointestinal hemorrhage requiring transfusion was more frequent in the aspirin group

(RR=1.40; 95% CI 1.07 to 1.83; $P=0.02$). The average gastrointestinal hemorrhage rates were 0.06%/year for aspirin and 0.05%/year for placebo (absolute risk increase=0.01% per year, number needed to harm=10 000). The most consistent benefit for aspirin was in women ≥ 65 years of age at study entry, among whom the risk of major cardiovascular events was reduced by 26% (RR=0.74; 95% CI 0.59 to 0.92; $P=0.008$), including a 30% reduction in the risk of ischemic stroke (RR=0.70; 95% CI 0.49 to 1.00; $P=0.05$); however, there was only a trend in the reduction of the overall (ischemic+hemorrhagic) risk of stroke (RR=0.78; 95% CI 0.57 to 1.08; $P=0.13$), likely related to an increase in the risk of brain hemorrhages. Subgroup analyses showed a reduction in stroke for those women with a history of hypertension (RR=0.76; 95% CI 0.59 to 0.98; $P=0.04$), hyperlipidemia (RR=0.62; 95% CI 0.47 to 0.83; $P=0.001$), or diabetes (RR=0.46; 95% CI 0.25 to 0.85; $P=0.01$) or a 10-year cardiovascular risk $\geq 10\%$ (RR=0.54; 95% CI 0.30 to 0.98; $P=0.04$).

Summary and Gaps

Previous guideline statements endorse the use of aspirin (dose as low as 75 mg/d as reflected in the US Preventive Services Task Force recommendation) for cardiovascular prophylaxis among men whose risk is sufficiently high for the benefits to outweigh the risks associated with treatment (a 10-year risk of 6% to 10%).^{542,543} These recommendations are based on a reduction of cardiovascular events, not stroke. The Women's Health Study shows a reduction in the risk of stroke in women, but not cardiac events or death from cardiovascular causes with aspirin.⁵⁴⁹ The overall benefit of aspirin is most consistent among women >65 years of age; however, there was not an overall reduction of stroke in this group. The reasons for the differences between men and women remain uncertain.

Recommendations

Aspirin is not recommended for the prevention of a first stroke in men (Class III, Level of Evidence A). Previous guideline statements have recommended the use of aspirin for cardiovascular (including but not specific to stroke) prophylaxis among persons whose risk is sufficiently high for the benefits to outweigh the risks associated with treatment (a 10-year risk of cardiovascular events of 6% to 10%), and this panel agrees (Class I, Level of Evidence A). Aspirin can be useful for prevention of a first stroke among women whose risk is sufficiently high for the benefits to outweigh the risks associated with treatment (Class IIa, Level of Evidence B). The use of aspirin for other specific situations (eg, atrial fibrillation, carotid artery stenosis) is discussed in the relevant sections of this statement.

Summary of Recommendations

Assessing the Risk of a First Stroke

Each individual patient should have an assessment of his or her stroke risk (Class I, Level of Evidence A). The use of a risk-assessment tool such as the Framingham Stroke Profile should be considered as these tools can help identify individuals who could benefit from therapeutic interventions and who may not be treated based on any 1 risk factor (Class IIa, Level of Evidence B).

Genetic Causes of Stroke

Referral for genetic counseling may be considered for patients with rare genetic causes of stroke (Class IIb, Level of Evidence C). There remain insufficient data to recommend genetic screening for the prevention of a first stroke.

Cardiovascular Disease

Persons with evidence of noncerebrovascular atherosclerotic vascular disease (coronary heart disease, cardiac failure, or intermittent claudication) are at increased risk of a first stroke. Treatments used in the management of these other conditions (eg, platelet antiaggregants) and as recommended in other sections of this guideline can reduce the risk of stroke (Class and Level of Evidence as indicated in the relevant sections).

Hypertension

Regular screening for hypertension (at least every 2 years in adults and more frequently in minority populations and the elderly) and appropriate management (Class I, Level of Evidence A), including dietary changes, lifestyle modification, and pharmacological therapy as summarized in the JNC 7, are recommended.

Cigarette Smoking

Abstention from cigarette smoking and smoking cessation for current smokers are recommended (Table 7) (Class I, Level of Evidence B). Data from cohort and epidemiological studies are consistent and overwhelming. Avoidance of environmental tobacco smoke for stroke prevention should also be considered (Class IIa, Level of Evidence C). The use of counseling, nicotine products, and oral smoking-cessation medications has been found to be effective for smokers and should be considered (Class IIa, Level of Evidence B).

Diabetes

It is recommended that hypertension be tightly controlled in patients with either type 1 or type 2 diabetes (the JNC 7 recommendation of $<130/80$ mm Hg in diabetic patients is endorsed) as part of a comprehensive risk-reduction program (Class I, Level of Evidence A). Treatment of adults with diabetes, especially those with additional risk factors, with a statin to lower the risk of a first stroke is recommended (Class I, Level of Evidence A). Recommendations to consider treatment of diabetic patients with an ACEI or ARB are endorsed.

Atrial Fibrillation

Anticoagulation of patients with atrial fibrillation who have valvular heart disease (particularly those with mechanical heart valves) is recommended (Class I, Level of Evidence A). Anti-thrombotic therapy (warfarin or aspirin) is recommended to prevent stroke in patients with nonvalvular atrial fibrillation based on assessment of their absolute stroke risk and estimated bleeding risk while considering patient preferences and access to high-quality anticoagulation monitoring (Class I, Level of Evidence A). Warfarin (INR 2.0 to 3.0) is recommended for high-risk ($>4\%$ annual risk of stroke) patients (and for most moderate-risk patients according to patient preferences) with atrial fibrillation who have no clinically significant contraindications to oral anticoagulants (Class I, Level of Evidence A).

Other Cardiac Conditions

Various AHA/ACC practice guidelines recommend strategies to reduce the risk of stroke in patients with a variety of cardiac conditions. These include the management of patients with valvular heart disease, unstable angina, chronic stable angina, and acute MI. Strategies to prevent postoperative neurological injury and stroke in patients undergoing surgical revascularization for atherosclerotic heart disease are discussed in detail in the recently published coronary artery bypass graft surgery guidelines. It is reasonable to prescribe warfarin for post–ST-segment–elevation patients with MI and LV dysfunction with extensive regional wall-motion abnormalities (Class IIa, Level of Evidence A), and warfarin may be considered in patients with severe LV dysfunction with or without congestive heart failure (Class IIb, Level of Evidence C).

Dyslipidemia

National Cholesterol Education Program III guidelines for the management of patients who have not had a cerebrovascular event with elevated total cholesterol, or with elevated non-HDL cholesterol in the presence of hypertriglyceridemia, are endorsed. It is recommended that patients with known coronary heart disease (CHD) and high-risk hypertensive patients even with normal LDL cholesterol levels be treated with lifestyle measures and a statin (Class I, Level of Evidence A). The use of lipid-lowering therapy in diabetic patients is specifically addressed in the diabetes section of this guideline. Suggested treatments for patients with known CHD and low HDL cholesterol include weight loss, increased physical activity, smoking cessation, and possibly niacin or gemfibrozil (Class IIa, Level of Evidence B).

Asymptomatic Carotid Stenosis

It is recommended that patients with asymptomatic carotid artery stenosis be screened for other treatable causes of stroke and that intensive therapy of all identified stroke risk factors be pursued (Class I, Level of Evidence C). The use of aspirin is recommended unless contraindicated because aspirin was used in all of the cited trials as an antiplatelet drug except in the surgical arm of 1 study, in which there was a higher rate of MI in those who were not given aspirin (Class I, Level of Evidence B). Prophylactic carotid endarterectomy is recommended in highly selected patients with high-grade asymptomatic carotid stenosis performed by surgeons with <3% morbidity/mortality rates (Class I, Level of Evidence A). Patient selection should be guided by an assessment of comorbid conditions and life expectancy, as well as other individual factors, and be balanced by an understanding of the overall impact of the procedure if all-cause mortality is considered as one of the end points, and it should include a thorough discussion of the risks and benefits of the procedure with an understanding of patient preferences. Carotid angioplasty–stenting might be a reasonable alternative to endarterectomy in asymptomatic patients at high risk for the surgical procedure (Class IIb, Level of Evidence B); however, given the reported periprocedural and overall 1-year event rates, it remains uncertain whether this group of patients should have either procedure.

Sickle Cell Disease

It is recommended that children with SCD be screened with TCD ultrasound starting at 2 years of age (Class I, Level of

Evidence B). It is recommended that transfusion therapy be considered for those at elevated stroke risk (Class I, Level of Evidence B). Although the optimal screening interval has not been established, it is reasonable that younger children and those with TCD velocities in the conditional range should be re-screened more frequently to detect development of high-risk TCD indications for intervention (Class IIa, Level of Evidence B). Pending further studies, it is reasonable to continue transfusion even in those whose TCD velocities revert to normal (Class IIa, Level of Evidence B). MRI and MRA criteria for selection of children for primary stroke prevention using transfusion have not been established, and these tests should not be substituted for TCD (Class III, Level of Evidence B). Adults with SCD should be evaluated for known stroke risk factors and managed according to the general guidelines in this statement (Class I, Level of Evidence A).

Postmenopausal Hormone Therapy

It is recommended that postmenopausal hormone therapy (with estrogen with or without a progestin) not be used for primary prevention of stroke (Class III, Level of Evidence A). The use of hormone replacement therapy for other indications should be informed by the risk estimate for vascular outcomes provided by the reviewed clinical trials. There are not sufficient data to provide recommendations about the use of other forms of therapy such as selective estrogen receptor modulators.

Diet and Nutrition

A reduced intake of sodium and increased intake of potassium is recommended to lower blood pressure in persons with hypertension (Class I, Level of Evidence A), which may thereby reduce the risk of stroke. The recommended sodium intake is ≤ 2.3 g/d (100 mmol/d), and the recommended potassium intake is ≥ 4.7 g/d (120 mmol/d). The DASH diet, which emphasizes fruit, vegetables, and low-fat dairy products and is reduced in saturated and total fat, also lowers blood pressure and is recommended (Class I, Level of Evidence A). A diet that is rich in fruits and vegetables may lower the risk of stroke and may be considered (Class IIb, Level of Evidence C).

Physical Inactivity

Increased physical activity is recommended because it is associated with a reduction in the risk of stroke (Class I, Level of Evidence B). Exercise guidelines as recommended by the CDC and the National Institutes of Health (≥ 30 minutes of moderate-intensity activity daily) as part of a healthy lifestyle are reasonable (Class IIa, Level of Evidence B).

Obesity and Body Fat Distribution

Epidemiological studies indicate that increased body weight and abdominal fat are directly associated with stroke risk. Weight reduction is recommended because it lowers blood pressure (Class I, Level of Evidence A) and may thereby reduce the risk of stroke.

Metabolic Syndrome

Management of individual components of the metabolic syndrome, including lifestyle measures and pharmacotherapy as recommended in the National Cholesterol Educa-

tion Program ATP III and the JNC 7 as reviewed in other sections of this guideline, are endorsed. Lifestyle management should include exercise, appropriate weight loss, and proper diet. Pharmacotherapy may include medications for blood pressure lowering, lipid lowering, glycemic control, treatment of microalbuminuria or proteinuria, and antiplatelet therapy (eg, aspirin) according to the individual circumstance and risk. It is not known whether agents that ameliorate aspects of the insulin resistance syndrome are useful for reducing stroke risk.

Alcohol Abuse

Reduction of alcohol consumption in heavy drinkers through established screening and counseling methods as outlined in the US Preventive Services Task Force Update 2004 is endorsed. For those who consume alcohol, a recommendation of ≤ 2 drinks per day for men and ≤ 1 drink per day for nonpregnant women best reflects the state of the science for alcohol and stroke risk (Class IIb, Level of Evidence B).

Drug Abuse

Successful identification and management of drug abuse can be challenging. When a patient is identified as having a drug addiction problem, referral for appropriate counseling may be considered (Class IIb, Level of Evidence C).

Oral Contraceptives

The incremental risk of stroke associated with use of low-dose OCs in women without additional risk factors appears low, if it exists (Class III, Level of Evidence B). It is suggested that OCs be discouraged in women with additional risk factors (eg, cigarette smoking or prior thromboembolic events [Class III, Level of Evidence C]). For those who elect to assume the increased risk, aggressive therapy of stroke risk factors may be useful (Class IIb, Level of Evidence C).

Sleep-Disordered Breathing

SDB is associated with stroke risk. Questioning bed partners and patients, particularly those with abdominal obesity and hypertension, about symptoms of SDB and referral to a sleep specialist for further evaluation as appropriate may be useful, especially in the setting of drug-resistant hypertension (Class IIb, Level of Evidence C).

Migraine

There are insufficient data to recommend a specific treatment approach that would reduce the risk of first stroke in women with migraine, including migraine with aura.

Hyperhomocysteinemia

Recommendations to meet current guidelines for daily intake of folate (400 $\mu\text{g}/\text{d}$), B₆ (1.7 mg/d), and B₁₂ (2.4 $\mu\text{g}/\text{d}$) by consumption of vegetables, fruits, legumes, meats, fish, and fortified grains and cereals (for nonpregnant, nonlactating individuals) may be useful in reducing the risk of stroke (Class IIb, Level of Evidence C). There are insufficient data to recommend a specific treatment approach that would reduce the risk of first stroke in patients with elevated homocysteine levels. In the interim,

use of folic acid and B vitamins in patients with known elevated homocysteine levels may be useful given their safety and low cost (Class IIb, Level of Evidence C).

Elevated Lipoprotein(a)

Although no definitive recommendations about Lp(a) modification can be made because of an absence of outcome studies showing clinical benefit, treatment with niacin (extended-release or immediate-release formulation at a total daily dose of 2000 mg/d as tolerated) can be considered because it reduces Lp(a) levels by $\approx 25\%$ (Class IIb, Level of Evidence C). Further recommendations must await the results of prospective trials utilizing niacin and statins in subjects stratified for Lp(a) concentration and apo(a) isoform subtypes.

Elevated Lipoprotein-Associated Phospholipase A₂

No recommendations about Lp-PLA₂ modification can be made because of an absence of outcome studies showing clinical benefit with reduction in its blood levels.

Hypercoagulability

There are insufficient data to support specific recommendations for primary stroke prevention in patients with a hereditary or acquired thrombophilia.

Inflammation

Currently, no evidence supports the use of hs-CRP screening of the entire adult population as a marker of general vascular risk. Aggressive risk factor modification is recommended for patients at high risk for stroke given exposure to traditional risk factors regardless of hs-CRP level. In agreement with AHA/CDC guidelines, hs-CRP can be useful in considering the intensity of risk factor modification in those at moderate general cardiovascular risk on the basis of traditional risk factors (Class IIa, Level of Evidence B).

Infection

Data are insufficient to recommend antibiotic therapy for stroke prevention on the basis of seropositivity for 1 or a combination of putative pathogenic organisms. Future studies on stroke risk reduction based on treatment of infectious diseases will require careful stratification and identification of patients at risk for organism exposure.

Aspirin

Aspirin is not recommended for the prevention of a first stroke in men (Class III, Level of Evidence A). The use of aspirin is recommended for cardiovascular (including but not specific to stroke) prophylaxis among persons whose risk is sufficiently high for the benefits to outweigh the risks associated with treatment (a 10-year risk of cardiovascular events of 6% to 10%) (Class I, Level of Evidence A). Aspirin can be useful for prevention of a first stroke among women whose risk is sufficiently high for the benefits to outweigh the risks associated with treatment (Class IIa, Level of Evidence B). The use of aspirin for other specific situations (eg, atrial fibrillation, carotid artery stenosis) is discussed in the relevant sections of this statement.

Disclosures

TABLE 10. Writing Group Disclosures

Writing Group Member Name	Employment	Research Grant	Speakers Bureau/Honoraria	Stock Ownership	Consultant/Advisory Board	Other
Larry B. Goldstein	Duke Center for Cerebrovascular Disease, Duke University Medical Center; Durham Veterans Administration Medical Center	Grants: NIH, Veterans Administration, CDC/University of North Carolina—Chapel Hill, Pfizer/Parke-Davis (SPARCL Steering Committee) Clinical trial site: Boehringer Ingelheim, AGA Corp	Speaking honoraria: Bayer, Pfizer/Parke Davis Speakers bureau: None	None	AstraZeneca, Bristol-Myers Squibb/Sanofi, CuraGen Corp, DPharm, GlaxoSmithKline, Johnson&Johnson, Merck Research Laboratories, Pfizer/Parke Davis	None
Robert Adams	Medical College of Georgia	None	Boehringer Ingelheim, BMS, Wyeth, Sanofi-Synthelabo, Novartis	None	Boehringer Ingelheim, BMS, Sanofi-Synthelabo, Wyeth	Acuson, ATL, BMS, Boehringer Ingelheim, Nicolet
Mark J. Alberts	Northwestern University Medical School	None	None	AstraZeneca, Bristol-Myers Squibb, Sanofi	None	None
Lawrence J. Appel	Johns Hopkins	None	None	None	None	None
Lawrence M. Brass	Yale University	Bristol-Myers Squibb, Sanofi/Synthelabo	Bristol-Myers Squibb, Sanofi/Synthelabo, Solvay Pharmaceuticals, Wyeth	None	AstraZeneca, Bristol-Myers Squibb, Merck, ONO Pharmaceuticals, Sanofi/Synthelabo, Solvay Pharmaceuticals, Wyeth	None
Cheryl D. Bushnell	Duke Center for Cerebrovascular Disease, Duke University Medical Center	None	None	None	None	None
Antonio Culebras	Upstate Medical University	None	Boehringer Ingelheim	None	None	None
Thomas J. DeGraba	National Naval Medical Center	Uniformed Services University of Health Sciences.	None	None	None	None
Philip B. Gorelick	University of Illinois at Chicago	None	Bayer, Bristol-Meyers Squibb—Sanofi, Boehringer-Ingelheim, Merck, Pfizer, Wyeth	None	Bayer, Bristol-Meyers Squibb—Sanofi, Boehringer-Ingelheim, Merck, Pfizer, Wyeth	None
John R. Guyton	Duke University Medical Center	AstraZeneca, Bayer, GlaxoSmithKline, Kos, Merck, Pfizer, Schering Plough	AstraZeneca, GlaxoSmithKline, Kos, Merck, Pfizer, Sankyo Pharma	None	AstraZeneca, Kos, Merck/Schering, Sankyo Pharma, Takeda	None
Robert G. Hart	University of Texas Health Science Center	None	None	None	None	Data safety monitoring boards of clinical trials sponsored by Pfizer (SPARCL), AstraZeneca (SPORTIF III and V), and Sanofi (CHARISMA)
George Howard	University of Alabama at Birmingham	None	None	None	None	None
Margaret Kelly-Hayes	Boston University School of Medicine	None	None	None	None	None
J. V. (Ian) Nixon	Medical College of Virginia	None	None	None	None	None
Ralph L. Sacco	Columbia University	None	Boehringer Ingelheim (Pharm), Sanofi (Pharm)/Bristol-Myers/Squibb	None	Boehringer Ingelheim (Pharm), GlaxoSmithKline (Pharm)	None

This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit.

TABLE 11. Reviewers' Disclosures

Reviewer	Employment	Research Grant	Other Research Support	Speakers Bureau/Honoraria	Ownership Interest	Consultant/Advisory Board	Other
Tamilyn Bakas	Indiana University School of Nursing	None	None	None	None	None	None
Vito M. Campese	University of Southern California	None	None	None	None	None	None
Christopher Cannon	Brigham & Women's Hospital/Harvard Medical School	Bristol-Myers Squibb, Merck, Sanofi-Aventis, AstraZeneca	None	AstraZeneca, Bristol-Myers Squibb, Guilford Pharmaceuticals, Merck, Millennium, Pfizer, Sanofi-Aventis, Schering Plough, BestMed, I3 Magnifi, NCME	None	AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Guilford Pharmaceuticals, Merck, Merck-Schering Plough Partnership, Pfizer, Sanofi-Aventis, Schering Plough, Vertex	None
J. Donald Easton	Rhode Island Hospital-Brown Medical School	None	None	None	None	None	None
S. Claiborne Johnston	University of California, San Francisco	NIH/NINDS, Centocor/Johnson&Johnson, St Jude Medical, Boston Scientific	None	None	None	Renovis	None
David A. Morrow	Brigham & Women's Hospital/Harvard Medical School	Merck & Co, Bayer, Biosite, Bristol-Myers Squibb, Beckman Coulter, Roche Diagnostics	None	Bayer, Beckman Coulter, Dade Behring, Sanofi-Aventis	None	GlaxoSmithKline	None

This table represents the relationships of reviewers that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all reviewers are required to complete and submit.

References

- American Heart Association. *Heart Disease and Stroke Statistics—2004 Update*. Dallas, Tex: American Heart Association; 2003.
- Howard G, Howard VJ, Katholi C, Oli MK, Huston S. Decline in US stroke mortality: an analysis of temporal patterns by sex, race, and geographic region. *Stroke*. 2001;32:2213–2220.
- Brown RD, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO. Stroke incidence, prevalence, and survival: secular trends in Rochester, Minnesota, through 1989. *Stroke*. 1996;27:373–380.
- Fang J, Alderman MH. Trend of stroke hospitalization, United States, 1988–1997. *Stroke*. 2001;32:2221–2226.
- Samsa GP, Matchar DB, Goldstein L, Bonito A, Duncan PW, Lipscomb J, Enarson C, Witter D, Venus P, Paul JE. Utilities for major stroke: results from a survey of preferences among persons at increased risk for stroke. *Am Heart J*. 1998;136:703–713.
- Adams H, Adams R, Del Zoppo G, Goldstein LB; Stroke Council of the American Heart Association; American Stroke Association. Guidelines for the early management of patients with ischemic stroke: 2005 guidelines update: a scientific statement from the Stroke Council of the American Heart Association/American Stroke Association (published corrections appear in *Stroke*. 2005;36:1626 and *Stroke*. 2005;36:1352). *Stroke*. 2005;36:916–923.
- Sacco RL, Benjamin EJ, Broderick JP, Dyken M, Easton JD, Feinberg WM, Goldstein LB, Gorelick PB, Howard G, Kittner SJ, Manolio TA, Whisnant JP, Wolf PA. American Heart Association Prevention Conference. IV. Prevention and Rehabilitation of Stroke Risk factors. *Stroke*. 1997;28:1507–1517.
- Gorelick PB. Stroke prevention. *Arch Neurol*. 1995;52:347–355.
- Rothwell PM, Coull AJ, Giles MF, Howard SC, Silver LE, Bull LM, Gutnikov SA, Edwards P, Mant D, Sackler CM, Farmer A, Sandercock PA, Dennis MS, Warlow CP, Bamford JM, Anslow P; Oxford Vascular Study. Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study). *Lancet*. 2004;363:1925–1933.
- Goldstein LB, Adams R, Becker K, Furberg CD, Gorelick PB, Hademenos G, Hill M, Howard G, Howard VJ, Jacobs B, Levine SR, Mosca L, Sacco RL, Sherman DG, Wolf PA, delZoppo GJ. Primary prevention of ischemic stroke: a statement for healthcare professionals from the Stroke Council of the American Heart Association. *Stroke*. 2001;32:280–299.
- Pearson TA, Bazzarre TL, Daniels SR, Fair JM, Fortmann SP, Franklin BA, Goldstein LB, Hong Y, Mensah GA, Sallis JF Jr, Smith S Jr, Stone NJ, Taubert KA. American Heart Association guide for improving cardiovascular health at the community level: a statement for public health practitioners, healthcare providers, and health policy makers from the American Heart Association Expert Panel on Population and Prevention Science. *Circulation*. 2003;107:645–651.
- Whisnant JP. Modeling of risk factors for ischemic stroke. The Willis Lecture. *Stroke*. 1997;28:1840–1844.
- Grundy SM, Pasternak R, Greenland P, Smith S Jr, Fuster V. AHA/ACC scientific statement: assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. *J Am Coll Cardiol*. 1999;34:1348–1359.
- Pocock SJ, McCormack V, Gueyffier F, Boutitie F, Fagard RH, Boissel JP. A score for predicting risk of death from cardiovascular disease in adults with raised blood pressure, based on individual patient data from randomised controlled trials. *BMJ*. 2001;323:75–81.
- Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham Study. *Stroke*. 1991;22:312–318.
- D'Agostino RB, Wolf PA, Belanger AJ, Kannel WB. Stroke risk profile: adjustment for antihypertensive medication. The Framingham Study. *Stroke*. 1994;25:40–43.

17. Wang TJ, Massaro JM, Levy D, Vasani RS, Wolf PA, D'Agostino RB, Larson MG, Kannel WB, Benjamin EJ. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. *JAMA*. 2003;290:1049–1056.
18. Cappuccio FP, Oakeshott P, Strazzullo P, Kerry SM. Application of Framingham risk estimates to ethnic minorities in United Kingdom and implications for primary prevention of heart disease in general practice: cross sectional population based study [published correction appears in *BMJ*. 2003;327:919]. *BMJ*. 2002;325:1271.
19. Lumley T, Kronmal RA, Cushman M, Manolio TA, Goldstein S. A stroke prediction score in the elderly: validation and Web-based application. *J Clin Epidemiol*. 2002;55:129–136.
20. Simons LA, McCallum J, Friedlander Y, Simons J. Risk factors for ischemic stroke: Dubbo Study of the elderly. *Stroke*. 1998;29:1341–1346.
21. Grundy SM, D'Agostino RB Sr, Mosca L, Burke GL, Wilson PW, Rader DJ, Cleeman JI, Roccella EJ, Cutler JA, Friedman LM. Cardiovascular risk assessment based on US cohort studies: findings from a National Heart, Lung, and Blood Institute workshop. *Circulation*. 2001;104:491–496.
22. Wilson SL, Poulter NR. Cardiovascular risk: its assessment in clinical practice. *Br J Biomed Sci*. 2001;58:248–251.
23. Wolf PA, D'Agostino RB, O'Neal MA, Sytkowski P, Kase CS, Belanger AJ, Kannel WB. Secular trends in stroke incidence and mortality: the Framingham Study. *Stroke*. 1992;23:1551–1555.
24. Sacco RL, Boden-Albala B, Gan R, Chen X, Kargman DE, Shea S, Paik MC, Hauser WA. Stroke incidence among white, black, and Hispanic residents of an urban community: the Northern Manhattan Stroke Study. *Am J Epidemiol*. 1998;147:259–268.
25. Kittner SJ, Stern BJ, Feeser BR, Hebel R, Nagey DA, Buchholz DW, Earley CJ, Johnson CJ, Macko RF, Sloan MA, Wityk RJ, Wozniak MA. Pregnancy and the risk of stroke. *N Engl J Med*. 1996;335:768–774.
26. Qureshi AI, Giles WH, Croft JB, Stern BJ. Number of pregnancies and risk for stroke and stroke subtypes. *Arch Neurol*. 1997;54:203–206.
27. Mosca L, Manson JE, Sutherland SE, Langer RD, Manolio T, Barrett-Connor E. Cardiovascular disease in women: a statement for healthcare professionals from the American Heart Association. *Circulation*. 1997;96:2468–2482.
28. Bousser MG. Stroke in women: the 1997 Paul Dudley White International Lecture. *Circulation*. 1999;99:463–467.
29. Barker DJ, Lackland DT. Prenatal influences on stroke mortality in England and Wales. *Stroke*. 2003;34:1598–1602.
30. Lackland DT, Egan BM, Ferguson PL. Low birth weight as a risk factor for hypertension. *J Clin Hypertens*. 2003;5:133–136.
31. Broderick J, Brott T, Kothari R, Miller R, Khoury J, Pancioli A, Gebel J, Mills D, Minnecci L, Shukla R. The Greater Cincinnati/Northern Kentucky Stroke Study: preliminary first-ever and total incidence rates of stroke among blacks. *Stroke*. 1998;29:415–421.
32. Gorelick PB. Cerebrovascular disease in African Americans. *Stroke*. 1998;29:2656–2664.
33. Howard G, Anderson R, Sorlie P, Andrews V, Backlund E, Burke GL. Ethnic differences in stroke mortality between non-Hispanic whites, Hispanic whites, and blacks: the National Longitudinal Mortality Study. *Stroke*. 1994;25:2120–2125.
34. Rosamond WD, Folsom AR, Chambless LE, Wang CH, McGovern PG, Howard G, Copper LS, Shahar E. Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort. *Stroke*. 1999;30:736–743.
35. Giles WH, Kittner SJ, Hebel JR, Losonczy KG, Sherwin RW. Determinants of black-white differences in the risk of cerebral infarction: the National Health and Nutrition Examination Survey Epidemiologic Follow-up Study. *Arch Intern Med*. 1995;155:1319–1324.
36. Gillum RF. Risk factors for stroke in blacks: a critical review. *Am J Epidemiol*. 1999;150:1266–1274.
37. Sheinart KF, Tuhim S, Horowitz DR, Weinberger J, Goldman M, Godbold JH. Stroke recurrence is more frequent in Blacks and Hispanics. *Neuroepidemiology*. 1998;17:188–198.
38. Frey JL, Jahnke HK, Bulfinch EW. Differences in stroke between white, Hispanic, and Native American patients: the Barrow Neurological Institute stroke database [published correction appears in *Stroke*. 1998;29:1257]. *Stroke*. 1998;29:29–33.
39. He J, Klag MJ, Wu Z, Whelton PK. Stroke in the People's Republic of China: I. Geographic variations in incidence and risk factors. *Stroke*. 1995;26:2222–2227.
40. Welin L, Svardsudd K, Wilhelmsen L, Larsson B, Tibblin G. Analysis of risk factors for stroke in a cohort of men born in 1913. *N Engl J Med*. 1987;317:521–526.
41. Kiely DK, Wolf PA, Cupples LA, Beiser AS, Myers RH. Familial aggregation of stroke: the Framingham Study. *Stroke*. 1993;24:1366–1371.
42. Liao D, Myers R, Hunt S, Shahar E, Paton C, Burke G, Province M, Heiss G. Familial history of stroke and stroke risk: the Family Heart Study. *Stroke*. 1997;28:1908–1912.
43. Rubattu S, Stanzione R, Gigante B, Bagalino A, Musumeci B, Volpe M. Genetic susceptibility to cerebrovascular accidents. *J Cardiovasc Pharmacol*. 2001;38(suppl 2):S71–S74.
44. Brass LM, Isaacsohn JL, Merikangas KR, Robinette CD. A study of twins and stroke. *Stroke*. 1992;23:221–223.
45. Nicolaou M, DeStefano AL, Gavras I, Cupples LA, Manolis AJ, Baldwin CT, Gavras H, Farrer LA. Genetic predisposition to stroke in relatives of hypertensives. *Stroke*. 2000;31:487–492.
46. Turner ST, Boerwinkle E. Genetics of blood pressure, hypertensive complications, and antihypertensive drug responses. *Pharmacogenomics*. 2003;4:53–65.
47. Hassan A, Hunt BJ, O'Sullivan M, Bell R, D'Souza R, Jeffery S, Bamford JM, Markus HS. Homocysteine is a risk factor for cerebral small vessel disease, acting via endothelial dysfunction. *Brain*. 2004;127(pt 1):212–219.
48. Scott CH, Sutton MS. Homocysteine: evidence for a causal relationship with cardiovascular disease. *Cardiol Rev*. 1999;7:101–107.
49. Fodinger M, Horl WH, Sunder-Plassmann G. Molecular biology of 5,10-methylenetetrahydrofolate reductase. *J Nephrol*. 2000;13:20–33.
50. Ortel TL. Genetics of coagulation disorders. In: Alberts MJ, ed. *Genetics of Cerebrovascular Disease*. Armonk, NY: Futura Publishing;1999:129–156.
51. De Lucia D, Renis V, Belli A, Conte M, Di Mauro C, Tortora V, d'Alessio D, Nina PP, Franco A, Schisano G, Papa ML. Familial coagulation-inhibiting and fibrinolytic protein deficiencies in juvenile transient ischaemic attacks. *J Neurosurg Sci*. 1996;40:25–35.
52. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. *Nature*. 1994;369:64–67.
53. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. *N Engl J Med*. 1995;332:912–917.
54. Hillier CE, Collins PW, Bowen DJ, Bowley S, Wiles CM. Inherited prothrombotic risk factors and cerebral venous thrombosis. *QJM*. 1998;91:677–680.
55. Kuwahara S, Abe T, Uga S, Mori K. Superior sagittal sinus and cerebral cortical venous thrombosis caused by congenital protein C deficiency: case report. *Neurol Med Chir*. 2000;40:645–649.
56. Deschiens MA, Conard J, Horellou MH, Ameri A, Preter M, Chedru F, Samama MM, Bousser MG. Coagulation studies, factor V Leiden, and anticardiolipin antibodies in 40 cases of cerebral venous thrombosis. *Stroke*. 1996;27:1724–1730.
57. Hankey GJ, Eikelboom JW, van Bockxmeer FM, Lofthouse E, Staples N, Baker RI. Inherited thrombophilia in ischemic stroke and its pathogenic subtypes. *Stroke*. 2001;32:1793–1799.
58. Juul K, Tybjaerg-Hansen A, Steffensen R, Kofoed S, Jensen G, Nordestgaard BG. Factor V Leiden: The Copenhagen City Heart Study and 2 meta-analyses. *Blood*. 2002;100:3–10.
59. Weber M, Hayem G, DeBandt M, Palazzo E, Roux S, Kahn MF, Meyer O. The family history of patients with primary or secondary antiphospholipid syndrome (APS). *Lupus*. 2000;9:258–263.
60. Goldberg SN, Conti-Kelly AM, Greco TP. A family study of anticardiolipin antibodies and associated clinical conditions. *Am J Med*. 1995;99:473–479.
61. Begelman SM, Olin JW. Fibromuscular dysplasia. *Curr Opin Rheumatol*. 2000;12:41–47.
62. Shetty-Alva N, Alva S. Familial moyamoya disease in Caucasians. *Pediatr Neurol*. 2000;23:445–447.
63. Gretarsdottir S, Thorleifsson G, Reynisdottir ST, Manolescu A, Jonsdottir S, Jonsdottir T, Gudmundsdottir T, Bjarnadottir SM, Einarsson OB, Gudjonsdottir HM, Hawkins M, Gudmundsson G, Gudmundsdottir H, Andrason H, Gudmundsdottir AS, Sigurdardottir M, Chou TT, Nahmias J, Goss S, Sveinbjornsdottir S, Valdimarsson EM, Jakobsson F, Agnarsson U, Gudnason V, Thorgeirsson G, Fingerle J,

- Gurney M, Gudbjartsson D, Frigge ML, Kong A, Stefansson K, Gulcher JR. The gene encoding phosphodiesterase 4D confers risk of ischemic stroke [published correction appears in *Nat Genet.* 2005;37:555]. *Nat Genet.* 2003;35:131–138.
64. Helgadóttir A, Manolescu A, Thorleifsson G, Sveinbjornsdóttir S, Valdimarsson EM, Matthiasson SE, Johannsson H, Gudmundsdóttir O, Gurney ME, Sainz J, Thorhallsdóttir M, Andresdóttir M, Frigge ML, Topol EJ, Kong A, Gudnason V, Hakonarson H, Gulcher JR, Stefansson K. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. *Nat Genet.* 2004;36:233–239.
 65. Tournier-Lasserre E, Joutel A, Chabriat H. Clinical phenotypes and genetic data in 15 unrelated families. *Neurology.* 1995;45(suppl 4):A273.
 66. Kalimo H, Viitanen M, Amberla K, Juvonen V, Marttila R, Poyhonen M, Rinne JO, Savontaus M, Tuisku S, Winblad B. CADASIL: hereditary disease of arteries causing brain infarcts and dementia. *Neuropathol Appl Neurobiol.* 1999;25:257–265.
 67. Forteza AM, Brozman B, Rabinstein AA, Romano JG, Bradley WG. Acetazolamide for the treatment of migraine with aura in CADASIL. *Neurology.* 2001;57:2144–2145.
 68. Durlach J. A possible advance in arterial gene therapy for aortic complications in the Marfan syndrome by local transfer of an antisense Mg-dependent hammerhead ribozyme. *Magn Res.* 2001;14:65–67.
 69. Desnick RJ, Ioannou YA, Eng CM. Alpha-galactosidase A deficiency: Fabry disease. In: Scriver CR, Beauder AL, Sly WS, et al, eds. *The Metabolic and Molecular Bases of Inherited Disease.* New York, NY: McGraw-Hill; 2001:3733–3774.
 70. De Schoenmakere G, Chauveau D, Grunfeld JP. Enzyme replacement therapy in Anderson-Fabry's disease: beneficial clinical effect on vital organ function. *Nephrol Dial Transplant.* 2003;18:33–35.
 71. Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, Caplan L, Linthorst GE, Desnick RJ; International Collaborative Fabry Disease Study Group. Safety and efficacy of recombinant human alpha-galactosidase A—replacement therapy in Fabry's disease. *N Engl J Med.* 2001;345:9–16.
 72. Schiffmann R, Kopp JB, Austin HA III, Sabnis S, Moore DF, Weibel T, Balow JE, Brady RO. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. *JAMA.* 2001;285:2743–2749.
 73. Moore DF, Altarescu G, Herscovitch P, Schiffmann R. Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease. *BMC Neurol.* 2002;2:4.
 74. Fields LE, Burt VL, Cutler JA, Hughes J, Roccella EJ, Sorlie P. The burden of adult hypertension in the United States 1999 to 2000: a rising tide. *Hypertension.* 2004;44:398–404.
 75. Wolf PA. Cerebrovascular risk. In: Izzo JLI, Black HR, eds. *Hypertension Primer: The Essentials of High Blood Pressure.* Baltimore, Md: Lippincott, Williams & Wilkins; 1999:239.
 76. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report [published correction appears in *JAMA.* 2003;290:197]. *JAMA.* 2003;289:2560–2572.
 77. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies [published correction appears in *Lancet.* 2003;361:1060]. *Lancet.* 2002;360:1903–1913.
 78. Burt VL, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M, Horan MJ, Labarthe D. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988–1991. *Hypertension.* 1995;25:305–313.
 79. Vasan RS, Beiser A, Seshadri S, Larson MG, Kannel WB, D'Agostino RB, Levy D. Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham Heart Study. *JAMA.* 2002;287:1003–1010.
 80. Psaty BM, Smith NL, Siscovick DS, Koepsell TD, Weiss NS, Heckbert SR, Lemaitre RN, Wagner EH, Furberg CD. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. *JAMA.* 1997;277:739–745.
 81. Neal B, MacMahon S, Chapman N. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. *Lancet.* 2000;356:1955–1964.
 82. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. *Lancet.* 1998;351:1755–1762.
 83. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) [published corrections appear in *JAMA.* 2003;289:178 and *JAMA.* 2004;18:2196]. *JAMA.* 2002;288:2981–2997.
 84. Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, White WB, Neaton JD, Grimm RH Jr, Hansson L, Lacourciere Y, Muller J, Sleight P, Weber MA, Williams G, Wittes J, Zanchetti A, Anders RJ; CONVINCe Research Group. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. *JAMA.* 2003;289:2073–2082.
 85. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. *Lancet.* 2002;359:995–1003.
 86. Turnbull F, Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. *Lancet.* 2003;362:1527–1535.
 87. Black HR, Elliott WJ, Neaton JD, Grandits G, Grambsch P, Grimm RH Jr, Hansson L, Lacourciere Y, Muller J, Sleight P, Weber MA, White WB, Williams G, Wittes J, Zanchetti A, Fakouhi TD, Anders RJ. Baseline characteristics and early blood pressure control in the CONVINCe Trial. *Hypertension.* 2001;37:12–18.
 88. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, Black HR, Hamilton BP, Holland J, Nwachuku C, Papademetriou V, Probstfield J, Wright JT Jr, Alderman MH, Weiss RJ, Piller L, Bettencourt J, Walsh SM, ALLHAT Collaborative Research Group. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). *J Clin Hypertens.* 2002;4:393–404.
 89. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, Bulpitt CJ, de Leeuw PW, Dollyer CT, Fletcher AE, Forette F, Leonetti G, Nachev C, O'Brien ET, Rosenfeld J, Rodicio JL, Tuomilehto J, Zanchetti A. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension: the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. *Lancet.* 1997;350:757–764.
 90. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). *JAMA.* 1991;265:3255–3264.
 91. Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States [published correction appears in *N Engl J Med.* 2002;346:544]. *N Engl J Med.* 2001;345:479–486.
 92. Douglas JG, Bakris GL, Epstein M, Ferdinand KC, Ferrario C, Flack JM, Jamerson KA, Jones WE, Hayward J, Macey R, Ofili EO, Saunders E, Schiffrin EL, Sica DA, Sowers JR, Vidt DG. Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. *Arch Intern Med.* 2003;163:525–541.
 93. Whelton PK, He J, Appel LJ, Cutler JA, Havas S, Kotchen TA, Roccella EJ, Stout R, Vallbona C, Winston MC, Karimbakas J. Primary prevention of hypertension: clinical and public health advisory from the National High Blood Pressure Education Program. *JAMA.* 2002;288:1882–1888.
 94. Manolio TA, Kronmal RA, Burke GL, O'Leary DH, Price TR. Short-term predictors of incident stroke in older adults: the Cardiovascular Health Study. *Stroke.* 1996;27:1479–1486.
 95. Rodriguez BL, D'Agostino R, Abbott RD, Kagan A, Burchfiel CM, Yano K, Ross GW, Silbershatz H, Higgins MW, Popper J, Wolf PA,

- Curb JD. Risk of hospitalized stroke in men enrolled in the Honolulu Heart Program and the Framingham Study: a comparison of incidence and risk factor effects. *Stroke*. 2002;33:230–236.
96. Kurth T, Kase CS, Berger K, Gaziano JM, Cook NR, Buring JE. Smoking and risk of hemorrhagic stroke in women. *Stroke*. 2003;34:2792–2795.
 97. Broderick JP, Viscoli CM, Brott T, Kernan WN, Brass LM, Feldmann E, Morgenstern LB, Wilterdink JL, Horwitz RI; Hemorrhagic Stroke Project Investigators. Major risk factors for aneurysmal subarachnoid hemorrhage in the young are modifiable. *Stroke*. 2003;34:1375–1381.
 98. Shinton R, Beevers G. Meta-analysis of relation between cigarette smoking and stroke. *BMJ*. 1989;298:789–794.
 99. Thun MJ, Apicella LF, Henley SJ. Smoking vs other risk factors as the cause of smoking-attributable deaths: confounding in the courtroom. *JAMA*. 2000;284:706–712.
 100. US Department of Health and Human Services. *Reducing the Health Consequences of Smoking: 25 Years of Progress. A Report of the Surgeon General*. Rockville, Md: US Department of Health and Human Services, Public Health Service, Centers for Disease Control, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 1989. DHHS Publication No. (CDC) 89-8411.
 101. The Centers for Disease Control. The Surgeon General's 1989 Report on Reducing the Health Consequences of Smoking: 25 Years of Progress. *MMWR Morb Mortal Wkly Rep*. 1989;38(suppl 2):1–32.
 102. Ischaemic stroke and combined oral contraceptives: results of an international, multicentre, case-control study: WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. *Lancet*. 1996;348:498–505.
 103. World Health Organization. Haemorrhagic stroke, overall stroke risk, and combined oral contraceptives: results of an international, multicentre, case-control study: WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. *Lancet*. 1996;348:505–510.
 104. Barnoya J, Glantz SA. Secondhand smoke: the evidence of danger keeps growing. *Am J Med*. 2004;116:201–202.
 105. Bonita R, Duncan J, Truelsen T, Jackson RT, Beaglehole R. Passive smoking as well as active smoking increases the risk of acute stroke. *Tob Control*. 1999;8:156–160.
 106. You RX, Thrift AG, McNeil JJ, Davis SM, Donnan GA. Ischemic stroke risk and passive exposure to spouses' cigarette smoking. Melbourne Stroke Risk Factor Study (MERFS) Group. *Am J Public Health*. 1999;89:572–575.
 107. Howard G, Thun MJ. Why is environmental tobacco smoke more strongly associated with coronary heart disease than expected? A review of potential biases and experimental data. *Environ Health Perspect*. 1999;107(suppl 6):853–858.
 108. Burns DM. Epidemiology of smoking-induced cardiovascular disease. *Prog Cardiovasc Dis*. 2003;46:11–29.
 109. Kool MJ, Hoeks AP, Struijker Boudier HA, Reneman RS, Van Bortel LM. Short- and long-term effects of smoking on arterial wall properties in habitual smokers. *J Am Coll Cardiol*. 1993;22:1881–1886.
 110. Silvestrini M, Troisi E, Matteis M, Cupini LM, Bernardi G. Effect of smoking on cerebrovascular reactivity. *J Cereb Blood Flow Metab*. 1996;16:746–749.
 111. Howard G, Wagenknecht LE, Burke GL, Diez-Roux A, Evans GW, McGovern P, Nieto FJ, Tell GS. Cigarette smoking and progression of atherosclerosis: the Atherosclerosis Risk in Communities (ARIC) Study. *JAMA*. 1998;279:119–124.
 112. Karttunen V, Alftan G, Hiltunen L, Rasi V, Kervinen K, Kesaniemi YA, Hillbom M. Risk factors for cryptogenic ischaemic stroke. *Eur J Neurol*. 2002;9:625–632.
 113. Fagerstrom K. The epidemiology of smoking: health consequences and benefits of cessation. *Drugs*. 2002;62(suppl 2):1–9.
 114. Robbins AS, Manson JE, Lee IM, Satterfield S, Hennekens CH. Cigarette smoking and stroke in a cohort of US male physicians. *Ann Intern Med*. 1994;120:458–462.
 115. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. *Cochrane Database Syst Rev*. 2003;(2):CD000031.
 116. Silagy C, Lancaster T, Stead L, et al. Nicotine replacement therapy for smoking cessation. *Cochrane Database Syst Rev*. 2004;(3):CD000146.
 117. Fiore MC. US Public Health Service clinical practice guideline: treating tobacco use and dependence. *Respiratory Care*. 2000;45:1200–1262.
 118. US Department of Health and Human Services. *The Health Consequences of Smoking: A Report of the Surgeon General*. Washington, DC: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2004.
 119. US Preventive Services Task Force. *Guide to Clinical Preventive Services*. 2nd ed. Baltimore, Md: Williams & Wilkins; 1996.
 120. Burchfiel CM, Curb JD, Rodriguez BL, Abbott RD, Chiu D, Yano K. Glucose intolerance and 22-year stroke incidence: the Honolulu Heart Program. *Stroke*. 1994;25:951–957.
 121. Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham Study. *JAMA*. 1979;241:2035–2038.
 122. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. *N Engl J Med*. 2003;348:383–393.
 123. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group [published correction appears in *Lancet*. 1998;352:1558]. *Lancet*. 1998;352:854–865.
 124. Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H, Camel G, Davis BR, Frost PH, Gonzalez N, Guthrie G, Oberman A, Rutan GH, Stamler J. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group [published correction appears in *JAMA*. 1997;277:1356]. *JAMA*. 1996;276:1886–1892.
 125. Tuomilehto J, Rastenyte D. Diabetes and glucose intolerance as risk factors for stroke. *J Cardiovasc Risk*. 1999;6:241–249.
 126. Implementation of treatment protocols in the Diabetes Control and Complications Trial. *Diabetes Care*. 1995;18:361–376.
 127. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators [published correction appears in *Lancet*. 2000;356:860]. *Lancet*. 2000;355:253–259.
 128. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S; LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. *Lancet*. 2002;359:1004–1010.
 129. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. *Lancet*. 2003;361:1149–1158.
 130. Goldberg RB, Mellies MJ, Sacks FM, Moye LA, Howard BV, Howard WJ, Davis BR, Cole TG, Pfeffer MA, Braunwald E. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the Cholesterol and Recurrent Events (CARE) trial. The CARE Investigators. *Circulation*. 1998;98:2513–2519.
 131. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. *Lancet*. 2002;360:7–22.
 132. Collins R, Armitage J, Parish S, Sleight P, Peto R, Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. *Lancet*. 2003;361:2005–2016.
 133. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH; CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. *Lancet*. 2004;364:685–696.
 134. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). *JAMA*. 2001;285:2486–2497.
 135. Bonow RO, Carabello B, de Leon AC Jr, Edmunds LH Jr, Fedderly BJ, Freed MD, Gaasch WH, McKay CR, Nishimura RA, O'Gara PT, O'Rourke RA, Rahimtoola SH, Ritchie JL, Cheitlin MD, Eagle KA,

- Gardner TJ, Garson A Jr, Gibbons RJ, Russell RO, Ryan TJ, Smith SC Jr. ACC/AHA guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Valvular Heart Disease). *J Am Coll Cardiol*. 1998;32(5):1486-1588.
136. Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. *Circulation*. 1994;89:635-641.
 137. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. *Stroke*. 1991;22:983-988.
 138. Go AS, Hylek EM, Chang Y, Phillips KA, Henault LE, Capra AM, Jensvold NG, Selby JV, Singer DE. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? *JAMA*. 2003;290:2685-2692.
 139. van Walraven C, Hart RG, Singer DE, Laupacis A, Connolly S, Petersen P, Koudstaal PJ, Chang Y, Hellemons B. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. *JAMA*. 2002;288:2441-2448.
 140. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. *JAMA*. 2001;285:2370-2375.
 141. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. *Circulation*. 1998;98:946-952.
 142. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD; Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. *N Engl J Med*. 2002;347:1825-1833.
 143. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. *Ann Intern Med*. 1999;131:492-501.
 144. Olsson SB, Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. *Lancet*. 2003;362:1691-1698.
 145. Albers GW, SPORTIF Investigators. Stroke prevention in atrial fibrillation: pooled analysis of SPORTIF III and V trials. *Am J Manag Care*. 2004;10(14 suppl):S462-S469; discussion S469-S473.
 146. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. *JAMA*. 2001;285:2864-2870.
 147. Gage BF, van Walraven C, Pearce L, Hart RG, Koudstaal PJ, Boode BS, Petersen P. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. *Circulation*. 2004;110:2287-2292.
 148. Hart RG, Halperin JL, Pearce LA, Anderson DC, Kronmal RA, McBride R, Nasco E, Sherman DG, Talbert RL, Marler JR; Stroke Prevention in Atrial Fibrillation Investigators. Lessons from the Stroke Prevention in Atrial Fibrillation trials. *Ann Intern Med*. 2003;138:831-838.
 149. Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, Halperin JL, Kay GN, Klein WW, Levy S, McNamara RL, Prystowsky EN, Wann LS, Wyse DG, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Hiratzka LF, Jacobs AK, Russell RO, Smith SC Jr, Klein WW, Alonso-Garcia A, Blomstrom-Lundqvist C, de Backer G, Flather M, Hradec J, Oto A, Parkhomenko A, Silber S, Torbicki A; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation); North American Society of Pacing and Electrophysiology. ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology. *Circulation*. 2001;104:2118-2150.
 150. Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. *Stroke*. 1999;30:1223-1229.
 151. van Walraven C, Hart RG, Wells GA, Petersen P, Koudstaal PJ, Gullov AL, Hellemons BS, Koefed BG, Laupacis A. A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin. *Arch Intern Med*. 2003;163:936-943.
 152. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. *JAMA*. 1998;279:1273-1277.
 153. Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, Halperin JL, Kay GN, Klein WW, Levy S, McNamara RL, Prystowsky EN, Wann LS, Wyse DG, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Hiratzka LF, Jacobs AK, Russell RO, Smith SC, Klein WW, Alonso-Garcia A, Blomstrom-Lundqvist C, De Backer G, Flather M, Hradec J, Oto A, Parkhomenko A, Silber S, Torbicki A; American College of Cardiology/American Heart Association/European Society of Cardiology Board. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the North American Society of Pacing and Electrophysiology. *J Am Coll Cardiol*. 2001;38:1231-1266.
 154. Stafford RS, Singer DE. National patterns of warfarin use in atrial fibrillation. *Arch Intern Med*. 1996;156:2537-2541.
 155. Brass LM, Krumholz HM, Scinto JM, Radford M. Warfarin use among patients with atrial fibrillation. *Stroke*. 1997;28:2382-2389.
 156. Gage BF, Boechler M, Doggette AL, Fortune G, Flaker GC, Rich MW, Radford MJ. Adverse outcomes and predictors of underuse of anti-thrombotic therapy in medicare beneficiaries with chronic atrial fibrillation. *Stroke*. 2000;31:822-827.
 157. Hart RG. Warfarin in atrial fibrillation: underused in the elderly, often inappropriately used in the young. *Heart*. 1999;82:539-540.
 158. Bleeding during antithrombotic therapy in patients with atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. *Arch Intern Med*. 1996;156:409-416.
 159. Oden A, Fahlen M, Hart R. Optimal INR for prevention of stroke and mortality in atrial fibrillation: a critical appraisal. *Thromb Res*. In press.
 160. Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, Singer DE. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. *N Engl J Med*. 2003;349:1019-1026.
 161. Hart RG. Intensity of anticoagulation to prevent stroke in patients with atrial fibrillation. *Ann Intern Med*. 1998;128:408.
 162. Singer DE, Albers GW, Dalen JE, Go AS, Halperin JL, Manning WJ. Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest*. 2004;126(3 suppl):429S-456S.
 163. Chapman N, Huxley R, Anderson C, Boussier MG, Chalmers J, Colman S, Davis S, Donnan G, MacMahon S, Neal B, Warlow C, Woodward M; Writing Committee for the PROGRESS Collaborative Group. Effects of a perindopril-based blood pressure-lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS Trial. *Stroke*. 2004;35:116-121.
 164. Arima H, Hart RG, Colman S, et al. Perindopril-based blood pressure lowering reduces major vascular events in patients with atrial fibrillation and prior stroke or transient ischemic attack. *Stroke*. 2005;36:2164-2169.
 165. Jencks SF, Cuerdon T, Burwen DR, Fleming B, Houck PM, Kussmaul AE, Nilasena DS, Ordin DL, Arday DR. Quality of medical care delivered to Medicare beneficiaries: a profile at state and national levels. *JAMA*. 2000;284:1670-1676.
 166. Di Pasquale G, Urbinati S, Pinelli G. Cardiac investigation in patients with cerebrovascular disease. In: Ginsberg M, Bogousslavsky J, eds. *Cerebrovascular Disease: Pathophysiology, Diagnosis, and Management*. Malden, Mass: Blackwell Science; 1998.
 167. Rokey R, Rolak LA, Harati Y, Kutica N, Verani MS. Coronary artery disease in patients with cerebrovascular disease: a prospective study. *Ann Neurol*. 1984;16:50-53.

168. Hertzner NR, Lees CD. Fatal myocardial infarction following carotid endarterectomy: three hundred thirty-five patients followed 6–11 years after operation. *Ann Surg.* 1981;194:212–218.
169. Komrad MS, Coffey CE, Coffey KS, McKinnis R, Massey EW, Califf RM. Myocardial infarction and stroke. *Neurology.* 1984;34:1403–1409.
170. Chimowitz MI, Mancini GB. Asymptomatic coronary artery disease in patients with stroke. Prevalence, prognosis, diagnosis, and treatment. *Stroke.* 1992;23:433–436.
171. Chimowitz MI, Poole RM, Starling MR, Schwaiger M, Gross MD. Frequency and severity of asymptomatic coronary disease in patients with different causes of stroke. *Stroke.* 1997;28:941–945.
172. Di Pasquale G, Andreoli A, Pinelli G, Grazi P, Manini G, Tognetti F, Testa C. Cerebral ischemia and asymptomatic coronary artery disease: a prospective study of 83 patients. *Stroke.* 1986;17:1098–1101.
173. Urbinati S, Di Pasquale G, Andreoli A, Lusa AM, Ruffini M, Lanzino G, Pinelli G. Frequency and prognostic significance of silent coronary artery disease in patients with cerebral ischemia undergoing carotid endarterectomy. *Am J Cardiol.* 1992;69:1166–1170.
174. Sen S, Oppenheimer SM. Cardiac disorders and stroke. *Curr Opin Neurol.* 1998;11:51–56.
175. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia. *Circulation.* 1994;89:1545–1556.
176. Mahaffey KW, Harrington RA, Simoons ML, Granger CB, Graffagnino C, Alberts MJ, Laskowitz DT, Miller JM, Sloan MA, Berdan LG, MacAulay CM, Lincoff AM, Deckers J, Topol EJ, Califf RM. Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators. *Circulation.* 1999;99:2371–2377.
177. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators. *N Engl J Med.* 1996;335:775–782.
178. Loh E, Sutton MS, Wun CC, Rouleau JL, Flaker GC, Gottlieb SS, Lamas GA, Moye LA, Goldhaber SZ, Pfeffer MA. Ventricular dysfunction and the risk of stroke after myocardial infarction. *N Engl J Med.* 1997;336:251–257.
179. Gardner TJ, Horneffer PJ, Manolio TA, Pearson TA, Gott VL, Baumgartner WA, Borkon AM, Watkins L Jr, Reitz BA. Stroke following coronary artery bypass grafting: a ten-year study. *Ann Thorac Surg.* 1985;40:574–581.
180. Reed GL 3rd, Singer DE, Picard EH, DeSanctis RW. Stroke following coronary-artery bypass surgery. A case-control estimate of the risk from carotid bruits. *N Engl J Med.* 1988;319:1246–1250.
181. Tuman KJ, McCarthy RJ, Najafi H, Ivankovich AD. Differential effects of advanced age on neurologic and cardiac risks of coronary artery operations. *J Thorac Cardiovasc Surg.* 1992;104:1510–1517.
182. Frye RL, Kronmal R, Schaff HV, et al. Stroke in coronary artery bypass graft surgery: an analysis of the CASS experience. The participants in the Coronary Artery Surgery Study. *Int J Cardiol.* 1992;36:213–221.
183. Gold JP, Charlson ME, Williams-Russo P, Szatrowski TP, Peterson JC, Pirraglia PA, Hartman GS, Yao FS, Hollenberg JP, Barbut D. Improvement of outcomes after coronary artery bypass: a randomized trial comparing intraoperative high versus low mean arterial pressure. *J Thorac Cardiovasc Surg.* 1995;110:1302–1311; discussion 1311–1314.
184. Newman MF, Wolman R, Kanchuger M, Marschall K, Mora-Mangano C, Roach G, Smith LR, Aggarwal A, Nussmeier N, Herskowitz A, Mangano DT. Multicenter preoperative stroke risk index for patients undergoing coronary artery bypass graft surgery. Multicenter Study of Perioperative Ischemia (McSPI) Research Group. *Circulation.* 1996;94(9 suppl):II-74–II-80.
185. Almassi GH, Sommers T, Moritz TE, Shroyer AL, London MJ, Henderson WG, Sethi GK, Grover FL, Hammermeister KE. Stroke in cardiac surgical patients: determinants and outcome. *Ann Thorac Surg.* 1999;68:391–397; discussion 397–398.
186. Hogue CW Jr, Murphy SF, Schechtman KB, Davila-Roman VG. Risk factors for early or delayed stroke after cardiac surgery. *Circulation.* 1999;100:642–647.
187. Alexander KP, Anstrom KJ, Muhlbaier LH, Grosswald RD, Smith PK, Jones RH, Peterson ED. Outcomes of cardiac surgery in patients > or = 80 years: results from the National Cardiovascular Network. *J Am Coll Cardiol.* 2000;35:731–738.
188. Peterson ED, Cowper PA, Jollis JG, Bechuk JD, DeLong ER, Muhlbaier LH, Mark DB, Pryor DB. Outcomes of coronary artery bypass graft surgery in 24,461 patients aged 80 years or older. *Circulation.* 1995;92(9 suppl):II-85–II-91.
189. Wolman RL, Nussmeier NA, Aggarwal A, Kanchuger MS, Roach GW, Newman MF, Mangano CM, Marschall KE, Ley C, Boisvert DM, Ozanne GM, Herskowitz A, Graham SH, Mangano DT. Cerebral injury after cardiac surgery: identification of a group at extraordinary risk. Multicenter Study of Perioperative Ischemia Research Group (McSPI) and the Ischemia Research Education Foundation (IREF) Investigators. *Stroke.* 1999;30:514–522.
190. Roach GW, Kanchuger M, Mangano CM, Newman M, Nussmeier N, Wolman R, Aggarwal A, Marschall K, Graham SH, Ley C. Adverse cerebral outcomes after coronary bypass surgery. Multicenter Study of Perioperative Ischemia Research Group and the Ischemia Research and Education Foundation Investigators. *N Engl J Med.* 1996;335:1857–1863.
191. Stern A, Tunick PA, Culliford AT, Lachmann J, Baumann FG, Kanchuger MS, Marschall K, Shah A, Grossi E, Kronzon I. Protruding aortic arch atheromas: risk of stroke during heart surgery with and without aortic arch endarterectomy. *Am Heart J.* 1999;138(4 pt 1):746–752.
192. Davila-Roman VG, Murphy SF, Nickerson NJ, Kouchoukos NT, Schechtman KB, Barzilai B. Atherosclerosis of the ascending aorta is an independent predictor of long-term neurologic events and mortality. *J Am Coll Cardiol.* 1999;33:1308–1316.
193. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, Jones RH, Kereiakes D, Kupersmith J, Levin TN, Pepine CJ, Schaeffer JW, Smith EE 3rd, Steward DE, Theroux P, Gibbons RJ, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Hiratzka LF, Jacobs AK, Smith SC Jr; American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). *Circulation.* 2002;106:1893–1900.
194. Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS, Ferguson TB Jr, Fihn SD, Fraker TD Jr, Gardin JM, O'Rourke RA, Pasternak RC, Williams SV, Gibbons RJ, Alpert JS, Antman EM, Hiratzka LF, Fuster V, Faxon DP, Gregoratos G, Jacobs AK, Smith SC Jr; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Committee on the Management of Patients With Chronic Stable Angina. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for the Management of Patients with Chronic Stable Angina). *Circulation.* 2003;107:149–158.
195. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC Jr, Alpert JS, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Gregoratos G, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK, Ornato JP. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). *J Am Coll Cardiol.* 2004;44:E1–E211.
196. Eagle KA, Guyton RA, Davidoff R, Edwards FH, Ewy GA, Gardner TJ, Hart JC, Herrmann HC, Hillis LD, Hutter AM Jr, Lytle BW, Marlow RA, Nugent WC, Orszulak TA; American College of Cardiology/American Heart Association. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). *Circulation.* 2004;110:e340–e437.
197. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC Jr, Alpert JS, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Gregoratos G, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; Canadian Cardiovascular Society. ACC/AHA guidelines for the management of patients

- with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction)[published correction appears in *Circulation*. 2005;111:2013–2014]. *Circulation*. 2004;110:e82–e292.
198. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts: prospective studies collaboration. *Lancet*. 1995;346:1647–1653.
 199. Iso H, Jacobs DR Jr, Wentworth D, Neaton JD, Cohen JD. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. *N Engl J Med*. 1989;320:904–910.
 200. Kagan A, Popper JS, Rhoads GG. Factors related to stroke incidence in Hawaii Japanese men. The Honolulu Heart Study. *Stroke*. 1980;11:14–21.
 201. Ueshima H, Iida M, Shimamoto T, Konishi M, Tsujioka K, Tanigaki M, Nakanishi N, Ozawa H, Kojima S, Komachi Y. Multivariate analysis of risk factors for stroke. Eight-year follow-up study of farming villages in Akita, Japan. *Prev Med*. 1980;9:722–740.
 202. Leppala JM, Virtamo J, Fogelholm R, Albanes D, Heinonen OP. Different risk factors for different stroke subtypes: association of blood pressure, cholesterol, and antioxidants. *Stroke*. 1999;30:2535–2540.
 203. Zhang X, Patel A, Horibe H, Wu Z, Barzi F, Rodgers A, MacMahon S, Woodward M; Asia Pacific Cohort Studies Collaboration. Cholesterol, coronary heart disease, and stroke in the Asia Pacific region. *Int J Epidemiol*. 2003;32:563–572.
 204. Bots ML, Elwood PC, Nikitin Y, Salonen JT, Freire de Concalves A, Inzitari D, Sivenius J, Benetou V, Tuomilehto J, Koudstaal PJ, Grobbee DE. Total and HDL cholesterol and risk of stroke. EUROSTROKE: a collaborative study among research centres in Europe. *J Epidemiol Community Health*. 2002;56(suppl 1):i19–i24.
 205. Horenstein RB, Smith DE, Mosca L. Cholesterol predicts stroke mortality in the Women's Pooling Project. *Stroke*. 2002;33:1863–1868.
 206. Gordon T, Kannel WB, Castelli WP, Dawber TR. Lipoproteins, cardiovascular disease, and death. The Framingham Study. *Arch Intern Med*. 1981;141:1128–1131.
 207. Koren-Morag N, Tanne D, Graff E, Goldbourt U. Low- and high-density lipoprotein cholesterol and ischemic cerebrovascular disease: the bezafibrate infarction prevention registry. *Arch Intern Med*. 2002;162:993–999.
 208. Shahar E, Chambless LE, Rosamond WD, Boland LL, Ballantyne CM, McGovern PG, Sharrett AR; Atherosclerosis Risk in Communities Study. Plasma lipid profile and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) Study. *Stroke*. 2003;34:623–631.
 209. Lindstrom E, Boysen G, Nyboe J. Influence of total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease: the Copenhagen City Heart Study [published correction appears in *BMJ*. 1994;309:1619]. *BMJ*. 1994;309:11–15.
 210. Wannamethee SG, Shaper AG, Ebrahim S. HDL-cholesterol, total cholesterol, and the risk of stroke in middle-aged British men. *Stroke*. 2000;31:1882–1888.
 211. Soyama Y, Miura K, Morikawa Y, Nishijo M, Nakanishi Y, Naruse Y, Kagamimori S, Nakagawa H, Oyabe Study. High-density lipoprotein cholesterol and risk of stroke in Japanese men and women: the Oyabe Study. *Stroke*. 2003;34:863–868.
 212. Heiss G, Sharrett AR, Barnes R, Chambless LE, Szklo M, Alzola C. Carotid atherosclerosis measured by B-mode ultrasound in populations: associations with cardiovascular risk factors in the ARIC study. *Am J Epidemiol*. 1991;134:250–256.
 213. Blankenhorn DH, Selzer RH, Crawford DW, Barth JD, Liu CR, Liu CH, Mack WJ, Alaupovic P. Beneficial effects of colestipol-niacin therapy on the common carotid artery. Two- and four-year reduction of intima-media thickness measured by ultrasound. *Circulation*. 1993;88:20–28.
 214. Crouse JR III, Byington RP, Bond MG, Espeland MA, Craven TE, Sprinkle JW, McGovern ME, Furberg CD. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II). *Am J Cardiol*. 1995;75:455–459.
 215. Furberg CD, Adams HP Jr, Applegate WB, Byington RP, Espeland MA, Hartwell T, Hunninghake DB, Lefkowitz DS, Probstfield J, Riley WA, et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. *Circulation*. 1994;90:1679–1687.
 216. Hodis HN, Mack WJ, LaBree L, Selzer RH, Liu C, Liu C, Alaupovic P, Kwong-Fu H, Azen SP. Reduction in carotid arterial wall thickness using lovastatin and dietary therapy: a randomized controlled clinical trial. *Ann Intern Med*. 1996;124:548–556.
 217. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins [published correction appears in *Circulation*. 2004;110:3615]. *Circulation*. 2004;110:3512–3517.
 218. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. *N Engl J Med*. 1996;335:1001–1009.
 219. Collins R, Armitage J, Parish S, Sleight P, Peto R; Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. *Lancet*. 2004;363:757–767.
 220. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG; PROSPER study group. PROSpective Study of Pravastatin in the Elderly at Risk: Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. *Lancet*. 2002;360:1623–1630.
 221. Amarenco P, Tonkin AM. Statins for stroke prevention: disappointment and hope. *Circulation*. 2004;109(23 suppl 1):III-44–III-49.
 222. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. *N Engl J Med*. 2005;352:1425–1435.
 223. Clofibrate and niacin in coronary heart disease. *JAMA*. 1975;231:360–381.
 224. Bloomfield Rubins H, Davenport J, Babikian V, Brass LM, Collins D, Wexler L, Wagner S, Papademetriou V, Rutan G, Robins SJ; VA-HIT Study Group. Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). *Circulation*. 2001;103:2828–2833.
 225. Guyton JR, Blazing MA, Hagar J, Kashyap ML, Knopp RH, McKenney JM, Nash DT, Nash SD. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group. *Arch Intern Med*. 2000;160:1177–1184.
 226. Kashyap ML, McGovern ME, Berra K, Guyton JR, Kwiterovich PO, Harper WL, Toth PD, Favrot LK, Kerzner B, Nash SD, Bays HE, Simmons PD. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. *Am J Cardiol*. 2002;89:672–678.
 227. National Institutes of Health. *Adult Treatment Panel III: Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults*. Bethesda, Md: National Institutes of Health; 2002.
 228. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. *Arterioscler Thromb Vasc Biol*. 2004;24:e149–e161.
 229. O'Leary DH, Polak JF, Kronmal RA, Kittner SJ, Bond MG, Wolfson SK Jr, Bommer W, Price TR, Gardin JM, Savage PJ. Distribution and correlates of sonographically detected carotid artery disease in the Cardiovascular Health Study. The CHS Collaborative Research Group. *Stroke*. 1992;23:1752–1760.
 230. Fine-Edelstein JS, Wolf PA, O'Leary DH, Poehlman H, Belanger AJ, Kase CS, D'Agostino RB. Precursors of extracranial carotid atherosclerosis in the Framingham Study. *Neurology*. 1994;44:1046–1050.
 231. Hillen T, Nieczaj R, Munzberg H, Schaub R, Borchelt M, Steinhagen-Thiessen E. Carotid atherosclerosis, vascular risk profile and mortality in a population-based sample of functionally healthy elderly subjects: the Berlin ageing study. *J Intern Med*. 2000;247:679–688.
 232. Mackey AE, Abrahamowicz M, Langlois Y, Battista R, Simard D, Bourque F, Leclerc J, Cote R. Outcome of asymptomatic patients with carotid disease. Asymptomatic Cervical Bruit Study Group. *Neurology*. 1997;48:896–903.

233. Hennerici M, Hulsbomer HB, Hefter H, Lammerts D, Rautenberg W. Natural history of asymptomatic extracranial arterial disease. Results of a long-term prospective study. *Brain*. 1987;110(pt 3):777-791.
234. Chambers BR, Norris JW. Outcome in patients with asymptomatic neck bruits. *N Engl J Med*. 1986;315:860-865.
235. Bogousslavsky J, Despland PA, Regli F. Asymptomatic tight stenosis of the internal carotid artery: long-term prognosis. *Neurology*. 1986;36:861-863.
236. Meissner I, Wiebers DO, Whisnant JP, O'Fallon WM. The natural history of asymptomatic carotid artery occlusive lesions. *JAMA*. 1987;258:2704-2707.
237. Autret A, Pourcelot L, Saudeau D, Marchal C, Bertrand P, de Boisvilliers S. Stroke risk in patients with carotid stenosis. *Lancet*. 1987;1:888-890.
238. Nadareishvili ZG, Rothwell PM, Beletsky V, Pagniello A, Norris JW. Long-term risk of stroke and other vascular events in patients with asymptomatic carotid artery stenosis. *Arch Neurol*. 2002;59:1162-1166.
239. Inzitari D, Eliasziw M, Gates P, Sharpe BL, Chan RK, Meldrum HE, Barnett HJ. The causes and risk of stroke in patients with asymptomatic internal-carotid-artery stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. *N Engl J Med*. 2000;342:1693-1700.
240. Barnett HJ, Gunton RW, Eliasziw M, Fleming L, Sharpe B, Gates P, Meldrum H. Causes and severity of ischemic stroke in patients with internal carotid artery stenosis. *JAMA*. 2000;283:1429-1436.
241. Salonen R, Nyyssönen K, Porkkala E, Rummukainen J, Belder R, Park JS, Salonen JT. Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. *Circulation*. 1995;92:1758-1764.
242. Corti R, Fuster V, Fayad ZA, Worthley SG, Helft G, Smith D, Weinberger J, Wentzel J, Mizsei G, Mercuri M, Badimon JJ. Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years' follow-up by high-resolution noninvasive magnetic resonance imaging. *Circulation*. 2002;106:2884-2887.
243. Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. *Circulation*. 2002;106:2055-2060.
244. Results of a randomized controlled trial of carotid endarterectomy for asymptomatic carotid stenosis. Mayo Asymptomatic Carotid Endarterectomy Study Group. *Mayo Clin Proc*. 1992;67:513-518.
245. Hobson RW 2nd, Weiss DG, Fields WS, Goldstone J, Moore WS, Towne JB, Wright CB. Efficacy of carotid endarterectomy for asymptomatic carotid stenosis. The Veterans Affairs Cooperative Study Group. *N Engl J Med*. 1993;328:221-227.
246. Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. *JAMA*. 1995;273:1421-1428.
247. Kapral MK, Wang H, Austin PC, Fang J, Kucey D, Bowyer B, Tu JV; Ontario Carotid Endarterectomy Registry. Sex differences in carotid endarterectomy outcomes: results from the Ontario Carotid Endarterectomy Registry. *Stroke*. 2003;34:1120-1125.
248. Goldstein LB, Samsa GP, Matchar DB, Oddone EZ. Multicenter review of preoperative risk factors for endarterectomy for asymptomatic carotid artery stenosis. *Stroke*. 1998;29:750-753.
249. Halliday A, Mansfield A, Marro J, Peto C, Peto R, Potter J, Thomas D; MRC Asymptomatic Carotid Surgery Trial (ACST) Collaborative Group. Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial [published correction appears in *Lancet*. 2004;364:416]. *Lancet*. 2004;363:1491-1502.
250. Rothwell PM, Goldstein LB. Carotid endarterectomy for asymptomatic carotid stenosis: asymptomatic carotid surgery trial. *Stroke*. 2004;35:2425-2427.
251. Kresowik TF, Bratzler DW, Kresowik RA, Hendel ME, Grund SL, Brown KR, Nilasena DS. Multistate improvement in process and outcomes of carotid endarterectomy. *J Vasc Surg*. 2004;39:372-380.
252. Goldstein LB, Bonito AJ, Matchar DB, Duncan PW, DeFries GH, Oddone EZ, Paul JE, Akin DR, Samsa GP. US national survey of physician practices for the secondary and tertiary prevention of ischemic stroke. Design, service availability, and common practices. *Stroke*. 1995;26:1607-1615.
253. Goldstein LB, Moore WS, Robertson JT, Chaturvedi S. Complication rates for carotid endarterectomy. A call to action. *Stroke*. 1997;28:889-890.
254. Perry JR, Szalai JP, Norris JW. Consensus against both endarterectomy and routine screening for asymptomatic carotid artery stenosis. Canadian Stroke Consortium. *Arch Neurol*. 1997;54:25-28.
255. Yin D, Carpenter JP. Cost-effectiveness of screening for asymptomatic carotid stenosis. *J Vasc Surg*. 1998;27:245-255.
256. Whitty CJ, Sudlow CL, Warlow CP. Investigating individual subjects and screening populations for asymptomatic carotid stenosis can be harmful. *J Neurol Neurosurg Psychiatry*. 1998;64:619-623.
257. Yadav JS, Wholey MH, Kuntz RE, Fayad P, Katzen BT, Mishkel GJ, Bajwa TK, Whitlow P, Strickman NE, Jaff MR, Popma JJ, Snead DB, Cutlip DE, Firth BG, Ouriel K; Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy Investigators. Protected carotid-artery stenting versus endarterectomy in high-risk patients. *N Engl J Med*. 2004;351:1493-1501.
258. Adams R. Neurological complications. In: Embury S, ed. *Sickle Cell Disease: Basic Principles and Clinical Practice*. New York, NY: Raven Press;1994:599-621.
259. Ohene-Frempong K, Weiner SJ, Sleeper LA, Miller ST, Embury S, Moohr JW, Wethers DL, Pegelow CH, Gill FM. Cerebrovascular accidents in sickle cell disease: rates and risk factors. *Blood*. 1998;91:288-294.
260. Armstrong FD, Thompson RJ Jr, Wang W, Zimmerman R, Pegelow CH, Miller S, Moser F, Bello J, Hurtig A, Vass K. Cognitive functioning and brain magnetic resonance imaging in children with sickle cell disease. Neuropsychology Committee of the Cooperative Study of Sickle Cell Disease. *Pediatrics*. 1996;97(6 pt 1):864-870.
261. Adams R, McKie V, Nichols F, Carl E, Zhang DL, McKie K, Figueroa R, Litaker M, Thompson W, Hess D. The use of transcranial ultrasonography to predict stroke in sickle cell disease. *N Engl J Med*. 1992;326:605-610.
262. Adams RJ, McKie VC, Carl EM, Nichols FT, Perry R, Brock K, McKie K, Figueroa R, Litaker M, Weiner S, Brambilla D. Long-term stroke risk in children with sickle cell disease screened with transcranial Doppler. *Ann Neurol*. 1997;42:699-704.
263. Adams RJ, McKie VC, Hsu L, Files B, Vichinsky E, Pegelow C, Abboud M, Gallagher D, Kutlar A, Nichols FT, Bonds DR, Brambilla D. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. *N Engl J Med*. 1998;339:5-11.
264. Jones A, Granger S, Brambilla D, Gallagher D, Vichinsky E, Woods G, Berman B, Roach S, Nichols F, Adams RJ. Can peak systolic velocities be used for prediction of stroke in sickle cell anemia? *Pediatr Radiol*. 2005;35:66-72.
265. Adams RJ, Brambilla DJ, Granger S, Gallagher D, Vichinsky E, Abboud MR, Pegelow CH, Woods G, Rohde EM, Nichols FT, Jones A, Luden JP, Bowman L, Hagner S, Morales KH, Roach ES; STOP Study. Stroke and conversion to high risk in children screened with transcranial Doppler ultrasound during the STOP study. *Blood*. 2004;103:3689-3694.
266. Wayne AS, Key SV, Nathan DG. Transfusion management of sickle cell disease. *Blood*. 1993;81:1109-1123.
267. Clinical Alert from the National Heart, Lung, and Blood Institute. Available at: <http://www.nhlbi.nih.gov/health/prof/blood/sickle/clinical-alert-scd.htm>. Accessed November 8, 2005.
268. Miller ST, Macklin EA, Pegelow CH, Kinney TR, Sleeper LA, Bello JA, DeWitt LD, Gallagher DM, Guarini L, Moser FG, Ohene-Frempong K, Sanchez N, Vichinsky EP, Wang WC, Wethers DL, Younk DP, Zimmerman RA, DeBaun MR; Cooperative Study of Sickle Cell Disease. Silent infarction as a risk factor for overt stroke in children with sickle cell anemia: a report from the Cooperative Study of Sickle Cell Disease. *J Pediatr*. 2001;139:385-390.
269. Washington University School of Medicine. The Silent Infarct Transfusion (SIT) Study. Available at: <http://www.strokecenter.org/trials>. Accessed April 21, 2006.
270. Walters MC, Sullivan KM, Bernaudin F, Souillet G, Vannier JP, Johnson FL, Lenarsky C, Powars D, Bunin N, Ohene-Frempong K, et al. Neurologic complications after allogeneic marrow transplantation for sickle cell anemia. *Blood*. 1995;85:879-884.
271. Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, McMahon RP, Bonds DR. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. *N Engl J Med*. 1995;332:1317-1322.

272. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. *N Engl J Med*. 1999;340:1801-1811.
273. Hurn PD, Brass LM. Estrogen and stroke: a balanced analysis. *Stroke*. 2003;34:338-341.
274. Viscogli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. A clinical trial of estrogen-replacement therapy after ischemic stroke. *N Engl J Med*. 2001;345:1243-1249.
275. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. *JAMA*. 1998;280:605-613.
276. Simon JA, Hsia J, Cauley JA, Richards C, Harris F, Fong J, Barrett-Connor E, Hulley SB. Postmenopausal hormone therapy and risk of stroke: the Heart and Estrogen-progestin Replacement Study (HERS). *Circulation*. 2001;103:638-642.
277. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. *JAMA*. 2002;288:321-333.
278. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O'Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S; Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. *JAMA*. 2004;291(14):1701-1712.
279. Riggs BL, Hartmann LC. Selective estrogen-receptor modulators: mechanisms of action and application to clinical practice [published correction appears in *N Engl J Med*. 2003;348:1192]. *N Engl J Med*. 2003;348:618-629.
280. Barrett-Connor E, Grady D, Sashegyi A, Anderson PW, Cox DA, Hoszowski K, Rautaharju P, Harper KD; Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. *JAMA*. 2002;287:847-857.
281. Bazzano LA, Serdula MK, Liu S. Dietary intake of fruits and vegetables and risk of cardiovascular disease. *Curr Atheroscler Rep*. 2003;5:492-499.
282. Johnsen SP, Overvad K, Stripp C, Tjonneland A, Husted SE, Sorensen HT. Intake of fruit and vegetables and the risk of ischemic stroke in a cohort of Danish men and women. *Am J Clin Nutr*. 2003;78:57-64.
283. Sauvaget C, Nagano J, Allen N, Kodama K. Vegetable and fruit intake and stroke mortality in the Hiroshima/Nagasaki Life Span Study. *Stroke*. 2003;34:2355-2360.
284. Steffen LM, Jacobs DR Jr, Stevens J, Shahar E, Carithers T, Folsom AR. Associations of whole-grain, refined-grain, and fruit and vegetable consumption with risks of all-cause mortality and incident coronary artery disease and ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) Study. *Am J Clin Nutr*. 2003;78:383-390.
285. JSHIPURA KJ, ASCHERIO A, MANSON JE, STAMPFER MJ, RIMM EB, SPEIZER FE, HENNEKENS CH, SPIEGELMAN D, WILLETT WC. Fruit and vegetable intake in relation to risk of ischemic stroke. *JAMA*. 1999;282:1233-1239.
286. Perry IJ, Beevers DG. Salt intake and stroke: a possible direct effect. *J Hum Hypertens*. 1992;6:23-25.
287. He J, Ogden LG, Vupputuri S, Bazzano LA, Loria C, Whelton PK. Dietary sodium intake and subsequent risk of cardiovascular disease in overweight adults. *JAMA*. 1999;282:2027-2034.
288. Nagata C, Takatsuka N, Shimizu N, Shimizu H. Sodium intake and risk of death from stroke in Japanese men and women. *Stroke*. 2004;35:1543-1547.
289. Khaw KT, Barrett-Connor E. Dietary potassium and stroke-associated mortality. A 12-year prospective population study. *N Engl J Med*. 1987;316:235-240.
290. Ascherio A, Rimm EB, Hernan MA, Giovannucci EL, Kawachi I, Stampfer MJ, Willett WC. Intake of potassium, magnesium, calcium, and fiber and risk of stroke among US men. *Circulation*. 1998;98:1198-1204.
291. MacGregor GA, Markandu ND, Sagnella GA, Singer DR, Cappuccio FP. Double-blind study of three sodium intakes and long-term effects of sodium restriction in essential hypertension. *Lancet*. 1989;2:1244-1247.
292. Johnson AG, Nguyen TV, Davis D. Blood pressure is linked to salt intake and modulated by the angiotensinogen gene in normotensive and hypertensive elderly subjects. *J Hypertens*. 2001;19:1053-1060.
293. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, Obarzanek E, Conlin PR, Miller ER 3rd, Simons-Morton DG, Karanja N, Lin PH; DASH-Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. *N Engl J Med*. 2001;344:3-10.
294. Whelton PK, He J, Cutler JA, Brancati FL, Appel LJ, Follmann D, Klag MJ. Effects of oral potassium on blood pressure. Meta-analysis of randomized controlled clinical trials. *JAMA*. 1997;277:1624-1632.
295. Morris RC Jr, Sebastian A, Forman A, Tanaka M, Schmidlin O. Normotensive salt sensitivity: effects of race and dietary potassium. *Hypertension*. 1999;33:18-23.
296. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, Bray GA, Vogt TM, Cutler JA, Windhauser MM, Lin PH, Karanja N. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. *N Engl J Med*. 1997;336:1117-1124.
297. John JH, Ziebland S, Yudkin P, Roe LS, Neil HA; Oxford Fruit and Vegetable Study Group. Effects of fruit and vegetable consumption on plasma antioxidant concentrations and blood pressure: a randomised controlled trial. *Lancet*. 2002;359:1969-1974.
298. Tobian L, Lange JM, Ulm KM, Wold LJ, Iwai J. Potassium prevents death from strokes in hypertensive rats without lowering blood pressure. *J Hypertens (suppl)*. 1984;2:S363-S366.
299. Institute of Medicine. *Dietary Reference Intakes: Water, Potassium, Sodium, Chloride, and Sulfate*. Washington, DC: National Academies Press; 2004.
300. Sauvaget C, Nagano J, Hayashi M, Yamada M. Animal protein, animal fat, and cholesterol intakes and risk of cerebral infarction mortality in the adult health study. *Stroke*. 2004;35:1531-1537.
301. He K, Merchant A, Rimm EB, Rosner BA, Stampfer MJ, Willett WC, Ascherio A. Dietary fat intake and risk of stroke in male US healthcare professionals: 14 year prospective cohort study. *BMJ*. 2003;327:777-782.
302. Fletcher GF. Exercise in the prevention of stroke. *Health Rep*. 1994;6:106-110.
303. Abbott RD, Rodriguez BL, Burchfiel CM, Curb JD. Physical activity in older middle-aged men and reduced risk of stroke: the Honolulu Heart Program. *Am J Epidemiol*. 1994;139:881-893.
304. Kiely DK, Wolf PA, Cupples LA, Beiser AS, Kannel WB. Physical activity and stroke risk: the Framingham Study [published correction appears in *Am J Epidemiol*. 1995;141:178]. *Am J Epidemiol*. 1994;140:608-620.
305. Haheim LL, Holme I, Hjermmann I, Leren P. Risk factors of stroke incidence and mortality. A 12-year follow-up of the Oslo Study. *Stroke*. 1993;24:1484-1489.
306. Gillum RF, Mussolino ME, Ingram DD. Physical activity and stroke incidence in women and men. The NHANES I Epidemiologic Follow-up Study. *Am J Epidemiol*. 1996;143:860-869.
307. Wannamethee G, Shaper AG. Physical activity and stroke in British middle aged men. *BMJ*. 1992;304:597-601.
308. Sacco RL, Gan R, Boden-Albala B, Lin IF, Kargman DE, Hauser WA, Shea S, Paik MC. Leisure-time physical activity and ischemic stroke risk: the Northern Manhattan Stroke Study. *Stroke*. 1998;29:380-387.
309. Lindstrom E, Boysen G, Nyboe J. Lifestyle factors and risk of cerebrovascular disease in women. The Copenhagen City Heart Study. *Stroke*. 1993;24:1468-1472.
310. Manson JE, Colditz GA, Stampfer MJ, Willett WC, Krolewski AS, Rosner B, Arky RA, Speizer FE, Hennekens CH. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. *Arch Intern Med*. 1991;151:1141-1147.
311. Shinton R, Sagar G. Lifelong exercise and stroke [published correction appears in *BMJ*. 1993;307:706]. *BMJ*. 1993;307:231-234.
312. Blair SN, Kampert JB, Kohl HW 3rd, Barlow CE, Macera CA, Paffenbarger RS Jr, Gibbons LW. Influences of cardiorespiratory fitness and other precursors on cardiovascular disease and all-cause mortality in men and women. *JAMA*. 1996;276:205-210.

313. Kokkinos PF, Holland JC, Pittaras AE, Narayan P, Dotson CO, Papademetriou V. Cardiorespiratory fitness and coronary heart disease risk factor association in women. *J Am Coll Cardiol*. 1995;26:358–364.
314. Lakka TA, Salonen JT. Moderate to high intensity conditioning leisure time physical activity and high cardiorespiratory fitness are associated with reduced plasma fibrinogen in eastern Finnish men. *J Clin Epidemiol*. 1993;46:1119–1127.
315. Williams PT. High-density lipoprotein cholesterol and other risk factors for coronary heart disease in female runners. *N Engl J Med*. 1996;334:1298–1303.
316. Wang HY, Bashore TR, Friedman E. Exercise reduces age-dependent decrease in platelet protein kinase C activity and translocation. *J Gerontol A Biol Sci Med Sci*. 1995;50A:M12–M16.
317. NIH develops consensus statement on the role of physical activity for cardiovascular health. *Am Fam Physician*. 1996;54:763–764, 767.
318. Pate RR, Pratt M, Blair SN, Haskell WL, Macera CA, Bouchard C, Buchner D, Ettinger W, Heath GW, King AC, et al. Physical activity and public health: a recommendation from the Centers for Disease Control and Prevention and the American College of Sports Medicine. *JAMA*. 1995;273:402–407.
319. Novak K. NIH increase efforts to tackle obesity. *Nat Med*. 1998;4:752–753.
320. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999–2000. *JAMA*. 2002;288:1723–1727.
321. Freedman DS, Khan LK, Serdula MK, Galuska DA, Dietz WH. Trends and correlates of class 3 obesity in the United States from 1990 through 2000. *JAMA*. 2002;288:1758–1761.
322. McTigue KM, Harris R, Hemphill B, Lux L, Sutton S, Bunton AJ, Lohr KN. Screening and interventions for obesity in adults: summary of the evidence for the US Preventive Services Task Force. *Ann Intern Med*. 2003;139:933–949.
323. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, Marks JS. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. *JAMA*. 2003;289:76–79.
324. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP. The continuing epidemics of obesity and diabetes in the United States. *JAMA*. 2001;286:1195–1200.
325. Strauss RS, Pollack HA. Epidemic increase in childhood overweight, 1986–1998. *JAMA*. 2001;286:2845–2848.
326. Hedley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR, Flegal KM. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999–2002. *JAMA*. 2004;291:2847–2850.
327. Rexrode KM, Hennekens CH, Willett WC, Colditz GA, Stampfer MJ, Rich-Edwards JW, Speizer FE, Manson JE. A prospective study of body mass index, weight change, and risk of stroke in women. *JAMA*. 1997;277:1539–1545.
328. Kurth T, Gaziano JM, Berger K, Kase CS, Rexrode KM, Cook NR, Buring JE, Manson JE. Body mass index and the risk of stroke in men. *Arch Intern Med*. 2002;162:2557–2562.
329. Song YM, Sung J, Davey Smith G, Ebrahim S. Body mass index and ischemic and hemorrhagic stroke: a prospective study in Korean men. *Stroke*. 2004;35:831–836.
330. Isozumi K. Obesity as a risk factor for cerebrovascular disease. *Keio J Med*. 2004;53:7–11.
331. Folsom AR, Prineas RJ, Kaye SA, Munger RG. Incidence of hypertension and stroke in relation to body fat distribution and other risk factors in older women. *Stroke*. 1990;21:701–706.
332. Walker SP, Rimm EB, Ascherio A, Kawachi I, Stampfer MJ, Willett WC. Body size and fat distribution as predictors of stroke among US men. *Am J Epidemiol*. 1996;144:1143–1150.
333. Suk SH, Sacco RL, Boden-Albala B, Cheun JF, Pittman JG, Elkind MS, Paik MC; Northern Manhattan Stroke Study. Abdominal obesity and risk of ischemic stroke: the Northern Manhattan Stroke Study. *Stroke*. 2003;34:1586–1592.
334. Neter JE, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. *Hypertension*. 2003;42:878–884.
335. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. *JAMA*. 2002;288:2709–2716.
336. Fontaine KR, Redden DT, Wang C, Westfall AO, Allison DB. Years of life lost due to obesity. *JAMA*. 2003;289:187–193.
337. Sowers JR. Recommendations for special populations: diabetes mellitus and the metabolic syndrome. *Am J Hypertens*. 2003;16(11 pt 2):41S–45S.
338. Qureshi AI, Giles WH, Croft JB. Impaired glucose tolerance and the likelihood of nonfatal stroke and myocardial infarction: the Third National Health and Nutrition Examination Survey. *Stroke*. 1998;29:1329–1332.
339. Haffner SM, D'Agostino R, Mykkanen L, Hales CN, Savage PJ, Bergman RN, O'Leary D, Rewers M, Selby J, Tracy R, Saad MF. Proinsulin and insulin concentrations in relation to carotid wall thickness: Insulin Resistance Atherosclerosis Study. *Stroke*. 1998;29:1498–1503.
340. Pyorala M, Miettinen H, Laakso M, Pyorala K. Hyperinsulinemia and the risk of stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. *Stroke*. 1998;29:1860–1866.
341. Wannamethee SG, Perry IJ, Shaper AG. Nonfasting serum glucose and insulin concentrations and the risk of stroke. *Stroke*. 1999;30:1780–1786.
342. Kuusisto J, Mykkanen L, Pyorala K, Laakso M. Non-insulin-dependent diabetes and its metabolic control are important predictors of stroke in elderly subjects. *Stroke*. 1994;25:1157–1164.
343. Bonora E, Willett J, Kiechl S, Oberhollenzer F, Egger G, Bonadonna R, Muggeo M. Relationship between insulin and carotid atherosclerosis in the general population: the Bruneck Study. *Stroke*. 1997;28:1147–1152.
344. Lindahl B, Dinesen B, Eliasson M, Roder M, Hallmans G, Stegmayr B. High proinsulin levels precede first-ever stroke in a nondiabetic population. *Stroke*. 2000;31:2936–2941.
345. Kernan WN, Inzucchi SE, Viscoli CM, Brass LM, Bravata DM, Horwitz RJ. Insulin resistance and risk for stroke. *Neurology*. 2002;59:809–815.
346. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. *JAMA*. 2002;287:356–359.
347. Hillbom M, Numminen H, Juvela S. Recent heavy drinking of alcohol and embolic stroke. *Stroke*. 1999;30:2307–2312.
348. Gill JS, Zezulka AV, Shipley MJ, Gill SK, Beevers DG. Stroke and alcohol consumption. *N Engl J Med*. 1986;315:1041–1046.
349. Klatsky AL, Armstrong MA, Friedman GD, Sidney S. Alcohol drinking and risk of hospitalization for ischemic stroke. *Am J Cardiol*. 2001;88:703–706.
350. Mazzaglia G, Britton AR, Altmann DR, Chenet L. Exploring the relationship between alcohol consumption and non-fatal or fatal stroke: a systematic review. *Addiction*. 2001;96:1743–1756.
351. Wannamethee SG, Shaper AG. Patterns of alcohol intake and risk of stroke in middle-aged British men. *Stroke*. 1996;27:1033–1039.
352. Gorelick PB, Rodin MB, Langenberg P, Hier DB, Costigan J. Weekly alcohol consumption, cigarette smoking, and the risk of ischemic stroke: results of a case-control study at three urban medical centers in Chicago, Illinois. *Neurology*. 1989;39:339–343.
353. Stampfer MJ, Colditz GA, Willett WC, Speizer FE, Hennekens CH. A prospective study of moderate alcohol consumption and the risk of coronary disease and stroke in women. *N Engl J Med*. 1988;319:267–273.
354. Berger K, Ajani UA, Kase CS, Gaziano JM, Buring JE, Glynn RJ, Hennekens CH. Light-to-moderate alcohol consumption and risk of stroke among US male physicians. *N Engl J Med*. 1999;341:1557–1564.
355. Sacco RL, Elkind M, Boden-Albala B, Lin IF, Kargman DE, Hauser WA, Shea S, Paik MC. The protective effect of moderate alcohol consumption on ischemic stroke. *JAMA*. 1999;281:53–60.
356. Djousse L, Ellison RC, Beiser A, Scaramucci A, D'Agostino RB, Wolf PA. Alcohol consumption and risk of ischemic stroke: the Framingham Study. *Stroke*. 2002;33:907–912.
357. Iso H, Baba S, Mannami T, Sasaki S, Okada K, Konishi M, Tsugane S; JPHC Study Group. Alcohol consumption and risk of stroke among middle-aged men: the JPHC Study Cohort I. *Stroke*. 2004;35:1124–1129.
358. Malarcher AM, Giles WH, Croft JB, Wozniak MA, Wityk RJ, Stolley PD, Stern BJ, Sloan MA, Sherwin R, Price TR, Macko RF, Johnson CJ, Earley CJ, Buchholz DW, Kittner SJ. Alcohol intake, type of beverage, and the risk of cerebral infarction in young women. *Stroke*. 2001;32:77–83.
359. US Department of Health and Human Services, US Department of Agriculture. Dietary Guidelines for Americans—2005. Available at: <http://www.healthierus.gov/dietaryguidelines/>. Accessed April 21, 2006.
360. Gaziano JM, Buring JE, Breslow JL, Goldhaber SZ, Rosner B, VanDenburgh M, Willett W, Hennekens CH. Moderate alcohol intake,

- increased levels of high-density lipoprotein and its subfractions, and decreased risk of myocardial infarction. *N Engl J Med.* 1993;329:1829–1834.
361. Torres Duarte AP, Dong QS, Young J, Abi-Younes S, Myers AK. Inhibition of platelet aggregation in whole blood by alcohol. *Thromb Res.* 1995;78:107–115.
 362. Pellegrini N, Pareti FI, Stabile F, Brusamolino A, Simonetti P. Effects of moderate consumption of red wine on platelet aggregation and haemostatic variables in healthy volunteers. *Eur J Clin Nutr.* 1996;50:209–213.
 363. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. *Ann Intern Med.* 1993;118(12):956–963.
 364. McKenzie CR, Abendschein DR, Eisenberg PR. Sustained inhibition of whole-blood clot procoagulant activity by inhibition of thrombus-associated factor Xa. *Arterioscler Thromb Vasc Biol.* 1996;16:1285–1291.
 365. Djousse L, Levy D, Benjamin EJ, Blease SJ, Russ A, Larson MG, Massaro JM, D'Agostino RB, Wolf PA, Ellison RC. Long-term alcohol consumption and the risk of atrial fibrillation in the Framingham Study. *Am J Cardiol.* 2004;93:710–713.
 366. Reynolds K, Lewis B, Nolen JD, Kinney GL, Sathya B, He J. Alcohol consumption and risk of stroke: a meta-analysis [published correction appears in *JAMA.* 2003;289:2798]. *JAMA.* 2003;289:579–588.
 367. Gronbaek M, Deis A, Sorensen TI, Becker U, Schnohr P, Jensen G. Mortality associated with moderate intakes of wine, beer, or spirits. *BMJ.* 1995;310:1165–1169.
 368. Truelsen T, Gronbaek M, Schnohr P, Boysen G. Intake of beer, wine, and spirits and risk of stroke: the Copenhagen City Heart Study. *Stroke.* 1998;29:2467–2472.
 369. Di Castelnuovo A, Rotondo S, Iacoviello L, Donati MB, DeGaetano G. Meta-analysis of wine and beer consumption in relation to vascular risk. *Circulation.* 2002;105:2836–2844.
 370. US Preventive Services Task Force. Screening and Behavioral Counseling Interventions in Primary Care to Reduce Alcohol Misuse: Recommendation Statement. Agency for Healthcare Research and Quality. Available at: <http://www.preventiveservices.ahrq.gov>. Accessed April 21, 2006.
 371. Cami J, Farre M. Drug addiction. *N Engl J Med.* 2003;349:975–986.
 372. Brust JCM. *Neurological Aspects of Substance Abuse*. 2nd ed. Philadelphia, Pa: Butterworth-Heinemann; 2004.
 373. Kaufman MJ, Levin JM, Ross MH, Lange N, Rose SL, Kukes TJ, Mendelson JH, Lukas SE, Cohen BM, Renshaw PF. Cocaine-induced cerebral vasoconstriction detected in humans with magnetic resonance angiography. *JAMA.* 1998;279:376–380.
 374. Perez JA Jr, Arsura EL, Strategos S. Methamphetamine-related stroke: four cases. *J Emerg Med.* 1999;17:469–471.
 375. Siegel AJ, Sholar MB, Mendelson JH, Lukas SE, Kaufman MJ, Renshaw PF, McDonald JC, Lewandrowski KB, Apple FS, Stec JJ, Lipinska I, Tofler GH, Ridker PM. Cocaine-induced erythrocytosis and increase in von Willebrand factor: evidence for drug-related blood doping and prothrombotic effects. *Arch Intern Med.* 1999;159:1925–1929.
 376. Neiman J, Haapaniemi HM, Hillbom M. Neurological complications of drug abuse: pathophysiological mechanisms. *Eur J Neurol.* 2000;7:595–606.
 377. Kaku DA, Lowenstein DH. Emergence of recreational drug abuse as a major risk factor for stroke in young adults. *Ann Intern Med.* 1990;113:821–827.
 378. Sloan MA, Kittner SJ, Feeser BR, Gardner J, Epstein A, Wozniak MA, Wityk RJ, Stern BJ, Price TR, Macko RF, Johnson CJ, Earley CJ, Buchholz D. Illicit drug-associated ischemic stroke in the Baltimore-Washington Young Stroke Study. *Neurology.* 1998;50:1688–1693.
 379. Petitti DB, Sidney S, Quesenberry C, Bernstein A. Stroke and cocaine or amphetamine use. *Epidemiology.* 1998;9:596–600.
 380. Levine SR, Brust JC, Futrell N, Ho KL, Blake D, Millikan CH, Brass LM, Fayad P, Schultz LR, Selwa JF, et al. Cerebrovascular complications of the use of the "crack" form of alkaloidal cocaine. *N Engl J Med.* 1990;323:699–704.
 381. Kittner SJ, Stern BJ, Wozniak M, Buchholz DW, Earley CJ, Feeser BR, Johnson CJ, Macko RF, McCarter RJ, Price TR, Sherwin R, Sloan MA, Wityk RJ. Cerebral infarction in young adults: the Baltimore-Washington Cooperative Young Stroke Study. *Neurology.* 1998;50:890–894.
 382. Johnson K, Noe T, Collins D, et al. Mobilizing church communities to prevent alcohol and other drug abuse: a model strategy and its evaluation. *J Community Practice.* 2000;7:1–27.
 383. Encourage healthy behavior by adolescents. *Am J Public Health.* 2001;91:508–510.
 384. Bushnell CD, Goldstein LB. Ischemic stroke: recognizing risks unique to women. *Womens Health Primary Care.* 1999;2:788–804.
 385. Oral contraceptives and stroke in young women: associated risk factors. *JAMA.* 1975;231:718–722.
 386. Hannaford PC, Croft PR, Kay CR. Oral contraception and stroke: evidence from the Royal College of General Practitioners' Oral Contraception Study. *Stroke.* 1994;25:935–942.
 387. Lidegaard O. Oral contraception and risk of a cerebral thromboembolic attack: results of a case-control study. *BMJ.* 1993;306:956–963.
 388. Petitti DB, Sidney S, Bernstein A, Wolf S, Quesenberry C, Ziel HK. Stroke in users of low-dose oral contraceptives. *N Engl J Med.* 1996;335:8–15.
 389. Schwartz SM, Siscovick DS, Longstreth WT Jr, Psaty BM, Beverly RK, Raghunathan TE, Lin D, Koepsell TD. Use of low-dose oral contraceptives and stroke in young women. *Ann Intern Med.* 1997;127(8 pt 1):596–603.
 390. Chan WS, Ray J, Wai EK, Ginsburg S, Hannah ME, Corey PN, Ginsberg JS. Risk of stroke in women exposed to low-dose oral contraceptives: a critical evaluation of the evidence [published correction appears in *Arch Intern Med.* 2005;165:2040]. *Arch Intern Med.* 2004;164:741–747.
 391. Heinemann LA, Lewis MA, Thorogood M, Spitzer WO, Guggenmoos-Holzmann I, Bruppacher R. Case-control study of oral contraceptives and risk of thromboembolic stroke: results from International Study on Oral Contraceptives and Health of Young Women. *BMJ.* 1997;315:1502–1504.
 392. Gillum LA, Mamidipudi SK, Johnston SC. Ischemic stroke risk with oral contraceptives: a meta-analysis. *JAMA.* 2000;284:72–78.
 393. Johnston SC, Colford JM Jr, Gress DR. Oral contraceptives and the risk of subarachnoid hemorrhage: a meta-analysis. *Neurology.* 1998;51:411–418.
 394. World Health Organization Scientific Group on Cardiovascular Disease and Steroid Hormone Contraception. *Cardiovascular disease and steroid hormone contraception: report of the World Health Organization Scientific Group*. Geneva, Switzerland: World Health Organization; 1998.
 395. Martinelli I, Sacchi E, Landi G, Taioli E, Duca F, Mannucci PM. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. *N Engl J Med.* 1998;338:1793–1797.
 396. Zuber M, Toulon P, Marnet L, Mas JL. Factor V Leiden mutation in cerebral venous thrombosis. *Stroke.* 1996;27:1721–1723.
 397. Becker WJ. Use of oral contraceptives in patients with migraine. *Neurology.* 1999;53(4 suppl 1):S19–S25.
 398. Siritho S, Thrift AG, McNeil JJ, You RX, Davis SM, Donnan GA; Melbourne Risk Factor Study (MERFS) Group. Risk of ischemic stroke among users of the oral contraceptive pill: the Melbourne Risk Factor Study (MERFS) Group. *Stroke.* 2003;34:1575–1580.
 399. Lidegaard O. Oral contraceptives, pregnancy and the risk of cerebral thromboembolism: the influence of diabetes, hypertension, migraine and previous thrombotic disease. *Br J Obstet Gynaecol.* 1995;102:153–159.
 400. Kristensen B, Malm J, Carlberg B, Stegmayr B, Backman C, Fagerlund M, Olsson T. Epidemiology and etiology of ischemic stroke in young adults aged 18 to 44 years in northern Sweden. *Stroke.* 1997;28:1702–1709.
 401. Farley TM, Meirik O, Chang CL, Poulter NR. Combined oral contraceptives, smoking, and cardiovascular risk. *J Epidemiol Community Health.* 1998;52:775–785.
 402. Nightingale AL, Farmer RD. Ischemic stroke in young women: a nested case-control study using the UK General Practice Research Database. *Stroke.* 2004;35:1574–1578.
 403. Hoyert DL, Arias E, Smith BL, Murphy SL, Kochanek KD. Deaths: final data for 1999. *Natl Vital Stat Rep.* 2001;49:1–113.
 404. Bousser MG, Conard J, Kittner S, de Lignieres B, MacGregor EA, Massiou H, Silberstein SD, Tzourio C. Recommendations on the risk of ischaemic stroke associated with use of combined oral contraceptives and hormone replacement therapy in women with migraine. The International Headache Society Task Force on Combined Oral Contraceptives & Hormone Replacement Therapy. *Cephalalgia.* 2000;20:155–156.

405. Partinen M, Palomaki H. Snoring and cerebral infarction. *Lancet*. 1985; 2:1325-1326.
406. Palomaki H, Partinen M, Erkinjuntti T, Kaste M. Snoring, sleep apnea syndrome, and stroke. *Neurology*. 1992;42(7 suppl 6):75-81; discussion 82.
407. Davies DP, Rodgers H, Walshaw D, James OF, Gibson GJ. Snoring, daytime sleepiness and stroke: a case-control study of first-ever stroke. *J Sleep Res*. 2003;12:313-318.
408. Marín JM, Carrizo SJ, Vicente E, Agusti AG. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. *Lancet*. 2005;365:1046-1053.
409. Culebras A. Cerebrovascular disease and sleep. *Curr Neurol Neurosci Rep*. 2004;4:164-169.
410. Yaggi H, Mohsenin V. Sleep-disordered breathing and stroke. *Clin Chest Med*. 2003;24:223-237.
411. Hermann DM, Bassetti CL. Sleep-disordered breathing and stroke. *Curr Opin Neurol*. 2003;16:87-90.
412. Nieto FJ, Young TB, Lind BK, Shahar E, Samet JM, Redline S, D'Agostino RB, Newman AB, Lebowitz MD, Pickering TG. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study: Sleep Heart Health Study [published correction appears in *JAMA*. 2002;288:1985]. *JAMA*. 2000;283:1829-1836.
413. Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. *N Engl J Med*. 2000;342:1378-1384.
414. Lavie P, Herer P, Hoffstein V. Obstructive sleep apnoea syndrome as a risk factor for hypertension: population study. *BMJ*. 2000;320:479-482.
415. Logan AG, Perlikowski SM, Mente A, Tisler A, Tkacova R, Niroumand M, Leung RS, Bradley TD, et al. High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. *J Hypertens*. 2001;19:2271-2277.
416. Guilleminault C, Connolly SJ, Winkle RA. Cardiac arrhythmia and conduction disturbances during sleep in 400 patients with sleep apnea syndrome. *Am J Cardiol*. 1983;52:490-494.
417. Rostagno C, Taddei T, Paladini B, Modesti PA, Utari P, Bertini G. The onset of symptomatic atrial fibrillation and paroxysmal supraventricular tachycardia is characterized by different circadian rhythms. *Am J Cardiol*. 1993;71:453-455.
418. Yamashita T, Murakawa Y, Sezaki K, Inoue M, Hayami N, Shuzui Y, Omata M. Circadian variation of paroxysmal atrial fibrillation. *Circulation*. 1997;96:1537-1541.
419. Moore T, Gullsbys S, Rabben T, Eriksson P. Sleep-disordered breathing: a novel predictor of atrial fibrillation after coronary artery bypass surgery. *Coron Artery Dis*. 1996;7:475-478.
420. Culebras A. REM-sleep related diaphragmatic insufficiency. *Neurology*. 1998;50(suppl 4):393-394.
421. Okosun IS, Prewitt TE, Cooper RS. Abdominal obesity in the United States: prevalence and attributable risk of hypertension. *J Hum Hypertens*. 1999;13:425-430.
422. Pepperell JC, Ramdassingh-Dow S, Crosthwaite N, Mullins R, Jenkinson C, Stradling JR, Davies RJ. Ambulatory blood pressure after therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomised parallel trial. *Lancet*. 2002; 359:204-210.
423. Becker HF, Jerrentrup A, Ploch T, Grote L, Penzel T, Sullivan CE, Peter JH. Effect of nasal continuous positive airway pressure treatment on blood pressure in patients with obstructive sleep apnea. *Circulation*. 2003;107:68-73.
424. Gotsopoulos H, Kelly JJ, Cistulli PA. Oral appliance therapy reduces blood pressure in obstructive sleep apnea: a randomized, controlled trial. *Sleep*. 2004;27:934-941.
425. Tzourio C, Iglesias S, Hubert JB, Visy JM, Alperovitch A, Tehindrazanarivelo A, Bioussé V, Woimant F, Bousser MG. Migraine and risk of ischaemic stroke: a case-control study. *BMJ*. 1993;307: 289-292.
426. Tzourio C, Tehindrazanarivelo A, Iglesias S, Alperovitch A, Chedru F, d'Anglejan-Chatillon J, Bousser MG. Case-control study of migraine and risk of ischaemic stroke in young women. *BMJ*. 1995;310:830-833.
427. Carolei A, Marini C, De Matteis G. History of migraine and risk of cerebral ischaemia in young adults. The Italian National Research Council Study Group on Stroke in the Young. *Lancet*. 1996;347: 1503-1506.
428. Haapaniemi H, Hillbom M, Juvela S. Lifestyle-associated risk factors for acute brain infarction among persons of working age. *Stroke*. 1997; 28:26-30.
429. Merikangas KR, Fenton BT, Cheng SH, et al. Association between migraine and stroke in a large-scale epidemiological study of the United States. *Arch Neurol*. 1997;54:362-368.
430. Chang CL, Donaghy M, Poulter N. Migraine and stroke in young women: case-control study. The World Health Organisation Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. *BMJ*. 1999;318:13-18.
431. Mosek A, Marom R, Korczyn AD, Bornstein N. A history of migraine is not a risk factor to develop an ischemic stroke in the elderly. *Headache*. 2001;41:399-401.
432. Schwaag S, Nabavi DG, Frese A, Husstedt IW, Evers S. The association between migraine and juvenile stroke: a case-control study. *Headache*. 2003;43:90-95.
433. Bushnell CD. Migraine and risk of ischemic stroke: an evidence-based medicine review. *J Clin Outcomes Manage*. 2001;8:33-39.
434. Kruit MC, van Buchem MA, Hofman PA, Bakkers JT, Terwindt GM, Ferrari MD, Launer LJ. Migraine as a risk factor for subclinical brain lesions. *JAMA*. 2004;291:427-434.
435. Bednarczyk EM, Remler B, Weikart C, Nelson AD, Reed RC. Global cerebral blood flow, blood volume, and oxygen metabolism in patients with migraine headache. *Neurology*. 1998;50:1736-1740.
436. Sanchez del Rio M, Bakker D, Wu O, Agosti R, Mitsikostas DD, Ostergaard L, Wells WA, Rosen BR, Sorensen G, Moskowitz MA, Cutrer FM. Perfusion weighted imaging during migraine: spontaneous visual aura and headache. *Cephalalgia*. 1999;19:701-707.
437. Webster MW, Chancellor AM, Smith HJ, Swift DL, Sharpe DN, Bass NM, Glasgow GL. Patent foramen ovale in young stroke patients. *Lancet*. 1988;2:11-12.
438. Lechat P, Mas JL, Lascault G, Loron P, Theard M, Klimczak M, Drobinski G, Thomas D, Grosgeat Y. Prevalence of patent foramen ovale in patients with stroke. *N Engl J Med*. 1988;318:1148-1152.
439. Overell JR, Bone I, Lees KR. Interatrial septal abnormalities and stroke: a meta-analysis of case-control studies. *Neurology*. 2000;55:1172-1179.
440. Anzola GP, Magoni M, Guindani M, Rozzini L, Dalla Volta G. Potential source of cerebral embolism in migraine with aura: a transcranial Doppler study. *Neurology*. 1999;52:1622-1625.
441. Olesen J, Friberg L, Olsen TS, Andersen AR, Lassen NA, Hansen PE, Karle A. Ischaemia-induced (symptomatic) migraine attacks may be more frequent than migraine-induced ischaemic insults. *Brain*. 1993; 116(pt 1):187-202.
442. Zeller JA, Frahm K, Baron R, Stिंगele R, Deuschl G. Platelet-leukocyte interaction and platelet activation in migraine: a link to ischemic stroke? *J Neurol Neurosurg Psychiatry*. 2004;75:984-987.
443. Jakubowski H, Zhang L, Bardeguez A, Aviv A. Homocysteine thio-lactone and protein homocysteinylated in human endothelial cells: implications for atherosclerosis. *Circ Res*. 2000;87:45-51.
444. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. *N Engl J Med*. 1998;338:1042-1050.
445. Giles WH, Croft JB, Greenlund KJ, Ford ES, Kittner SJ. Total homocyst(e)ine concentration and the likelihood of nonfatal stroke: results from the Third National Health and Nutrition Examination Survey, 1988-1994. *Stroke*. 1998;29:2473-2477.
446. Bostom AG, Silbershatz H, Rosenberg IH, Selhub J, D'Agostino RB, Wolf PA, Jacques PF, Wilson PW. Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women. *Arch Intern Med*. 1999;159: 1077-1080.
447. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. *JAMA*. 2002;288: 2015-2022.
448. Tanne D, Haim M, Goldbourt U, Boyko V, Doolman R, Adler Y, Brunner D, Behar S, Sela BA. Prospective study of serum homocysteine and risk of ischemic stroke among patients with preexisting coronary heart disease. *Stroke*. 2003;34:632-636.
449. Brattstrom L, Wilcken DE, Ohrvik J, Brudin L. Common methylene-tetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis. *Circulation*. 1998;98:2520-2526.
450. Kronenberg F, Kronenberg MF, Kiechl S, Trenkwalder E, Santer P, Oberhollenzer F, Egger G, Utermann G, Willeit J. Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck study. *Circulation*. 1999;100:1154-1160.

451. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. *BMJ*. 2002;325:1202.
452. Malinow MR. Homocyst(e)ine, vitamins and genetic interactions in vascular disease. *Can J Cardiol*. 1999;15(suppl B):31B-34B.
453. Eikelboom JW, Lonn E, Genest J Jr, Hankey G, Yusuf S. Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. *Ann Intern Med*. 1999;131:363-375.
454. Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg H. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. *JAMA*. 1993;270:2693-2698.
455. Jacques PF, Rosenberg IH, Rogers G, Selhub J, Bowman BA, Gunter EW, Wright JD, Johnson CL. Serum total homocysteine concentrations in adolescent and adult Americans: results from the third National Health and Nutrition Examination Survey. *Am J Clin Nutr*. 1999;69:482-489.
456. Selhub J, Jacques PF, Rosenberg IH, Rogers G, Bowman BA, Gunter EW, Wright JD, Johnson CL. Serum total homocysteine concentrations in the third National Health and Nutrition Examination Survey (1991-1994): population reference ranges and contribution of vitamin status to high serum concentrations. *Ann Intern Med*. 1999;131:331-339.
457. Wald DS, Bishop L, Wald NJ, Law M, Hennessy E, Weir D, McPartlin J, Scott J. Randomized trial of folic acid supplementation and serum homocysteine levels. *Arch Intern Med*. 2001;161:695-700.
458. Rifai N, Ma J, Sacks FM, Ridker PM, Hernandez WJ, Stampfer MJ, Marcovina SM. Apolipoprotein(a) size and lipoprotein(a) concentration and future risk of angina pectoris with evidence of severe coronary atherosclerosis in men: the Physicians' Health Study. *Clin Chem*. 2004;50:1364-1371.
459. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, Sides EG, Wang CH, Stampfer M. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. *JAMA*. 2004;291:565-575.
460. Utermann G. The mysteries of lipoprotein(a). *Science*. 1989;246:904-910.
461. Morrisett JD. The role of lipoprotein[a] in atherosclerosis. *Curr Atheroscler Rep*. 2000;2:243-250.
462. Marcovina SM, Koschinsky ML. Evaluation of lipoprotein(a) as a prothrombotic factor: progress from bench to bedside. *Curr Opin Lipidol*. 2003;14:361-366.
463. Emanuele E, Peros E, Tomaino C, Feudatari E, Bernardi L, Binetti G, Maletta R, Miciceli G, Bruni AC, Geroldi D. Relation of apolipoprotein(a) size to Alzheimer's disease and vascular dementia. *Dement Geriatr Cogn Disord*. 2004;18:189-196.
464. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. *Circulation*. 2000;102:1082-1085.
465. Milionis HJ, Winder AF, Mikhailidis DP. Lipoprotein(a) and stroke. *J Clin Pathol*. 2000;53:487-496.
466. Nowak-Gottl U, Strater R, Heinecke A, Junker R, Koch HG, Schuierer G, von Eckardstein A. Lipoprotein(a) and genetic polymorphisms of clotting factor V, prothrombin, and methylenetetrahydrofolate reductase are risk factors of spontaneous ischemic stroke in childhood. *Blood*. 1999;94:3678-3682.
467. Chan AK, deVeber G. Prothrombotic disorders and ischemic stroke in children. *Semin Pediatr Neurol*. 2000;7:301-308.
468. Arenillas JF, Molina CA, Chacon P, Rovira A, Montaner J, Coscojuela P, Sanchez E, Quintana M, Alvarez-Sabin J. High lipoprotein(a), diabetes, and the extent of symptomatic intracranial atherosclerosis [published correction appears in *Neurology*. 2004;63:944]. *Neurology*. 2004;63:27-32.
469. Guyton JR, Goldberg AC, Kreisberg RA, Sprecher DL, Superko HR, O'Connor CM. Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. *Am J Cardiol*. 1998;82:737-743.
470. Caslake MJ, Packard CJ, Suckling KE, Holmes SD, Chamberlain P, Macphree CH. Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. *Atherosclerosis*. 2000;150:413-419.
471. Brilakis ES, McConnell JP, Lennon RJ, Elesber AA, Meyer JG, Berger PB. Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. *Eur Heart J*. 2005;26:137-144.
472. Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Heiss G, Sharrett AR. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. *Circulation*. 2004;109:837-842.
473. Koenig W, Khuseyinova N, Lowel H, Trischler G, Meisinger C. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. *Circulation*. 2004;110:1903-1908.
474. Oei HH, van der Meer IM, Hofman A, Koudstaal PJ, Stijnen T, Breteler MM, Witteman JC. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. *Circulation*. 2005;111:570-575.
475. Schaefer EJ, McNamara JR, Asztalos BF, Taylor T, Daly JA, Gleason JL, Seman LJ, Ferrari A, Rubenstein JJ. Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein-associated phospholipase A2 in patients with coronary heart disease versus control subjects. *Am J Cardiol*. 2005;95(9):1025-1032.
476. Tsimihodimos V, Kakafika A, Tambaki AP, Bairaktari E, Chapman MJ, Elisaf M, Tselepis AD. Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins. *J Lipid Res*. 2003;44:927-934.
477. Winkler K, Winkelmann BR, Schrnagl H, Hoffmann MM, Grawitz AB, Nauck M, Bohm BO, Marz W. Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors: the Ludwigshafen Risk and Cardiovascular Health Study [published correction appears in *Circulation*. 2005;111:e444]. *Circulation*. 2005;111:980-987.
478. Anticardiolipin antibodies are an independent risk factor for first ischemic stroke. The Antiphospholipid Antibodies in Stroke Study (APASS) Group. *Neurology*. 1993;43:2069-2073.
479. Levine SR, Brey RL, Tilley BC, Thompson JL, Sacco RL, Sciaccia RR, Murphy A, Lu Y, Costigan TM, Rhine C, Levin B, Triplett DA, Mohr JP; APASS Investigators. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. *JAMA*. 2004;291:576-584.
480. Heinzlef O, Abuaf N, Cohen A, Amarengo P; French Study of Aortic Plaques in Stroke Group. Recurrent stroke and vascular events in elderly patients with anticardiolipin antibodies: a prospective study. *J Neurol*. 2001;248:373-379.
481. Tanne D, D'Olhaberriague L, Trivedi AM, Salowich-Palm L, Schultz LR, Levine SR. Anticardiolipin antibodies and mortality in patients with ischemic stroke: a prospective follow-up study. *Neuroepidemiology*. 2002;21:93-99.
482. Janardhan V, Wolf PA, Kase CS, Massaro JM, D'Agostino RB, Franzblau C, Wilson PW. Anticardiolipin antibodies and risk of ischemic stroke and transient ischemic attack: the Framingham cohort and offspring study. *Stroke*. 2004;35:736-741.
483. Brey RL, Abbott RD, Curb JD, Sharp DS, Ross GW, Stallworth CL, Kittner SJ. Beta(2)-glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: the Honolulu Heart Program. *Stroke*. 2001;32:1701-1706.
484. Brey RL, Stallworth CL, McGlasson DL, Wozniak MA, Wityk RJ, Stern BJ, Sloan MA, Sherwin R, Price TR, Macko RF, Johnson CJ, Earley CJ, Buchholz DW, Hebel JR, Kittner SJ. Antiphospholipid antibodies and stroke in young women. *Stroke*. 2002;33:2396-2400.
485. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, Brey R, Derksen R, Harris EN, Hughes GR, Triplett DA, Khamashta MA. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. *Arthritis Rheum*. 1999;42:1309-1311.
486. Petri M. Management of thrombosis in antiphospholipid antibody syndrome. *Rheum Dis Clin North Am*. 2001;27:633-642, viii.
487. Pezzini A, Del Zotto E, Magoni M, Costa A, Archetti S, Grassi M, Akkawi NM, Albertini A, Assanelli D, Vignolo LA, Padovani A. Inherited thrombophilic disorders in young adults with ischemic stroke and patent foramen ovale. *Stroke*. 2003;34:28-33.
488. Ross R. Atherosclerosis—an inflammatory disease. *N Engl J Med*. 1999;340:115-126.
489. Folsom AR, Aleksic N, Catellier D, Juneja HS, Wu KK. C-reactive protein and incident coronary heart disease in the Atherosclerosis Risk In Communities (ARIC) Study. *Am Heart J*. 2002;144:233-238.

490. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. *N Engl J Med.* 2002; 347:1557–1565.
491. Rost NS, Wolf PA, Kase CS, Kelly-Hayes M, Silbershatz H, Massaro JM, D'Agostino RB, Franzblau C, Wilson PW. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham Study. *Stroke.* 2001;32:2575–2579.
492. Albert MA, Glynn RJ, Ridker PM. Plasma concentration of C-reactive protein and the calculated Framingham Coronary Heart Disease Risk Score. *Circulation.* 2003;108:161–165.
493. MacGregor AJ, Gallimore JR, Spector TD, Pepys MB. Genetic effects on baseline values of C-reactive protein and serum amyloid a protein: a comparison of monozygotic and dizygotic twins. *Clin Chem.* 2004;50:130–134.
494. Cipollone F, Toniato E, Martinotti S, Fazio M, Iezzi A, Cucurullo C, Pini B, Ursi S, Vitullo G, Averna M, Arca M, Montali A, Campagna F, Ucchino S, Spigonardo F, Taddei S, Viridis A, Ciabattini G, Notarbartolo A, Cucurullo F, Mezzetti A; Identification of New Elements of Plaque Stability (INES) Study Group. A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke. *JAMA.* 2004; 291:2221–2228.
495. Albert MA, Glynn RJ, Buring J, Ridker PM. C-reactive protein levels among women of various ethnic groups living in the United States (from the Women's Health Study). *Am J Cardiol.* 2004;93: 1238–1242.
496. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, Crowe T, Howard G, Cooper CJ, Brodie B, Grines CL, DeMaria AN; REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. *JAMA.* 2004;291: 1071–1080.
497. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. *N Engl J Med.* 2004;350:1495–1504.
498. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, Orszag J, Magorien RD, O'Shaughnessy C, Ganz P; Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. *N Engl J Med.* 2005;352:29–38.
499. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. *N Engl J Med.* 2005;352:20–28.
500. Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. *N Engl J Med.* 2001;344(26):1959–1965.
501. Bevilacqua MP, Pober JS, Majeau GR, Cotran RS, Gimbrone MA Jr. Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. *J Exp Med.* 1984;160:618–623.
502. Nawroth PP, Handley DA, Esmon CT, Stern DM. Interleukin 1 induces endothelial cell procoagulant while suppressing cell-surface anticoagulant activity. *Proc Natl Acad Sci U S A.* 1986;83: 3460–3464.
503. Nawroth PP, Stern DM. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. *J Exp Med.* 1986;163:740–745.
504. DeGraba TJ, Siren AL, Penix L, McCarron RM, Hargraves R, Sood S, Pettigrew KD, Hallenbeck JM. Increased endothelial expression of intercellular adhesion molecule-1 in symptomatic versus asymptomatic human carotid atherosclerotic plaque. *Stroke.* 1998;29: 1405–1410.
505. Jander S, Sitzer M, Schumann R, Schroeter M, Siebler M, Steinmetz H, Stoll G. Inflammation in high-grade carotid stenosis: a possible role for macrophages and T cells in plaque destabilization. *Stroke.* 1998;29:1625–1630.
506. DeGraba TJ. Immunogenetic susceptibility of atherosclerotic stroke: implications on current and future treatment of vascular inflammation. *Stroke.* 2004;35(11 suppl 1):2712–2719.
507. Schonbeck U, Varo N, Libby P, Buring J, Ridker PM. Soluble CD40L and cardiovascular risk in women. *Circulation.* 2001;104: 2266–2268.
508. Schonbeck U, Libby P. CD40 signaling and plaque instability. *Circ Res.* 2001;89:1092–1103.
509. Garlich CD, Kozina S, Fateh-Moghadam S, Handschu R, Tomandl B, Stumpf C, Eskafi S, Raaz D, Schmeisser A, Yilmaz A, Ludwig J, Neundorfer B, Daniel WG. Upregulation of CD40-CD40 ligand (CD154) in patients with acute cerebral ischemia [published correction appears in *Stroke.* 2003;34:1820]. *Stroke.* 2003;34: 1412–1418.
510. Mallat Z, Corbaz A, Scoazec A, Besnard S, Leseche G, Chvatchko Y, Tedgui A. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. *Circulation.* 2001;104: 1598–1603.
511. Blankenberg S, Luc G, Ducimetiere P, Arveiler D, Ferrieres J, Amouyel P, Evans A, Cambien F, Tiret L; PRIME Study Group. Interleukin-18 and the risk of coronary heart disease in European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). *Circulation.* 2003;108:2453–2459.
512. Flex A, Gaetani E, Papaleo P, Straface G, Proia AS, Pecorini G, Tondi P, Pola P, Pola R. Proinflammatory genetic profiles in subjects with history of ischemic stroke. *Stroke.* 2004;35:2270–2275.
513. Cipollone F, Fazio M, Iezzi A, Pini B, Cucurullo C, Zucchelli M, de Cesare D, Ucchino S, Spigonardo F, De Luca M, Muraro R, Bei R, Bucci M, Cucurullo F, Mezzetti A. Blockade of the angiotensin II type 1 receptor stabilizes atherosclerotic plaques in humans by inhibiting prostaglandin E2-dependent matrix metalloproteinase activity. *Circulation.* 2004;109:1482–1488.
514. Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. *Circulation.* 2001;103:926–933.
515. Bova IY, Bornstein NM, Korczyn AD. Acute infection as a risk factor for ischemic stroke. *Stroke.* 1996;27:2204–2206.
516. Grau AJ, Bugge F, Becher H, Zimmermann E, Spiel M, Fent T, Maiwald M, Werle E, Zorn M, Hengel H, Hacke W. Recent bacterial and viral infection is a risk factor for cerebrovascular ischemia: clinical and biochemical studies. *Neurology.* 1998;50:196–203.
517. Grau AJ, Bugge F, Ziegler C, Schwarz W, Meuser J, Tasman AJ, Buhler A, Benesch C, Becher H, Hacke W. Association between acute cerebrovascular ischemia and chronic and recurrent infection. *Stroke.* 1997;28:1724–1729.
518. LaBiche R, Koziol D, Quinn TC, Gaydos C, Azhar S, Ketron G, Sood S, DeGraba TJ. Presence of *Chlamydia pneumoniae* in human symptomatic and asymptomatic carotid atherosclerotic plaque. *Stroke.* 2001;32:855–860.
519. Elkind MS, Lin IF, Grayston JT, Sacco RL. *Chlamydia pneumoniae* and the risk of first ischemic stroke: the Northern Manhattan Stroke Study. *Stroke.* 2000;31:1521–1525.
520. Wimmer ML, Sandmann-Strupp R, Saikku P, Haberl RL. Association of chlamydial infection with cerebrovascular disease. *Stroke.* 1996;27:2207–2210.
521. Fagerberg B, Gnarpe J, Gnarpe H, Agewall S, Wikstrand J. *Chlamydia pneumoniae* but not cytomegalovirus antibodies are associated with future risk of stroke and cardiovascular disease: a prospective study in middle-aged to elderly men with treated hypertension. *Stroke.* 1999;30:299–305.
522. Cook PJ, Honeybourne D, Lip GY, Beevers DG, Wise R, Davies P. *Chlamydia pneumoniae* antibody titers are significantly associated with acute stroke and transient cerebral ischemia: the West Birmingham Stroke Project. *Stroke.* 1998;29:404–410.
523. Gurfinkel E, Bozovich G, Daroca A, Beck E, Mautner B. Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot Study. ROXIS Study Group. *Lancet.* 1997;350: 404–407.
524. Gurfinkel E, Bozovich G, Beck E, Testa E, Livellara B, Mautner B. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS Study. *Eur Heart J.* 1999;20:121–127.
525. Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ. Elevated *Chlamydia pneumoniae* antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. *Circulation.* 1997;96:404–407.

526. Anderson JL, Muhlestein JB, Carlquist J, Allen A, Trehan S, Nielson C, Hall S, Brady J, Egger M, Horne B, Lim T. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for *Chlamydia pneumoniae* infection: the Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study. *Circulation*. 1999;99:1540–1547.
527. Muhlestein JB, Anderson JL, Carlquist JF, Salunkhe K, Horne BD, Pearson RR, Bunch TJ, Allen A, Trehan S, Nielson C. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: primary clinical results of the ACADEMIC study. *Circulation*. 2000;102:1755–1760.
528. O'Connor CM, Dunne MW, Pfeffer MA, Muhlestein JB, Yao L, Gupta S, Benner RJ, Fisher MR, Cook TD; Investigators in the WIZARD Study. Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. *JAMA*. 2003;290:1459–1466.
529. Cannon CP, Braunwald E, McCabe CH, Grayston JT, Muhlestein B, Giugliano RP, Cairns R, Skene AM. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Antibiotic treatment of *Chlamydia pneumoniae* after acute coronary syndrome. *N Engl J Med*. 2005;352:1646–1654.
530. Grayston JT, Kronmal RA, Jackson LA, Parisi AF, Muhlestein JB, Cohen JD, Rogers WJ, Crouse JR, Borrowdale SL, Schron E, Knirsch C; ACES Investigators. Azithromycin for the secondary prevention of coronary events. *N Engl J Med*. 2005;352:1637–1645.
531. Wu T, Trevisan M, Genco RJ, Dorn JP, Falkner KL, Sempos CT. Periodontal disease and risk of cerebrovascular disease: the first national health and nutrition examination survey and its follow-up study. *Arch Intern Med*. 2000;160:2749–2755.
532. Espinola-Klein C, Rupprecht HJ, Blankenberg S, Bickel C, Kopp H, Rippin G, Hafner G, Pfeifer U, Meyer J. Are morphological or functional changes in the carotid artery wall associated with *Chlamydia pneumoniae*, *Helicobacter pylori*, cytomegalovirus, or herpes simplex virus infection? *Stroke*. 2000;31:2127–2133.
533. Tarnacka B, Gromadzka G, Czlonkowska A. Increased circulating immune complexes in acute stroke: the triggering role of *Chlamydia pneumoniae* and cytomegalovirus. *Stroke*. 2002;33:936–940.
534. Smieja M, Gnarp J, Lonn E, Gnarp H, Olsson G, Yi Q, Dzavik V, McQueen M, Yusuf S; Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Multiple infections and subsequent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. *Circulation*. 2003;107:251–257.
535. Ameriso SF, Fridman EA, Leiguarda RC, Seviever GE. Detection of *Helicobacter pylori* in human carotid atherosclerotic plaques. *Stroke*. 2001;32:385–391.
536. Preusch MR, Grau AJ, Bugge F, Lichy C, Bartel J, Black C, Rudi J. Association between cerebral ischemia and cytotoxin-associated gene-A-bearing strains of *Helicobacter pylori*. *Stroke*. 2004;35:1800–1804.
537. Gabrielli M, Santoliquido A, Cremonini F, Cicconi V, Candelli M, Serricchio M, Tondi P, Pola R, Gasbarrini G, Pola P, Gasbarrini A. CagA-positive cytotoxic *H. pylori* strains as a link between plaque instability and atherosclerotic stroke. *Eur Heart J*. 2004;25:64–68.
538. Diomedes M, Pietrouisti A, Silvestrini M, Rizzato B, Cupini LM, Ferrante F, Magrini A, Bergamaschi A, Galante A, Bernardi G. CagA-positive *Helicobacter pylori* strains may influence the natural history of atherosclerotic stroke. *Neurology*. 2004;63:800–804.
539. Espinola-Klein C, Rupprecht HJ, Blankenberg S, Bickel C, Kopp H, Victor A, Hafner G, Prellwitz W, Schlumberger W, Meyer J. Impact of infectious burden on progression of carotid atherosclerosis. *Stroke*. 2002;33:2581–2586.
540. Espinola-Klein C, Rupprecht HJ, Blankenberg S, Bickel C, Kopp H, Rippin G, Victor A, Hafner G, Schlumberger W, Meyer J; AtheroGene Investigators. Impact of infectious burden on extent and long-term prognosis of atherosclerosis. *Circulation*. 2002;105:15–21.
541. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. *N Engl J Med*. 2004;351:2611–2618.
542. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the US Preventive Services Task Force. *Ann Intern Med*. 2002;136:161–172.
543. Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP, Franklin BA, Goldstein LB, Greenland P, Grundy SM, Hong Y, Miller NH, Lauer RM, Ockene IS, Sacco RL, Sallis JF Jr, Smith SC Jr, Stone NJ, Taubert KA. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. *Circulation*. 2002;106:388–391.
544. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients [published correction appears in *BMJ*. 2002;324:141]. *BMJ*. 2002;324:71–86.
545. Albers GW, Amareno P, Easton JD, Sacco RL, Teal P. Anti-thrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest*. 2004;126(3 suppl):483S–512S.
546. Wolf PA, Clagett GP, Easton JD, Goldstein LB, Gorelick PB, Kelly-Hayes M, Sacco RL, Whisnant JP. Preventing ischemic stroke in patients with prior stroke and transient ischemic attack: a statement for healthcare professionals from the Stroke Council of the American Heart Association. *Stroke*. 1999;30:1991–1994.
547. Collaborative overview of randomised trials of antiplatelet therapy—I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration [published correction appears in *BMJ*. 1994;308:1540]. *BMJ*. 1994;308:81–106.
548. Hart RG, Halperin JL, McBride R, Benavente O, Man-Son-Hing M, Kronmal RA. Aspirin for the primary prevention of stroke and other major vascular events: meta-analysis and hypotheses. *Arch Neurol*. 2000;57:326–332.
549. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. *N Engl J Med*. 2005;352:1293–1304.
550. American Heart Association. *Heart Disease and Stroke Statistics—2005 Update*. American Heart Association.
551. Whisnant JP, Wiebers DO, O'Fallon WM, Sicks JD, Frye RL. A population-based model of risk factors for ischemic stroke: Rochester, Minnesota. *Neurology*. 1996;47:1420–1428.
552. Wolf PA, D'Agostino RB, Kannel WB, Bonita R, Belanger AJ. Cigarette smoking as a risk factor for stroke: the Framingham Study. *JAMA*. 1988;259:1025–1029.
553. Colgan MP, Strode GR, Sommer JD, Gibbs JL, Sumner DS. Prevalence of asymptomatic carotid disease: results of duplex scanning in 348 unselected volunteers. *J Vasc Surg*. 1988;8:674–678.
554. Prati P, Vanuzzo D, Casaroli M, Di Chiara A, De Biasi F, Feruglio GA, Touboul PJ. Prevalence and determinants of carotid atherosclerosis in a general population. *Stroke*. 1992;23:1705–1711.
555. Pujia A, Rubba P, Spencer MP. Prevalence of extracranial carotid artery disease detectable by echo-Doppler in an elderly population. *Stroke*. 1992;23:818–822.
556. Ramsey DE, Miles RD, Lambeth A, Sumner DS. Prevalence of extracranial carotid artery disease: a survey of an asymptomatic population with noninvasive techniques. *J Vasc Surg*. 1987;5:584–588.
557. Wilterdink JL, Easton JD. Vascular event rates in patients with atherosclerotic cerebrovascular disease. *Arch Neurol*. 1992;49:857–863.
558. Ahmed A, Adams RJ. Sickle cell disorders and cerebrovascular disease. In: Gillum RF, Gorelick PB, Cooper ES, eds. *Stroke in Blacks: A Guide to Management and Prevention*. Basel: Karger; 1999:62–69.
559. Stamler J. Blood pressure and high blood pressure: aspects of risk. *Hypertension*. 1991;18(3 suppl):I95–I107.
560. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. *JAMA*. 1995;274:1049–1057.
561. Majumdar SR, Almasi EA, Stafford RS. Promotion and prescribing of hormone therapy after report of harm by the Women's Health Initiative. *JAMA*. 2004;292:1983–1988.
562. Haas JS, Kaplan CP, Gerstenberger EP, Kerlikowske K. Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. *Ann Intern Med*. 2004;140:184–188.

563. Gorelick PB. Stroke prevention: windows of opportunity and failed expectations? A discussion of modifiable cardiovascular risk factors and a prevention proposal. *Neuroepidemiology*. 1997;16:163–173.
564. Lundberg V, Tolonen H, Stegmayr B, Kuulasmaa K, Asplund K; WHO MONICA Project. Use of oral contraceptives and hormone replacement therapy in the WHO MONICA project. *Maturitas*. 2004;48:39–49.
565. Williams RC. Periodontal disease. *N Engl J Med*. 1990;322:373–382.
566. Beck JD, Koch GG, Rozier RG, et al. Prevalence and risk indicators for periodontal attachment loss in a population of old community-dwelling blacks and whites. *J Periodontol*. 1990;61:521–528.
567. Kuo CC, Jackson LA, Campbell LA, Grayston JT. *Chlamydia pneumoniae* (TWAR). *Clin Microbiol Rev*. 1995;8:451–461.
568. Tuuminen T, Varjo S, Ingman H, Weber T, Oksi J, Viljanen M. Prevalence of *Chlamydia pneumoniae* and *Mycoplasma pneumoniae* immunoglobulin G and A antibodies in a healthy Finnish population as analyzed by quantitative enzyme immunoassays. *Clin Diagn Lab Immunol*. 2000;7:734–738.
569. Ridker PM; JUPITER Study Group. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. *Circulation*. 2003;108:2292–2297.
570. Ariyo AA, Thach C, Tracy R; Cardiovascular Health Study Investigators. Lp(a) lipoprotein, vascular disease, and mortality in the elderly. *N Engl J Med*. 2003;349:2108–2115.
571. Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. *N Engl J Med*. 1993;328:1230–1235.
572. Kiely JL, McNicholas WT. Cardiovascular risk factors in patients with obstructive sleep apnoea syndrome. *Eur Respir J*. 2000;16:128–133.